Methods and uses of variant CD80 fusion proteins and related constructs
Variant CD80 fusion proteins with enhanced binding properties are used to modulate immune responses at immunological synapses, addressing the limitations of current agents and improving cancer treatment by enhancing immune activation and therapeutic efficacy.
Patent Information
- Application Number
- JP2024139417
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-03-13
- Filing Date
- 2024-08-21
- Publication Date
- 2024-11-26
AI Technical Summary
Current therapeutic agents for modulating immune responses at immunological synapses are inadequate, necessitating improved immunomodulatory proteins that can enhance cancer treatment by targeting specific interactions between antigen-presenting cells and lymphocytes.
Development of variant CD80 fusion proteins with altered binding affinity and selectivity to cognate partners like CD28, PD-L1, and CTLA-4, administered in conjunction with immune checkpoint inhibitors or chemotherapeutic agents to modulate immune responses in cancer treatment.
The variant CD80 fusion proteins enhance immune activation and cancer treatment efficacy by increasing binding affinity to CD28, PD-L1, and CTLA-4, potentially improving treatment outcomes through targeted immune modulation.
Smart Images

Figure 2024164118000001_ABST
Abstract
Description
[Technical Field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Patent Application No. 62 / 733,625, filed September 19, 2018, entitled "METHODS AND USES OF VARIANT CD80 FUSION PROTEINS AND RELATED CONSTRUCTS"; U.S. Provisional Patent Application No. 62 / 733,623, filed September 19, 2018, entitled "VARIANT CD80 FUSION PROTEINS AND RELATED COMPOSITIONS AND METHODS"; and U.S. Provisional Patent Application No. 62 / 818,058, filed March 13, 2019, entitled "METHODS AND USES OF VARIANT CD80 FUSION PROTEINS AND RELATED CONSTRUCTS," the contents of each of which are incorporated by reference in their entirety.
[0002] INCORPORATION-BY-REFERENCE TO SEQUENCE LISTING This application is filed with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled 761612003040SeqList.txt, created on September 18, 2019, and is 2,178,803 bytes in size. The information in the electronic format of the Sequence Listing is incorporated by reference in its entirety.
[0003] Field The present disclosure relates to therapeutic compositions and methods of using the same for modulating immune responses in the treatment of cancer. In some aspects, the present disclosure relates to particular variants of CD80 that exhibit altered binding, e.g., binding affinity or selectivity, to cognate binding partners, e.g., increased affinity for CD28, PD-L1, and / or CTLA-4. [Background technology]
[0004] background There is growing medical interest in modulating immune responses by intervening in processes occurring at the immunological synapse (IS) formed by and between antigen-presenting cells (APCs) or target cells and lymphocytes. Mechanistically, cell surface proteins at the IS can involve the coordinated and often simultaneous interaction of multiple protein targets with a single protein to which they bind. IS interactions occur in close association with the junction of two cells, allowing a single protein in this structure to potentially interact simultaneously with proteins on both the same cell (cis) and related cells (trans). While therapeutic agents capable of modulating the IS are known, improved therapeutic agents are needed. Immunomodulatory proteins, including soluble or transmembrane immunomodulatory proteins expressible on cells, are provided to meet this need. Summary of the Invention
[0005] overview Provided herein are methods of treating cancer in a subject. In some embodiments, the methods include administering to a subject having cancer a variant CD80 fusion protein that specifically binds to PD-L1, wherein the variant CD80 fusion protein comprises a variant CD80 extracellular domain or portion thereof comprising an IgV domain or a specific-binding fragment thereof, and a multimerization domain, and the variant CD80 extracellular domain or portion thereof comprises one or more amino acid modifications at one or more positions in the amino acid sequence of the extracellular domain or portion thereof of an unmodified CD80 polypeptide; and administering to the subject a therapeutically effective amount of an anti-cancer agent.
[0006] In some embodiments, the anti-cancer agent is an immune checkpoint inhibitor or a chemotherapeutic agent. In some embodiments, the anti-cancer agent is a chemotherapeutic agent that is a platinum-based chemotherapeutic agent. In some embodiments, the chemotherapeutic agent is oxilaplatin. In some embodiments, the anti-cancer agent is a CTLA-4 immune checkpoint inhibitor, and optionally, the checkpoint inhibitor is an anti-CTLA-4 antibody or an antigen-binding fragment thereof. In some embodiments, the immune checkpoint inhibitor is ipilimumab or tremelimumab, or an antigen-binding fragment thereof. In some embodiments, the anti-cancer agent is a PD-1 immune checkpoint inhibitor (PD-1 inhibitor), and optionally, the PD-1 inhibitor is an anti-PD-1 antibody or an antigen-binding fragment thereof.
[0007] Provided herein are methods of treating cancer in a subject. In some embodiments, the methods include administering to a subject having cancer a variant CD80 fusion protein that specifically binds to PD-L1, wherein the variant CD80 fusion protein comprises a variant CD80 extracellular domain or portion thereof comprising an IgV domain or a specific-binding fragment thereof, and a multimerization domain, and the variant CD80 extracellular domain or portion thereof contains one or more amino acid modifications at one or more positions in the amino acid sequence of the extracellular domain or portion thereof of an unmodified CD80 polypeptide; and administering to the subject a therapeutically effective amount of a PD-1 inhibitor, wherein the PD-1 inhibitor disrupts the interaction of programmed death-1 (PD-1) with its ligand.
[0008] In some embodiments, the ligand is programmed death-ligand-1 (PD-L1) or PD-L2. In some embodiments, the PD-1 inhibitor specifically binds to PD-1. In some embodiments, the PD-1 inhibitor does not compete with the variant CD80 fusion protein for binding to PD-L1. In some embodiments, the PD-1 inhibitor is a peptide, protein, antibody or antigen-binding fragment thereof, or small molecule. In some embodiments, the PD-1 inhibitor is an antibody or antigen-binding fragment thereof that specifically binds to PD-1. In some examples, the antibody or antigen-binding portion is selected from nivolumab, pembrolizumab, MEDI0680 (AMP514), PDR001, cemiplimab (REGN2810), pidilizumab (CT011), or an antigen-binding portion thereof.
[0009] In some embodiments, the PD-1 inhibitor contains the extracellular domain of PD-L2, or a portion thereof, that binds to PD-1, and an Fc region. In some embodiments, the PD-1 inhibitor is AMP-224.
[0010] In some embodiments, the initiation of administration of the PD-1 inhibitor occurs simultaneously with or sequentially with the initiation of administration of the variant CD80 fusion protein. In some examples, the initiation of administration of the PD-1 inhibitor occurs after the initiation of administration of the variant CD80 fusion protein. In some embodiments, the initiation of administration of the anti-PD-1 antibody occurs after the administration of the final therapeutically effective dose of the variant CD80 fusion protein. In some of any such embodiments, the variant CD80 fusion protein is administered in a therapeutically effective amount, as a single dose or in multiple doses of up to six.
[0011]
[0010] Provided herein are methods of treating cancer in a subject. In some embodiments, the methods comprise administering to a subject having cancer a therapeutically effective amount of a variant CD80 fusion protein, wherein the variant CD80 fusion protein comprises a variant CD80 extracellular domain or portion thereof comprising an IgV domain or a specific-binding fragment thereof, and a multimerization domain, wherein the variant CD80 extracellular domain or portion thereof contains one or more amino acid modifications at one or more positions in the amino acid sequence of the extracellular domain or portion thereof of an unmodified CD80 polypeptide, wherein the therapeutically effective amount of the variant CD80 fusion protein is administered as a single dose or in multiple doses of up to six.
[0012] In some embodiments, the variant CD80 fusion protein, e.g., a variant CD80 Fc fusion, is administered parenterally. In some embodiments, the variant CD80 fusion protein, e.g., a variant CD80 Fc fusion, is administered subcutaneously. In some embodiments, the variant CD80 Fc fusion protein is administered intravenously. In some embodiments, administration is by injection, wherein the injection is a bolus injection.
[0013] In any embodiment of the provided methods, the therapeutically effective amount administered is from about 0.5 mg / kg to about 40 mg / kg, from about 0.5 mg / kg to about 30 mg / kg, from about 0.5 mg / kg to about 20 mg / kg, from about 0.5 mg / kg to about 18 mg / kg, from about 0.5 mg / kg to about 12 mg / kg, from about 0.5 mg / kg to about 10 mg / kg, from about 0.5 mg / kg to about 6 mg / kg, from about 0.5 mg / kg to about 3 mg / kg, from about 1 mg / kg to about 40 mg / kg, inclusive. kg, about 1 mg / kg to about 30 mg / kg, about 1 mg / kg to about 20 mg / kg, about 1 mg / kg to about 18 mg / kg, about 1 mg / kg to about 12 mg / kg, about 1 mg / kg to about 10 mg / kg, about 1 mg / kg to about 6 mg / k g, about 1 mg / kg to about 3 mg / kg, about 3 mg / kg to about 40 mg / kg, about 3 mg / kg to about 30 mg / kg, about 3 mg / kg to about 20 mg / kg, about 3 mg / kg to about 18 mg / kg, about 3 mg / kg to about 12 mg / kg, Approximately 3 mg / kg to approximately 10 mg / kg, approximately 3 mg / kg to approximately 6 mg / kg, approximately 6 mg / kg to approximately 40 mg / kg, approximately 6 mg / kg to approximately 30 mg / kg, approximately 6 mg / kg to approximately 20 mg / kg, approximately 6 mg / kg to approximately 18 mg / kg, approximately 6mg / kg to about 12mg / kg, about 6mg / kg to about 10mg / kg, about 10mg / kg to about 40mg / kg, about 10mg / kg to about 30mg / kg, about 10mg / kg to about 20mg / kg, about 10mg / kg to about 18mg / k g, about 10 mg / kg to about 12 mg / kg, about 12 mg / kg to about 40 mg / kg, about 12 mg / kg to about 30 mg / kg, about 12 mg / kg to about 20 mg / kg, about 12 mg / kg to about 18 mg / kg, about 18 mg / kg to about 40 mg / kg, about 18 mg / kg to about 30 mg / kg, about 18 mg / kg to about 20 mg / kg, about 20 mg / kg to about 40 mg / kg, about 20 mg / kg to about 30 mg / kg, or about 30 mg / kg to about 40 mg / kg. In some embodiments, the therapeutically effective amount is about 3.0 mg / kg to 18 mg / kg, inclusive. In some embodiments, the therapeutically effective amount is about 6 mg / kg to about 20 mg / kg, inclusive.
[0014] In some of any such embodiments, the therapeutically effective amount is from about 1 mg / kg to about 10 mg / kg, inclusive. In some embodiments, the therapeutically effective amount is from about 2.0 mg / kg to about 6.0 mg / kg, inclusive. In some embodiments, the variant CD80 fusion protein, e.g., a variant CD80 Fc fusion, is administered intratumorally.
[0015] Methods of treating cancer in a subject are provided herein. In some embodiments, the methods comprise intratumorally administering to a subject with cancer a therapeutically effective amount of a variant CD80 fusion protein, wherein the variant CD80 fusion protein comprises a variant CD80 extracellular domain or portion thereof comprising an IgV domain or a specific-binding fragment thereof, and a multimerization domain, wherein the variant CD80 extracellular domain or portion thereof contains one or more amino acid modifications at one or more positions in the amino acid sequence of the extracellular domain or portion thereof of an unmodified CD80 polypeptide. In some of any such embodiments, the variant CD80 fusion protein is administered in a therapeutically effective amount, as a single dose or in up to six multiple doses. In some embodiments, the therapeutically effective amount is from about 0.1 mg / kg to about 1 mg / kg, inclusive. In some examples, the therapeutically effective amount is from about 0.2 mg / kg to about 0.6 mg / kg. In some embodiments, the therapeutically effective amount is administered in a single dose.
[0016] In some of any such provided embodiments, the therapeutically effective amount is administered in six or fewer multiple doses, where six or fewer multiple doses are two doses, three doses, four doses, five doses, or six doses. In some embodiments, the therapeutically effective amount is administered in four doses. In some embodiments, the therapeutically effective amount is administered in three doses. In some examples, the therapeutically effective amount is administered in two doses.
[0017] In some embodiments, each dose of the multiple doses is administered weekly, every two weeks, every three weeks, or every four weeks. In some embodiments, each of the six or fewer multiple doses is administered weekly, every two weeks, every three weeks, or every four weeks. In some aspects, the interval between each multiple dose is about one week.
[0018] In some of any of the provided embodiments, the single dose or each of the multiple doses, e.g., each of up to six multiple doses, is administered once weekly (Q1W) in an amount of about 0.5 mg / kg to about 10 mg / kg.
[0019] Provided herein are methods of treating cancer in a subject, the method comprising administering to a subject having cancer a variant CD80 fusion protein once weekly (Q1W) in an amount of about 1.0 mg / kg to 10 mg / kg, inclusive, wherein the variant CD80 fusion protein comprises a variant CD80 extracellular domain or portion thereof comprising an IgV domain or a specific-binding fragment thereof, and a multimerization domain, wherein the variant CD80 extracellular domain or portion thereof comprises one or more amino acid modifications at one or more positions in the amino acid sequence of the extracellular domain or portion thereof of an unmodified CD80 polypeptide.
[0020] In some embodiments, the amount of variant CD80 fusion protein administered Q1W is from about 1 mg / kg to about 3 mg / kg.
[0021] In some of any of the provided embodiments, the single dose or each of the multiple doses, e.g., each of up to six multiple doses, is administered once every three weeks (Q3W) in an amount of about 1.0 mg / kg to about 40 mg / kg.
[0022] Provided herein are methods of treating cancer in a subject, the method comprising administering to a subject having cancer a variant CD80 fusion protein in an amount of about 1.0 mg / kg to 40 mg / kg, inclusive, once every three weeks (Q3W), wherein the variant CD80 fusion protein comprises a variant CD80 extracellular domain or portion thereof comprising an IgV domain or a specific-binding fragment thereof, and a multimerization domain, wherein the variant CD80 extracellular domain or portion thereof comprises one or more amino acid modifications at one or more positions in the amino acid sequence of the extracellular domain or portion thereof of an unmodified CD80 polypeptide.
[0023] In some embodiments, the amount of variant CD80 fusion protein administered Q3W is from about 3.0 mg / kg to about 10 mg / kg Q3W.
[0024] In some of any of the provided embodiments, the variant CD80 fusion protein is administered parenterally, optionally subcutaneously. In some embodiments, the variant CD80 fusion protein is administered by injection, which is a bolus injection.
[0025] In some of any of the provided embodiments, administration is over a period of more than one week. In some examples, the therapeutically effective amount is administered for a period of six weeks or less. In some embodiments, the therapeutically effective amount is administered for a period of four weeks or less or about four weeks. In some embodiments, each of the multiple doses is an equal amount.
[0026] In some of any such embodiments, the method includes, prior to the administering step, selecting for treatment a subject having a tumor comprising cells that are surface-positive for PD-L1 or CD28 and / or surface-negative for a cell surface ligand selected from CD80 or CD86. In some embodiments, a subject having a tumor comprising cells that are surface-positive for PD-L1 is selected for treatment. In some embodiments, a subject having a tumor comprising cells that are surface-positive for CD28 is selected for treatment. In some embodiments, a subject having a tumor comprising cells that are surface-negative for CD80 is selected for treatment. In some embodiments, a subject having a tumor comprising cells that are surface-negative for CD86 is selected for treatment. In certain aspects, such cells are tumor cells. In certain aspects, such cells are tumor-infiltrating immune cells, e.g., tumor-infiltrating T lymphocytes.
[0027] Provided herein are methods of treating cancer in a subject, the methods comprising administering to a subject selected as having a tumor containing cells that are surface-negative for a cell surface ligand selected from CD80 or CD86 and / or surface-positive for CD28 a variant CD80 fusion protein, wherein the variant CD80 fusion protein contains a variant CD80 extracellular domain or portion thereof comprising an IgV domain or a specific-binding fragment thereof, and a multimerization domain, wherein the variant CD80 extracellular domain or portion thereof comprises one or more amino acid modifications at one or more positions in the amino acid sequence of the extracellular domain or portion thereof of an unmodified CD80 polypeptide.
[0028] In some embodiments, the CD80 or CD86 surface-negative cells comprise tumor cells or antigen-presenting cells. In some embodiments, the CD28 surface-positive cells comprise tumor-infiltrating T lymphocytes. In some examples, the subject is further selected as having a tumor comprising cells that are surface-positive for PD-L1. In some embodiments, the PD-L1 surface-positive cells are tumor cells or tumor-infiltrating immune cells, optionally tumor-infiltrating T lymphocytes.
[0029] In some embodiments, the method includes determining an immunoscore based on the presence or density of tumor-infiltrating T lymphocytes in the subject's tumor. In some embodiments, if the immunoscore is low, the subject is selected for treatment. In some of any such embodiments, the subject is selected by immunohistochemistry (IHC) using a reagent that specifically binds to at least one binding partner.
[0030] In some embodiments, the variant CD80 fusion protein exhibits increased binding of at least one binding partner selected from among CD28, PD-L1, and CTLA-4 compared to a fusion protein comprising the extracellular domain of unmodified CD80. In some examples, the variant CD80 fusion protein exhibits increased binding to PD-L1 compared to a fusion protein comprising the extracellular domain of unmodified CD80 for the binding partner. In some embodiments, the variant CD80 fusion protein further exhibits increased binding to at least one binding partner selected from among CD28 and CTLA-4 compared to a fusion protein comprising the extracellular domain of unmodified CD80 for the binding partner. In some of any such embodiments, the binding, e.g., affinity, is increased by more than 1.2-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 60-fold, 80-fold, 100-fold, 150-fold, 200-fold, 250-fold, 300-fold, 400-fold, or 450-fold compared to the binding, e.g., affinity, of unmodified CD80 to the ectodomain of the binding partner.
[0031] In some embodiments, the variant CD80 fusion protein exhibits increased binding to at least one binding partner selected from among CD28, PD-L1, and CTLA-4 as compared to a fusion protein comprising the extracellular domain of unmodified CD80, or a portion thereof, for the at least one binding partner. In some examples, the variant CD80 fusion protein exhibits increased binding to PD-L1 as compared to a fusion protein comprising the extracellular domain of unmodified CD80, or a portion thereof, for the binding partner PD-L1. In some embodiments, the variant CD80 fusion protein further exhibits increased binding to at least one binding partner selected from among CD28 and CTLA-4 as compared to a fusion protein comprising the extracellular domain of unmodified CD80, or a portion thereof. In some of any such embodiments, the binding affinity is increased by more than 1.2-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 60-fold, 80-fold, 100-fold, 150-fold, 200-fold, 250-fold, 300-fold, 400-fold, or 450-fold compared to the binding affinity of unmodified CD80 for the ectodomain of the binding partner.
[0032] In some of any of the provided embodiments, the one or more amino acid modifications are amino acid substitutions. In some examples, the one or more amino acid modifications contain one or more amino acid substitutions selected from among H18Y, A26E, E35D, D46E, D46V, M47I, M47L, M47V, V68M, A71D, A71G, L85M, L85Q, or D90G, or conservative amino acid substitutions thereof, with reference to the numbering of SEQ ID NO:2. In some embodiments, the one or more amino acid modifications contain two or more amino acid substitutions selected from among H18Y, A26E, E35D, D46E, D46V, M47I, M47L, M47V, V68M, A71D, A71G, L85M, L85Q, or D90G, or conservative amino acid substitutions thereof, with reference to the numbering of SEQ ID NO:2.
[0033] In some examples, the one or more amino acid modifications are the amino acid substitutions H18Y / E35D, E35D / D46E, E35D / D46V, E35D / M47I, E35D / M47L, E35D / M47V, E35D / V68M, E35D / L85M, E35D / L85Q, D46E / M47I, D46E / M47L, D46E / M47V, D46V / M47I, D46V / M47L , D46V / M47L, D46E / V68M, D46V / V68M, H18Y / M47I, H18Y / M47L, H18Y / M47V, M47I / V68M, M47L / V68M or M47V / V68M, M47I / E85M, M47L / E85M, M47V / E85M, M47I / E85Q, M47L / E85Q or M47V / E85Q. In some embodiments, the one or more amino acid modifications contain the amino acid substitutions E35D / M47L / V68M, E35D / M47V / V68M or E35D / M47I / L70M.
[0034] In some of any such embodiments, the one or more amino acid modifications contain amino acid substitutions E35D / M47V / N48K / V68M / K89N.
[0035] In some of any such embodiments, the one or more amino acid modifications contain amino acid substitutions H18Y / A26E / E35D / M47L / V68M / A71G / D90G.
[0036] In some of any such embodiments, the one or more amino acid modifications contain amino acid substitutions E35D / D46E / M47V / V68M / D90G / K93E.
[0037] In some of any such embodiments, the one or more amino acid modifications contain amino acid substitutions E35D / D46V / M47L / V68M / L85Q / E88D.
[0038] In some of any such embodiments, the unmodified CD80 is human CD80.
[0039] In some of any such embodiments, the extracellular domain of unmodified CD80, or portion thereof, (i) contains the amino acid sequence set forth in SEQ ID NO:2, (ii) contains an amino acid sequence having at least 95% sequence identity to SEQ ID NO:2; or (iii) is a portion of (i) or (ii) that includes an IgV domain or a specific-binding fragment thereof.
[0040] In some embodiments, the extracellular domain of unmodified CD80, or a portion thereof, is an extracellular domain portion that is or contains an IgV domain or a specific-binding fragment thereof. In some embodiments, the extracellular domain portion of unmodified CD80 contains an IgV domain but does not contain an IgC domain or a portion of an IgC domain. In some embodiments, the extracellular domain portion of unmodified CD80 is set forth as amino acids 35-135 of SEQ ID NO:2 (SEQ ID NO:76) or 35-141 of SEQ ID NO:2 (SEQ ID NO:150). In some embodiments, the variant CD80 extracellular domain, or a portion thereof, is an extracellular domain portion that does not contain an IgC domain or a portion of an IgC domain.
[0041] In some embodiments, the variant CD80 extracellular domain contains the sequence of amino acids 35-135 of SEQ ID NO:2 (SEQ ID NO:76) or 35-141 of SEQ ID NO:2 (SEQ ID NO:150), which contains one or more amino acid substitutions. In some embodiments, the variant CD80 extracellular domain is the sequence of amino acids 35-135 of SEQ ID NO:2 (SEQ ID NO:76) or 35-141 of SEQ ID NO:2 (SEQ ID NO:150), which contains one or more amino acid substitutions. In some embodiments, the variant CD80 extracellular domain contains 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid modifications, optionally, the amino acid modifications are amino acid substitutions.
[0042] In some of any such embodiments, the variant CD80 extracellular domain contains no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 amino acid modifications. In some of any such embodiments, the variant CD80 extracellular domain or portion thereof contains no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 amino acid modifications. In some such embodiments, the amino acid modifications are amino acid substitutions. In some embodiments, the amino acid sequence of the variant CD80 extracellular domain has at least, or at least about, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the sequence of amino acids 35-135 of SEQ ID NO:2 (SEQ ID NO:76) or 35-141 of SEQ ID NO:2 (SEQ ID NO:150).
[0043] In some of any such embodiments, the multimerization domain is an Fc region. In some embodiments, the Fc region is that of an immunoglobulin G1 (IgG1) or immunoglobulin G2 (IgG2) protein. In some embodiments, the Fc region exhibits one or more effector functions. In some embodiments, the Fc region is a variant Fc region comprising one or more amino acid substitutions in a wild-type Fc region, and the variant Fc region exhibits one or more effector functions that are reduced compared to the wild-type Fc region, e.g., reduced compared to a wild-type human Fc, is that of human IgG1.
[0044] In some embodiments, the Fc region contains the amino acid substitution N297G, and the residues are numbered according to the EU index of Kabat. In some embodiments, the Fc region contains the amino acid substitutions R292C / N297G / V302C, and the residues are numbered according to the EU index of Kabat. In some embodiments, the Fc region contains the amino acid substitutions L234A / L235E / G237A, and the residues are numbered according to the EU index of Kabat. In some embodiments, the Fc region further contains the amino acid substitution C220S, and the residues are numbered according to the EU index of Kabat. In some embodiments, the Fc region contains K447del, and the residues are numbered according to the EU index of Kabat.
[0045] In some of any such embodiments, the variant CD80 fusion protein antagonizes the activity of CTLA-4. In some embodiments, the variant CD80 fusion protein blocks PD-1 / PD-L1 interaction. In some embodiments, the variant CD80 fusion protein binds to CD28 and mediates CD28 agonism. In some embodiments, CD28 agonism is PD-L1 dependent. In some embodiments, the subject is human.
[0046] Provided herein are kits containing a variant CD80 fusion protein that specifically binds to PD-L1, the variant CD80 fusion protein comprising a variant CD80 extracellular domain or a portion thereof comprising an IgV domain or a specific-binding fragment thereof, and a multimerization domain, wherein the variant CD80 extracellular domain or portion thereof comprises one or more amino acid modifications at one or more positions in the amino acid sequence of the extracellular domain or portion thereof of an unmodified CD80 polypeptide; and an anti-cancer agent.
[0047] In some embodiments, the anti-cancer agent is an immune checkpoint inhibitor or a chemotherapeutic agent. In some embodiments, the anti-cancer agent is a chemotherapeutic agent that is a platinum-based chemotherapeutic agent. In some embodiments, the chemotherapeutic agent is oxilaplatin. In some embodiments, the anti-cancer agent is a CTLA-4 immune checkpoint inhibitor, and optionally, the checkpoint inhibitor is an anti-CTLA-4 antibody or an antigen-binding fragment thereof. In some embodiments, the immune checkpoint inhibitor is ipilimumab or tremelimumab, or an antigen-binding fragment thereof. In some embodiments, the anti-cancer agent is a PD-1 immune checkpoint inhibitor (PD-1 inhibitor), and optionally, the PD-1 inhibitor is an anti-PD-1 antibody or an antigen-binding fragment thereof.
[0048] Provided herein are kits containing a variant CD80 fusion protein that specifically binds to PD-L1, the variant CD80 fusion protein comprising a variant CD80 extracellular domain or portion thereof comprising an IgV domain or a specific-binding fragment thereof, and a multimerization domain, wherein the variant CD80 extracellular domain or portion thereof contains one or more amino acid modifications at one or more positions in the amino acid sequence of the extracellular domain or portion thereof of an unmodified CD80 polypeptide; and a programmed death-1 (PD-1) inhibitor that disrupts the interaction of PD-1 with its ligand.
[0049] In some embodiments, the ligand is programmed death-ligand-1 (PD-L1) or PD-L2. In some embodiments, the PD-1 inhibitor specifically binds to PD-1. In some embodiments, the PD-1 inhibitor does not compete with the variant CD80 fusion protein for binding to PD-L1. In some embodiments, the PD-1 inhibitor is a peptide, protein, antibody or antigen-binding fragment thereof, or small molecule. In some embodiments, the PD-1 inhibitor is an antibody or antigen-binding fragment thereof that specifically binds to PD-1.
[0050] In some of any such embodiments, the antibody or antigen-binding portion is selected from nivolumab, pembrolizumab, MEDI0680 (AMP514), PDR001, cemiplimab (REGN2810), pidilizumab (CT011), or an antigen-binding portion thereof.
[0051] In some embodiments, the PD-1 inhibitor contains the extracellular domain of PD-L2, which binds to PD-1, or a portion thereof, and an Fc region. In some embodiments, the PD-1 inhibitor is AMP-224. In some embodiments, the variant CD80 fusion protein exhibits increased binding to at least one binding partner selected from among CD28, PD-L1, and CTLA-4, as compared to a fusion protein comprising the extracellular domain of unmodified CD80, or a portion thereof, to the at least one binding partner. In some embodiments, the variant CD80 fusion protein exhibits increased binding to PD-L1, as compared to a fusion protein comprising the extracellular domain of unmodified CD80, or a portion thereof, to PD-1.
[0052] In some embodiments, the variant CD80 fusion protein further exhibits increased binding to at least one binding partner selected from among CD28 and CTLA-4 as compared to a fusion protein comprising the extracellular domain of unmodified CD80 for said at least one binding partner. In some embodiments, the variant CD80 fusion protein exhibits increased binding to at least one binding partner selected from among CD28 and CTLA-4 as compared to a fusion protein comprising the extracellular domain of unmodified CD80 or a portion thereof. In some embodiments, the binding, e.g., affinity, is increased by more than 1.2-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 60-fold, 80-fold, 100-fold, 150-fold, 200-fold, 250-fold, 300-fold, 400-fold, or 450-fold as compared to the binding affinity of unmodified CD80 for the ectodomain of the binding partner.
[0053] In some of any such embodiments, the one or more amino acid modifications are amino acid substitutions. In some embodiments, the one or more amino acid modifications contain one or more amino acid substitutions selected from among H18Y, A26E, E35D, D46E, D46V, M47I, M47L, M47V, V68M, A71D, A71G, L85M, L85Q, or D90G, with reference to the numbering of SEQ ID NO:2, or conservative amino acid substitutions thereof. In some embodiments, the one or more amino acid modifications contain two or more amino acid substitutions selected from among H18Y, A26E, E35D, D46E, D46V, M47I, M47L, M47V, V68M, A71D, A71G, L85M, L85Q, or D90G, with reference to the numbering of SEQ ID NO:2, or conservative amino acid substitutions thereof.
[0054] In some of any of the provided embodiments, the one or more amino acid modifications are, with reference to the numbering of SEQ ID NO:2, amino acid substitutions H18Y / E35D, E35D / D46E, E35D / D46V, E35D / M47I, E35D / M47L, E35D / M47V, E35D / V68M, E35D / L85M, E35D / L85Q, D46E / M47I, D46E / M47L, D46E / M47V, D46V / M47I, D46V / M47L , D46V / M47L, D46E / V68M, D46V / V68M, H18Y / M47I, H18Y / M47L, H18Y / M47V, M47I / V68M, M47L / V68M or M47V / V68M, M47I / E85M, M47L / E85M, M47V / E85M, M47I / E85Q, M47L / E85Q or M47V / E85Q. In some embodiments, the one or more amino acid modifications contain the amino acid substitutions E35D / M47L / V68M, E35D / M47V / V68M or E35D / M47I / L70M. In some embodiments, the one or more amino acid modifications contain amino acid substitutions E35D / M47V / N48K / V68M / K89N, H18Y / A26E / E35D / M47L / V68M / A71G / D90G, E35D / D46E / M47V / V68M / D90G / K93E, or E35D / D46V / M47L / V68M / L85Q / E88D.
[0055] In some of any such embodiments, the unmodified CD80 is human CD80. In some embodiments, the extracellular domain of unmodified CD80, or a portion thereof, (i) contains the amino acid sequence set forth in SEQ ID NO:2, (ii) contains an amino acid sequence having at least 95% sequence identity to SEQ ID NO:2; or (iii) is a portion of (i) or (ii) that includes an IgV domain or a specific-binding fragment thereof.
[0056] In some embodiments, the extracellular domain of unmodified CD80 or a portion thereof is an extracellular domain portion that is or contains an IgV domain or a specific-binding fragment thereof. In some embodiments, the extracellular domain portion of unmodified CD80 contains an IgV domain but does not contain an IgC domain or a portion of an IgC domain.
[0057] In some embodiments, the extracellular domain portion of unmodified CD80 is set forth as amino acids 35-135 of SEQ ID NO:2 (SEQ ID NO:76) or 35-141 of SEQ ID NO:2 (SEQ ID NO:150). In some embodiments, the variant CD80 extracellular domain or portion thereof is an extracellular domain portion that does not contain an IgC domain or a portion of an IgC domain.
[0058] In some embodiments, the variant CD80 extracellular domain contains the sequence of amino acids 35-135 of SEQ ID NO:2 (SEQ ID NO:76) or 35-141 of SEQ ID NO:2 (SEQ ID NO:150), which contains one or more amino acid substitutions. In some embodiments, the variant CD80 extracellular domain is the sequence of amino acids 35-135 of SEQ ID NO:2 (SEQ ID NO:76) or 35-141 of SEQ ID NO:2 (SEQ ID NO:150), which contains one or more amino acid substitutions. In some embodiments, the variant CD80 extracellular domain contains 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid modifications, optionally, the amino acid modifications are amino acid substitutions.
[0059] In some embodiments, the variant CD80 extracellular domain contains no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 amino acid modifications. In some such embodiments, the amino acid modifications are amino acid substitutions. In some embodiments, the variant CD80 extracellular domain has at least, or at least about, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the sequence of amino acids 35-135 of SEQ ID NO:2 (SEQ ID NO:76) or 35-141 of SEQ ID NO:2 (SEQ ID NO:150).
[0060] In some of any such provided embodiments, the multimerization domain is an Fc region. In some embodiments, the Fc region is that of an immunoglobulin G1 (IgG1) or immunoglobulin G2 (IgG2) protein. In some embodiments, the Fc region exhibits one or more effector functions. In some embodiments, the Fc region is a variant Fc region containing one or more amino acid substitutions in a wild-type Fc region, wherein the variant Fc region exhibits one or more reduced effector functions compared to the wild-type Fc region, and optionally, the wild-type human Fc is that of human IgG1.
[0061] Provided herein are articles of manufacture containing the kits and instructions of any of such embodiments. In some embodiments, the instructions provide information for administering a variant CD80 fusion protein, e.g., a variant CD80 Fc fusion protein or a PD-1 inhibitor, according to any of the provided methods.
[0062] Provided herein is a multivalent CD80 polypeptide containing two copies of a fusion protein comprising: at least two variant CD80 extracellular domains or portions thereof (vCD80) comprising an IgV domain or a specific binding fragment thereof, wherein the vCD80 contains one or more amino acid modifications at one or more positions in the amino acid sequence of the extracellular domain or portion thereof of an unmodified CD80 polypeptide; and Fc polypeptide.
[0063] In some embodiments, the polypeptide is tetravalent. In some embodiments, the fusion protein contains the structure: (vCD80)-linker-Fc-linker-(vCD80). In some embodiments, the fusion protein contains the structure: (vCD80)-linker-(vCD80)-linker-Fc.
[0064] In some embodiments, vCD80 exhibits increased binding to at least one binding partner selected from among CD28, PD-L1, and CTLA-4 compared to vCD80 comprising the extracellular domain of unmodified CD80, or a portion thereof. In some embodiments, vCD80 exhibits increased binding to PD-L1 compared to the extracellular domain of unmodified CD80, or a portion thereof, for PD-L1. In some embodiments, vCD80 exhibits increased binding to at least one binding partner selected from among CD28, PD-L1, and CTLA-4 compared to vCD80 comprising the extracellular domain of unmodified CD80 for PD-L1. In some embodiments, the binding, e.g., affinity, is increased by more than 1.2-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 60-fold, 80-fold, 100-fold, 150-fold, 200-fold, 250-fold, 300-fold, 400-fold, or 450-fold compared to the binding affinity of unmodified CD80 for the ectodomain of the binding partner.
[0065] In some embodiments, the one or more amino acid modifications are amino acid substitutions. In some embodiments, the one or more amino acid modifications contain one or more amino acid substitutions selected from among H18Y, A26E, E35D, D46E, D46V, M47I, M47L, M47V, V68M, A71D, A71G, L85M, L85Q, or D90G, or conservative amino acid substitutions thereof, with reference to the numbering of SEQ ID NO:2.
[0066] In some of any such embodiments, the one or more amino acid modifications are amino acid substitutions. In some embodiments, the one or more amino acid modifications contain one or more amino acid substitutions selected from among H18Y, A26E, E35D, D46E, D46V, M47I, M47L, M47V, V68M, A71D, A71G, L85M, L85Q, or D90G, or conservative amino acid substitutions thereof, with reference to the numbering of SEQ ID NO:2.
[0067] In some embodiments, the one or more amino acid modifications contain two or more amino acid substitutions selected from among H18Y, A26E, E35D, D46E, D46V, M47I, M47L, M47V, V68M, A71D, A71G, L85M, L85Q, or D90G, or conservative amino acid substitutions thereof, with reference to the numbering of SEQ ID NO:2. With reference to the numbering of NO:2, amino acid substitutions H18Y / E35D, E35D / D46E, E35D / D46V, E35D / M47I, E35D / M47L, E35D / M47V, E35D / V68M, E35D / L85M, E35D / L85Q, D46E / M47I, D46E / M47L, D46E / M47V, D46V / M47I, D46V / M47L , D46V / M47L, D46E / V68M, D46V / V68M, H18Y / M47I, H18Y / M47L, H18Y / M47V, M47I / V68M, M47L / V68M or M47V / V68M, M47I / E85M, M47L / E85M, M47V / E85M, M47I / E85Q, M47L / E85Q or M47V / E85Q.
[0068] In some embodiments, the one or more amino acid modifications contain the amino acid substitutions E35D / M47L / V68M, E35D / M47V / V68M, or E35D / M47I / L70M. In some embodiments, the one or more amino acid modifications contain the amino acid substitutions E35D / M47V / N48K / V68M / K89N, H18Y / A26E / E35D / M47L / V68M / A71G / D90G, E35D / D46E / M47V / V68M / D90G / K93E, or E35D / D46V / M47L / V68M / L85Q / E88D. In some embodiments, the unmodified CD80 is human CD80.
[0069] In some embodiments, the extracellular domain of unmodified CD80, or a portion thereof, (i) contains the amino acid sequence set forth in SEQ ID NO:2, (ii) contains an amino acid sequence having at least 95% sequence identity to SEQ ID NO:2, or (iii) is a portion of (i) or (ii) that comprises an IgV domain or a specific-binding fragment thereof. In some examples, the extracellular domain of unmodified CD80, or a portion thereof, is an extracellular domain portion that is or contains an IgV domain or a specific-binding fragment thereof.
[0070] In some embodiments, the extracellular domain portion of unmodified CD80 contains an IgV domain but does not contain an IgC domain or a portion of an IgC domain. In some embodiments, the extracellular domain portion of unmodified CD80 is set forth as amino acids 35-135 of SEQ ID NO:2 (SEQ ID NO:76) or 35-141 of SEQ ID NO:2 (SEQ ID NO:150). In some examples, vCD80 is an extracellular domain portion that does not contain an IgC domain or a portion of an IgC domain.
[0071] In some of any such embodiments, vCD80 contains the sequence of amino acids 35-135 of SEQ ID NO:2 (SEQ ID NO:76) or 35-141 of SEQ ID NO:2 (SEQ ID NO:150), which contains one or more amino acid substitutions. In some embodiments, vCD80 has the sequence of amino acids 35-135 of SEQ ID NO:2 (SEQ ID NO:76) or 35-141 of SEQ ID NO:2 (SEQ ID NO:150), which contains one or more amino acid substitutions. In some embodiments, vCD80 contains 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid modifications, optionally, the amino acid modifications are amino acid substitutions. In some embodiments, vCD80 contains no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 amino acid modifications, optionally, wherein the amino acid modifications are amino acid substitutions. In some embodiments, vCD80 has at least, or at least about, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to amino acids 35-135 of SEQ ID NO:2 (SEQ ID NO:76) or 35-141 of SEQ ID NO:2 (SEQ ID NO:150).
[0072] In some embodiments, the multimerization domain is an Fc region. In some embodiments, the Fc region is that of an immunoglobulin G1 (IgG1) or immunoglobulin G2 (IgG2) protein. In some embodiments, the Fc region exhibits one or more effector functions. In some embodiments, the Fc region is a variant Fc region comprising one or more amino acid substitutions in a wild-type Fc region, wherein the variant Fc region exhibits one or more reduced effector functions compared to the wild-type Fc region, and optionally the wild-type human Fc is that of human IgG1.
[0073] In some of any such embodiments, each vCD80 is the same. In some embodiments, the linker is a flexible linker. In some embodiments, the linker is a peptide linker. In some embodiments, the linker is The file is TIFF2024164118000002.tif4128.
[0074] Nucleic acid molecules encoding any of the multivalent CD80 polypeptides of any such embodiments are provided herein.
[0075] Nucleic acid molecules encoding fusion proteins of any of the multivalent CD80 polypeptides of any such embodiments are provided herein.
[0076] Provided herein are vectors containing the nucleic acid of any of these embodiments. In some embodiments, the vector is an expression vector.
[0077] Host cells containing the nucleic acids or vectors of any of these embodiments are provided herein.
[0078] Provided herein are methods for producing a multivalent CD80 polypeptide of any of such embodiments, the methods comprising introducing a nucleic acid of any of such embodiments or a vector of any of such embodiments into a host cell under conditions to express the protein in the cell. In some embodiments, the methods comprise isolating or purifying a protein comprising the multivalent CD80 polypeptide.
[0079] Provided herein are engineered cells comprising the multivalent CD80 polypeptide of any of these embodiments. In some embodiments, the multivalent CD80 polypeptide comprises a fusion protein encoded by a nucleic acid molecule operably linked to a sequence encoding a secretory signal peptide. In some embodiments, the multivalent CD80 polypeptide, when expressed, can be secreted from the engineered cell.
[0080] Provided herein are engineered cells comprising the nucleic acid molecule or vector of any of these embodiments. In some embodiments, the nucleic acid molecule comprises a sequence encoding a secretory signal peptide operably linked to a sequence encoding a fusion protein. In some embodiments, the nucleic acid molecule encodes a fusion protein of a multivalent CD80 polypeptide, wherein the multivalent CD80 polypeptide, when expressed, can be secreted from the engineered cell. In some embodiments, the signal peptide is a non-native signal sequence. In some embodiments, the signal peptide is an IgGκ signal peptide, an IL-2 signal peptide, a CD33 signal peptide, or a VH signal peptide.
[0081] In some embodiments, the nucleic acid molecule further comprises at least one promoter operably linked to control the expression of the fusion protein. In some embodiments, the promoter is a constitutively active promoter. In some embodiments, the promoter is an inducible promoter. In some embodiments, the promoter is responsive to an element that responds to T cell activation signaling, and optionally, the promoter comprises a binding site for NFAT or a binding site for NF-κB.
[0082] In some embodiments, the cells are immune cells, optionally antigen-presenting cells (APCs) or lymphocytes. In some embodiments, the cells are lymphocytes that are T cells, B cells, or NK cells, and optionally, the lymphocytes are T cells that are CD4+ or CD8+. In some embodiments, the cells are primary cells obtained from a subject, and optionally, the subject is a human subject.
[0083] In some embodiments, the cells further comprise a chimeric antigen receptor (CAR) or an engineered T cell receptor (TCR).
[0084] Pharmaceutical compositions containing the multivalent CD80 polypeptide of any of these embodiments are provided herein.
[0085] Pharmaceutical compositions comprising the engineered cells of any of these embodiments are provided herein.
[0086] Provided herein are variant CD80 fusion proteins comprising: (i) a variant extracellular domain comprising one or more amino acid substitutions at one or more positions in the amino acid sequence set forth as amino acid residues 35-230 of the wild-type human CD80 extracellular domain corresponding to the residues set forth in SEQ ID NO:1; and (ii) an Fc region having effector activity, wherein the extracellular domain of the variant CD80 fusion protein specifically binds to the ectodomain of human CD28 and either does not bind to the ectodomain of human PD-L1 or binds to the ectodomain of PD-L1 with a binding affinity similar to that of the extracellular domain of wild-type human CD80 for the ectodomain of PD-L1.
[0087] In some embodiments, the extracellular domain of the variant CD80 fusion protein exhibits increased binding affinity to the ectodomain of human CTLA-4 compared to the binding affinity of the extracellular domain of wild-type CD80 to the ectodomain of human CTLA-4. In some embodiments, the extracellular domain of the variant CD80 fusion protein exhibits increased binding affinity to the ectodomain of human CD28 compared to the binding affinity of the extracellular domain of wild-type CD80 to the ectodomain of human CD28.
[0088] In some embodiments, the wild-type human CD80 extracellular domain has the amino acid sequence set forth in SEQ ID NO:2, or a sequence having at least 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:2. In some embodiments, the one or more amino acid substitutions comprise one or more amino acid substitutions selected from L70Q, K89R, D90G, D90K, A91G, F92Y, K93R, I118V, T120S, or T130A, or conservative amino acid substitutions thereof, with reference to the numbering set forth in SEQ ID NO:2. In some embodiments, the one or more amino acid substitutions are selected from the group consisting of amino acid modifications L70Q / K89R, L70Q / D90G, L70Q / D90K, L70Q / A91G, L70Q / F92Y, L70Q / K93R, L70Q / I118V, L70Q / T120S, L70Q / T130A, K89R / D90G, K89R / D90K, K89R / A91G, K89R / F92Y, K89R / K93R, K89R / I118V, K89R / T120S, K89R / T130A, D90G / A91G, D90G / F9 Includes 2Y, D90G / K93R, D90G / I118V, D90G / T120S, D90G / T130A, D90K / A91G, D90K / F92Y, D90K / K93R, D90K / I118V, D90K / T120S, D90K / T130A, F92Y / K93R, F92Y / I118V, F92Y / T120S, F92Y / T130A, K93R / I118V, K93R / T120S, K93R / T130A, I118V / T120S, I118V / T130A or T120S / T130A.
[0089] In some embodiments, the one or more amino acid substitutions comprise one or more amino acid substitutions selected from among H18Y, A26E, E35D, D46E, D46V, M47I, M47L, M47V, V68M, A71D, A71G, L85M, L85Q, or D90G, or conservative amino acid substitutions thereof, with reference to the numbering of SEQ ID NO:2. With reference to the numbering of NO:2, amino acid substitutions H18Y / E35D, E35D / D46E, E35D / D46V, E35D / M47I, E35D / M47L, E35D / M47V, E35D / V68M, E35D / L85M, E35D / L85Q, D46E / M47I, D46E / M47L, D46E / M47V, D46V / M47I, D46V / M47 Includes L, D46V / M47L, D46E / V68M, D46V / V68M, H18Y / M47I, H18Y / M47L, H18Y / M47V, M47I / V68M, M47L / V68M or M47V / V68M, M47I / E85M, M47L / E85M, M47V / E85M, M47I / E85Q, M47L / E85Q or M47V / E85Q.
[0090] In some embodiments, the Fc region is that of immunoglobulin G1 (IgG1).
[0091] Nucleic acid molecules encoding the variant CD80 fusion proteins of any of these embodiments are provided herein.
[0092] Provided herein is a vector comprising the nucleic acid of any of these embodiments, optionally wherein the vector is an expression vector.
[0093] Host cells comprising the nucleic acids or vectors of any of these aspects are provided herein.
[0094] Provided herein are methods for producing a variant CD80 fusion protein of any of such embodiments, comprising introducing a nucleic acid or vector of any of such embodiments into a host cell under conditions for expression of the protein in the cell, and optionally, the method further comprises isolating or purifying the protein comprising the variant CD80 fusion protein.
[0095] Pharmaceutical compositions comprising the variant CD80 fusion proteins of any of these embodiments are provided herein.
[0096] In some embodiments, the pharmaceutical composition comprises a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition is sterile.
[0097] Provided herein are articles of manufacture containing the pharmaceutical composition of any of these embodiments in a container, which in some embodiments is optionally a vial. In some embodiments, the container is hermetically sealed.
[0098] Provided herein are methods of modulating an immune response in a subject, comprising administering to the subject a pharmaceutical composition of such embodiments, or a multivalent CD80 polypeptide of any of such embodiments, In some embodiments, the method comprises treating a disease or condition in the subject, wherein modeling the immune response comprises treating a disease or condition in the subject.
[0099] Provided herein are methods of modulating an immune response in a subject comprising administering to the subject a multivalent CD80 polypeptide of any of such embodiments.
[0100] Provided herein are methods of modulating an immune response in a subject, comprising administering to the subject the engineered cells of any of these embodiments. In some embodiments, the engineered cells are autologous to the subject. In some embodiments, modulating the immune response treats a disease or condition in the subject. In some embodiments, the disease or condition is a tumor or cancer.
[0101] Provided herein are methods of treating cancer in a subject comprising administering to the subject a pharmaceutical composition of any of such embodiments, or a multivalent CD80 polypeptide of any of such embodiments.
[0102] Provided herein are methods of treating cancer in a subject comprising administering to the subject the pharmaceutical composition, multivalent CD80 polypeptide, or engineered cell of any of such embodiments.
[0103] Provided herein are variant CD80 fusion proteins containing a variant extracellular domain comprising one or more amino acid substitutions at one or more positions in the amino acid sequence set forth as amino acid residues 35-230 of the wild-type human CD80 extracellular domain, and an Fc region with effector activity, wherein the extracellular domain of the variant CD80 fusion protein specifically binds to the ectodomain of human CD28 and either does not bind to the ectodomain of human PD-L1, or binds to the ectodomain of PD-L1 with a binding affinity similar to that of the extracellular domain of wild-type human CD80 for the ectodomain of PD-L1.
[0104] In some embodiments, the extracellular domain of the variant CD80 fusion protein exhibits increased binding affinity with the ectodomain of human CTLA-4 compared to the binding affinity of the extracellular domain of wild-type CD80 to the ectodomain of human CTLA-4. In some of any such embodiments, the extracellular domain of the variant CD80 fusion protein exhibits increased binding affinity with the ectodomain of human CD28 compared to the binding affinity of the extracellular domain of wild-type CD80 to the ectodomain of human CD28. In some embodiments, the affinity is increased by about 1.2-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold or more, or by more than 1.2-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold or more.
[0105] In some embodiments, the variant CD80 fusion protein increases immunological activity in a mixed lymphocyte reaction, and optionally, the increased immunological activity comprises increased production of IFN-γ or interleukin-2 in a mixed lymphocyte reaction. In some embodiments, the variant CD80 fusion protein increases immunological activity as assessed in a T cell reporter assay incubated with antigen-presenting cells. In some embodiments, the variant CD80 fusion protein increases CD28-mediated costimulation of T lymphocytes. In some aspects, the increase is about or greater than 1.2-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold or more.
[0106] In some of any such embodiments, the wild-type human CD80 extracellular domain has the amino acid sequence set forth in SEQ ID NO:2, or a sequence having at least 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:2. In some embodiments, the wild-type human CD80 extracellular domain has the amino acid sequence set forth in SEQ ID NO:2.
[0107] In some embodiments, the one or more amino acid substitutions contain one or more amino acid substitutions selected from L70Q, K89R, D90G, D90K, A91G, F92Y, K93R, I118V, T120S, or T130A, or conservative amino acid substitutions thereof, with reference to the numbering set forth in SEQ ID NO: 2. In some examples, the one or more amino acid substitutions contain two or more amino acid substitutions selected from L70Q, K89R, D90G, D90K, A91G, F92Y, K93R, I118V, T120S, or T130A, with reference to the numbering set forth in SEQ ID NO: 2, or conservative amino acid substitutions thereof.
[0108] In some embodiments, the one or more amino acid substitutions are selected from the group consisting of amino acid modifications L70Q / K89R, L70Q / D90G, L70Q / D90K, L70Q / A91G, L70Q / F92Y, L70Q / K93R, L70Q / I118V, L70Q / T120S, L70Q / T130A, K89R / D90G, K89R / D90K, K89R / A91G, K89R / F92Y, K89R / K93R, K89R / I118V, K89R / T120S, K89R / T130A, D90G / A91G, D90G / F92 Contains Y, D90G / K93R, D90G / I118V, D90G / T120S, D90G / T130A, D90K / A91G, D90K / F92Y, D90K / K93R, D90K / I118V, D90K / T120S, D90K / T130A, F92Y / K93R, F92Y / I118V, F92Y / T120S, F92Y / T130A, K93R / I118V, K93R / T120S, K93R / T130A, I118V / T120S, I118V / T130A, or T120S / T130A.
[0109] In some embodiments, the one or more amino acid substitutions contain amino acid substitutions A91G / I118V / T120S / T130A. In some examples, the one or more amino acid substitutions contain amino acid substitutions S21P / L70Q / D90G / I118V / T120S / T130A. In some embodiments, the one or more amino acid substitutions contain amino acid substitutions E88D / K89R / D90K / A91G / F92Y / K93R. In some examples, the one or more amino acid substitutions contain one or more amino acid substitutions selected from among H18Y, A26E, E35D, D46E, D46V, M47I, M47L, M47V, V68M, A71D, A71G, L85M, L85Q, or D90G, or conservative amino acid substitutions thereof, with reference to the numbering of SEQ ID NO:2.
[0110] In some of any such embodiments, the one or more amino acid substitutions are, with reference to the numbering of SEQ ID NO:2, amino acid substitutions H18Y / E35D, E35D / D46E, E35D / D46V, E35D / M47I, E35D / M47L, E35D / M47V, E35D / V68M, E35D / L85M, E35D / L85Q, D46E / M47I, D46E / M47L, D46E / M47V, D46V / M47I, D46V / M47L , D46V / M47L, D46E / V68M, D46V / V68M, H18Y / M47I, H18Y / M47L, H18Y / M47V, M47I / V68M, M47L / V68M or M47V / V68M, M47I / E85M, M47L / E85M, M47V / E85M, M47I / E85Q, M47L / E85Q or M47V / E85Q. In some embodiments, the one or more amino acid modifications contain the amino acid substitutions E35D / M47L / V68M, E35D / M47V / V68M or E35D / M47I / L70M.
[0111] In some embodiments, the one or more amino acid modifications contain amino acid substitutions E35D / M47V / N48K / V68M / K89N, H18Y / A26E / E35D / M47L / V68M / A71G / D90G, E35D / D46E / M47V / V68M / D90G / K93E, or E35D / D46V / M47L / V68M / L85Q / E88D. In some aspects, the variant CD80 extracellular domain has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions. In some examples, the variant CD80 extracellular domain contains no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 amino acid substitutions. In some embodiments, the variant CD80 extracellular domain has at least or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the amino acid sequence set forth in SEQ ID NO:2.
[0112] In some of any such embodiments, the Fc region is that of immunoglobulin G1 (IgG1). In some examples, the Fc region contains the amino acid substitution C220S, where residues are numbered according to the EU index of Kabat. In some embodiments, the Fc region contains K447del, where residues are numbered according to the EU index of Kabat.
[0113] In some aspects, the Fc region has the amino acid sequence set forth in SEQ ID NO:1502, 1510, 1517, or 1527. In some embodiments, the one or more effector functions are selected from among antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity, programmed cell death, and cellular phagocytosis. In some of any such embodiments, the variant CD80 fusion protein is a dimer.
[0114] Nucleic acid molecules encoding the variant CD80 fusion proteins of any of these embodiments are provided herein.
[0115] Provided herein are vectors containing the nucleic acid of any of these embodiments. In some embodiments, the vector is an expression vector.
[0116] Provided herein are host cells containing the nucleic acid of any of such embodiments or the vector of any of such embodiments.
[0117] Provided herein are methods for producing a variant CD80 fusion protein of any of such embodiments, comprising introducing the nucleic acid or vector of any of such embodiments into a host cell under conditions for expressing the protein in the cell. In some embodiments, the method further comprises isolating or purifying a protein comprising the variant CD80 fusion protein.
[0118] Provided herein are pharmaceutical compositions containing the variant CD80 fusion protein of any of these embodiments. In some embodiments, the pharmaceutical composition contains a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition is sterile.
[0119] Provided herein is an article of manufacture containing the pharmaceutical composition of any of these embodiments in a container, optionally the container is a vial. In some embodiments, the container is hermetically sealed.
[0120] Provided herein are methods of modulating an immune response in a subject, comprising administering to the subject a pharmaceutical composition of any of such embodiments, or a variant CD80 fusion protein of any of such embodiments. In some aspects, modulating the immune response treats a disease or condition in the subject. In some examples, the disease or condition is a tumor or cancer.
[0121] Provided herein are methods of treating cancer in a subject comprising administering to the subject a pharmaceutical composition of any of such embodiments, or a variant CD80 fusion protein of any of such embodiments. [The present invention 1001] 1. A method of treating cancer in a subject, comprising: (a) administering to a subject having cancer a variant CD80 fusion protein that specifically binds to PD-L1, wherein the variant CD80 fusion protein comprises a variant CD80 extracellular domain or portion thereof comprising an IgV domain or a specific-binding fragment thereof, and a multimerization domain, wherein the variant CD80 extracellular domain or portion thereof comprises one or more amino acid modifications at one or more positions in the amino acid sequence of the extracellular domain or portion thereof of an unmodified CD80 polypeptide; and (b) administering to said subject a therapeutically effective amount of an anti-cancer agent. [The present invention 1002] 1001. The method of claim 1001, wherein the anticancer agent is an immune checkpoint inhibitor or a chemotherapeutic agent. [The present invention 1003] The method of claim 1001 or 1002, wherein the anti-cancer agent is a chemotherapeutic agent which is a platinum-based chemotherapeutic agent. [The present invention 1004] 1004. The method of claim 1003, wherein the chemotherapeutic agent is oxilaplatin. [The present invention 1005] 1001 or 1002, wherein the anti-cancer agent is an immune checkpoint inhibitor of CTLA-4, and optionally the checkpoint inhibitor is an anti-CTLA-4 antibody or an antigen-binding fragment thereof. [The present invention 1006] 1005. The method of claim 10, wherein said immune checkpoint inhibitor is ipilimumab or tremelimumab, or an antigen-binding fragment thereof. [The present invention 1007] The method of invention 1001 or invention 1002, wherein the anti-cancer agent is an immune checkpoint inhibitor of PD-1 (PD-1 inhibitor), and optionally, the PD-1 inhibitor is an anti-PD-1 antibody or an antigen-binding fragment thereof. [The present invention 1008] 1. A method of treating cancer in a subject, comprising: (a) administering to a subject having cancer a variant CD80 fusion protein that specifically binds to PD-L1, wherein the variant CD80 fusion protein comprises a variant CD80 extracellular domain or portion thereof comprising an IgV domain or a specific-binding fragment thereof, and a multimerization domain, wherein the variant CD80 extracellular domain or portion thereof comprises one or more amino acid modifications at one or more positions in the amino acid sequence of the extracellular domain or portion thereof of an unmodified CD80 polypeptide; and (b) administering to the subject a therapeutically effective amount of a PD-1 inhibitor, wherein the PD-1 inhibitor disrupts the interaction between programmed death-1 (PD-1) and its ligand. [The present invention 1009] 1008. The method of claim 10, wherein said ligand is programmed death-ligand-1 (PD-L1) or PD-L2. [The present invention 1010] 1009. The method of any one of claims 1007 to 1009, wherein the PD-1 inhibitor specifically binds to PD-1. [The present invention 1011] 1009. The method of any of claims 1007 to 1009, wherein the PD-1 inhibitor does not compete with the variant CD80 fusion protein for binding to PD-L1. [The present invention 1012] 1012. The method of any of claims 1007 to 1011, wherein the PD-1 inhibitor is a peptide, a protein, an antibody or an antigen-binding fragment thereof, or a small molecule. [The present invention 1013] The method of any of claims 1007 to 1012, wherein the PD-1 inhibitor is an antibody that specifically binds to PD-1 or an antigen-binding fragment thereof. [The present invention 1014] 1014. The method of any of claims 1007 to 1013, wherein the antibody or antigen-binding portion thereof is selected from nivolumab, pembrolizumab, MEDI0680 (AMP514), PDR001, cemiplimab (REGN2810), pidilizumab (CT011), or an antigen-binding portion thereof. [The present invention 1015] The method of any of claims 1007 to 1014, wherein the PD-1 inhibitor comprises the extracellular domain of PD-L2 that binds to PD-1, or a portion thereof, and an Fc region. [The present invention 1016] The method of claim 1015, wherein the PD-1 inhibitor is AMP-224. [The present invention 1017] The method of any of claims 1007 to 1016, wherein the initiation of administration of the PD-1 inhibitor is performed simultaneously or sequentially with the initiation of administration of the variant CD80 fusion protein. [The present invention 1018] The method of any of claims 1007 to 1017, wherein the initiation of administration of the PD-1 inhibitor occurs after the initiation of administration of the variant CD80 fusion protein. [The present invention 1019] 1019. The method of any of claims 1007 to 1018, wherein the initiation of administration of the anti-PD-1 antibody occurs after the administration of the final dose of the therapeutically effective amount of the variant CD80 fusion protein. [The present invention 1020] 1020. The method of any of claims 1001 to 1019, wherein the variant CD80 fusion protein is administered in a therapeutically effective amount, either as a single dose or in multiple doses of up to six. [The present invention 1021] 1. A method of treating cancer in a subject comprising administering to a subject having cancer a therapeutically effective amount of a variant CD80 fusion protein, wherein the variant CD80 fusion protein comprises a variant CD80 extracellular domain or portion thereof comprising an IgV domain or a specific-binding fragment thereof, and a multimerization domain, wherein the variant CD80 extracellular domain or portion thereof comprises one or more amino acid modifications at one or more positions in the amino acid sequence of the extracellular domain or portion thereof of an unmodified CD80 polypeptide, wherein the therapeutically effective amount of the variant CD80 fusion protein is administered as a single dose or in multiple doses of not more than six. [The present invention 1022] The method of any of claims 1001 to 1021, wherein the variant CD80 fusion protein is administered parenterally. [The present invention 1023] The method of any of claims 1001 to 1022, wherein the variant CD80 fusion protein is administered subcutaneously. [The present invention 1024] The method of any of claims 1001 to 1022, wherein the variant CD80 fusion protein is administered intravenously. [The present invention 1025] The method of any of claims 1001 to 1024, wherein the variant CD80 fusion protein is administered by injection, which is a bolus injection. [The present invention 1026] A therapeutically effective amount is about 0.5 mg / kg to about 140 mg / kg, about 0.5 mg / kg to about 30 mg / kg, about 0.5 mg / kg to about 20 mg / kg, about 0.5 mg / kg to about 18 mg / kg, about 0.5 mg / kg to about 12 mg / kg, about 0.5 mg / kg to about 10 mg / kg, about 0.5 mg / kg to about 6 mg / kg, about 0.5 mg / kg to about 3 mg / kg, about 1 mg / kg to about 40 mg / kg, about 1 mg / kg to about 30 mg / kg, about 1 mg / kg to about 20 mg / kg, inclusive of both end values. mg / kg~about 20mg / kg, about 1mg / kg~about 18mg / kg, about 1mg / kg~about 12mg / kg, about 1mg / kg~about 10mg / kg, about 1mg / kg~about 6mg / kg, about 1mg / kg~about 3mg / kg, about 3mg / kg~about 40mg / kg, about 3mg / kg~about 30mg / kg, about 3mg / kg~about 20mg / kg, about 3mg / kg~about 18mg / kg, about 3mg / kg~about 12mg / kg, about 3mg / kg~about 10mg / kg, about 3mg / kg kg~about 6mg / kg, about 6mg / kg~about 40mg / kg, about 6mg / kg~about 30mg / kg, about 6mg / kg~about 20mg / kg, about 6mg / kg~about 18mg / kg, about 6mg / kg~about 12mg / kg, about 6mg / k g ~ about 10mg / kg, about 10mg / kg - about 40mg / kg, about 10mg / kg - about 30mg / kg, about 10mg / kg - about 20mg / kg, about 10mg / kg - about 18mg / kg, about 10mg / kg - about 12mg / kg, about 1 Any of the methods of present inventions 1020 to 1025, wherein the dose is 2 mg / kg to about 40 mg / kg, about 12 mg / kg to about 30 mg / kg, about 12 mg / kg to about 20 mg / kg, about 12 mg / kg to about 18 mg / kg, about 18 mg / kg to about 40 mg / kg, about 18 mg / kg to about 30 mg / kg, about 18 mg / kg to about 20 mg / kg, about 20 mg / kg to about 40 mg / kg, about 20 mg / kg to about 30 mg / kg, or about 30 mg / kg to about 40 mg / kg. [The present invention 1027] 1027. The method of any of claims 1020 to 1026, wherein the therapeutically effective amount is from about 3.0 mg / kg to 18 mg / kg, inclusive. [The present invention 1028] The method of any of claims 1020 to 1026, wherein the therapeutically effective amount is from about 6 mg / kg to about 20 mg / kg, inclusive. [The present invention 1029] 1027. The method of any of claims 1020 to 1026, wherein the therapeutically effective amount is from about 1 mg / kg to about 10 mg / kg, inclusive. [The present invention 1030] The method of any of claims 1020 to 1026 and 1029, wherein the therapeutically effective amount is from about 2.0 mg / kg to about 6.0 mg / kg, inclusive. [The present invention 1031] The method of any of claims 1001 to 1030, wherein the variant CD80 fusion protein is administered intratumorally. [The present invention 1032] 1. A method of treating cancer in a subject comprising intratumorally administering to a subject having cancer a therapeutically effective amount of a variant CD80 fusion protein, wherein the variant CD80 fusion protein comprises a variant CD80 extracellular domain or a portion thereof comprising an IgV domain or a specific-binding fragment thereof, and a multimerization domain, wherein the variant CD80 extracellular domain or portion thereof comprises one or more amino acid modifications at one or more positions in the amino acid sequence of the extracellular domain or portion thereof of an unmodified CD80 polypeptide. [The present invention 1033] The method of claim 1032, wherein the variant CD80 fusion protein is administered in a therapeutically effective amount, either as a single dose or in multiple doses of up to six. [The present invention 1034] The method of any of claims 1019 to 1025 and 1031 to 1033, wherein the therapeutically effective amount is from about 0.1 mg / kg to about 1 mg / kg, inclusive. [This invention 1035] The method of any one of claims 1019 to 1025 and 1031 to 1034, wherein the therapeutically effective amount is about 0.2 mg / kg to about 0.6 mg / kg. [The present invention 1036] The method of any of claims 1020 to 1031 and 1033 to 1035, wherein the therapeutically effective amount is administered in a single dose. [This invention 1037] Any of the methods of claims 1020 to 1031 and 1033 to 1035, wherein the therapeutically effective amount is administered in six or fewer multiple doses, and the six or fewer multiple doses are two doses, three doses, four doses, five doses, or six doses. [The present invention 1038] The method of claim 1037, wherein the therapeutically effective amount is administered in four doses. [This invention 1039] The method of claim 1037, wherein the therapeutically effective amount is administered in three doses. [The present invention 1040] The method of claim 1037, wherein the therapeutically effective amount is administered in two doses. [The present invention 1041] The method of any of claims 1037 to 1040, wherein each of the six or fewer multiple doses is administered weekly, every two weeks, every three weeks, or every four weeks. [The present invention 1042] The method of any of claims 1037 to 1040, wherein the interval between each of the multiple doses is about one week. [This invention 1043] The method of any of claims 1020 to 1026 and 1036 to 1042, wherein the single dose or each of the six or fewer multiple doses is individually administered once a week (Q1W) in an amount of about 0.5 mg / kg to about 10 mg / kg. [This invention 1044] 1. A method of treating cancer in a subject, comprising administering to a subject having cancer a variant CD80 fusion protein once weekly (Q1W) in an amount of about 1.0 mg / kg to 10 mg / kg, inclusive, wherein the variant CD80 fusion protein comprises a variant CD80 extracellular domain or portion thereof comprising an IgV domain or a specific-binding fragment thereof, and a multimerization domain, wherein the variant CD80 extracellular domain or portion thereof comprises one or more amino acid modifications at one or more positions in the amino acid sequence of the extracellular domain or portion thereof of an unmodified CD80 polypeptide. [This invention 1045] The method of any one of claims 1043 to 1044, wherein the amount of variant CD80 fusion protein administered Q1W is from about 1 mg / kg to about 3 mg / kg. [The present invention 1046] 1046. The method of any of claims 1043 to 1045, wherein said administration is for a period of more than one week. [This invention 1047] The method of any of claims 1020 to 1026 and 1036 to 1041, wherein a single dose or up to six multiple doses are administered individually in an amount of from about 1.0 mg / kg to about 40 mg / kg once every three weeks (Q3W). [This invention 1048] 1. A method of treating cancer in a subject, comprising administering to a subject having cancer a variant CD80 fusion protein in an amount of about 1.0 mg / kg to 40 mg / kg, inclusive, once every three weeks (Q3W), wherein the variant CD80 fusion protein comprises a variant CD80 extracellular domain or portion thereof comprising an IgV domain or a specific-binding fragment thereof, and a multimerization domain, wherein the variant CD80 extracellular domain or portion thereof comprises one or more amino acid modifications at one or more positions in the amino acid sequence of the extracellular domain or portion thereof of an unmodified CD80 polypeptide. [This invention 1049] The method of claim 1046 or claim 1047, wherein the amount of variant CD80 fusion protein administered Q3W is from about 3.0 mg / kg to about 10 mg / kg. [The present invention 1050] 1049. The method of any of claims 1044 to 1046, 1048 and 1049, wherein the variant CD80 fusion protein is administered parenterally, optionally subcutaneously. [This invention 1051] The method of any of claims 1044-1046 and 1048-1050, wherein the variant CD80 fusion protein is administered by injection that is a bolus injection. [This invention 1052] 1020. The method of any one of claims 1020 to 1051, wherein the therapeutically effective amount is administered for a period of not more than 6 weeks. [This invention 1053] The method of any of claims 1020 to 1051, wherein the therapeutically effective amount is administered for a period of less than or equal to 4 weeks or about 4 weeks. [This invention 1054] 1020-1051. The method of any of claims 1020-1051, wherein each of the multiple doses is an equal amount. [This invention 1055] Any of the methods of claims 1001 to 1054, wherein prior to the administering step, a subject having a tumor comprising cells that are surface positive for PD-L1 or CD28 and / or surface negative for a cell surface ligand selected from CD80 or CD86 is selected for treatment. [This invention 1056] 1. A method of treating cancer in a subject comprising administering to a subject selected as having a tumor comprising cells that are surface negative for a cell surface ligand selected from CD80 or CD86 and / or surface positive for CD28 a variant CD80 fusion protein, wherein the variant CD80 fusion protein comprises a variant CD80 extracellular domain or portion thereof comprising an IgV domain or a specific-binding fragment thereof, and a multimerization domain, wherein the variant CD80 extracellular domain or portion thereof comprises one or more amino acid modifications at one or more positions in the amino acid sequence of the extracellular domain or portion thereof of an unmodified CD80 polypeptide. [This invention 1057] The method of claim 1055 or claim 1056, wherein the cells surface negative for CD80 or CD86 comprise tumor cells or antigen presenting cells. [This invention 1058] The method of claim 1055 or claim 1056, wherein the cells surface positive for CD28 comprise tumor-infiltrating T lymphocytes. [This invention 1059] The method of any of claims 1055 to 1058, wherein the subject is further selected as having a tumor comprising cells that are surface positive for PD-L1. [The present invention 1060] The method of claim 1055 or claim 1059, wherein the cells surface positive for PD-L1 are tumor cells or tumor-infiltrating immune cells, optionally tumor-infiltrating T lymphocytes. [This invention 1061] The method of any of claims 1055 to 1060, further comprising determining an immunoscore based on the presence or density of tumor-infiltrating T lymphocytes in the subject's tumor. [This invention 1062] The method of claim 1061, wherein the subject is selected for treatment if the immune score is low. [This invention 1063] 1063. The method of any of claims 1001 to 1062, wherein the variant CD80 fusion protein exhibits increased binding to at least one binding partner selected from among CD28, PD-L1, and CTLA-4 compared to a fusion protein comprising the extracellular domain of unmodified CD80 or a portion thereof for said at least one binding partner. [This invention 1064] The method of any of claims 1001 to 1063, wherein the variant CD80 fusion protein exhibits increased binding to PD-L1 compared to a fusion protein comprising the extracellular domain of unmodified CD80 or a portion thereof to PD-L1. [This invention 1065] 1065. The method of any of claims 1001 to 1064, wherein the variant CD80 fusion protein exhibits increased binding to at least one binding partner selected from among CD28 and CTLA-4 compared to a fusion protein comprising the extracellular domain of unmodified CD80 or a portion thereof for said at least one binding partner. [The present invention 1066] 1066. The method of any of claims 1063 to 1065, wherein the binding affinity is increased by more than 1.2-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 60-fold, 80-fold, 100-fold, 150-fold, 200-fold, 250-fold, 300-fold, 400-fold, or 450-fold compared to the binding affinity of unmodified CD80 for the ectodomain of the binding partner. [This invention 1067] The method of any of claims 1001 to 1066, wherein the one or more amino acid modifications are amino acid substitutions. [The present invention 1068] 8. The method of any of claims 1001 to 1067, wherein the one or more amino acid modifications comprise one or more amino acid substitutions selected from among H18Y, A26E, E35D, D46E, D46V, M47I, M47L, M47V, V68M, A71D, A71G, L85M, L85Q or D90G, with reference to the numbering of SEQ ID NO:2, or conservative amino acid substitutions thereof. [The present invention 1069] Any of the methods of claims 1001 to 1068, wherein the one or more amino acid modifications comprise two or more amino acid substitutions selected from among H18Y, A26E, E35D, D46E, D46V, M47I, M47L, M47V, V68M, A71D, A71G, L85M, L85Q or D90G, with reference to the numbering of SEQ ID NO:2, or conservative amino acid substitutions thereof. [The present invention 1070] The one or more amino acid modifications may be selected from the group consisting of amino acid substitutions H18Y / E35D, E35D / D46E, E35D / D46V, E35D / M47I, E35D / M47L, E35D / M47V, E35D / V68M, E35D / L85M, E35D / L85Q, D46E / M47I, D46E / M47L, D46E / M47V, D46V / M47I, D46V / M47L, D46V / M47V, and D46V / M47V. Any of methods 1001-1069 of the present invention, comprising: L, D46E / V68M, D46V / V68M, H18Y / M47I, H18Y / M47L, H18Y / M47V, M47I / V68M, M47L / V68M or M47V / V68M, M47I / E85M, M47L / E85M, M47V / E85M, M47I / E85Q, M47L / E85Q or M47V / E85Q. [This invention 1071] 1070. The method of any of claims 1001 to 1070, wherein the one or more amino acid modifications comprise the amino acid substitutions E35D / M47L / V68M, E35D / M47V / V68M, or E35D / M47I / L70M. [This invention 1072] 1072. The method of any of claims 1001 to 1071, wherein the one or more amino acid modifications comprise amino acid substitutions E35D / M47V / N48K / V68M / K89N. [This invention 1073] 1072. The method of any of claims 1001 to 1071, wherein the one or more amino acid modifications comprise amino acid substitutions H18Y / A26E / E35D / M47L / V68M / A71G / D90G. [This invention 1074] 1072. The method of any of claims 1001 to 1071, wherein the one or more amino acid modifications comprise amino acid substitutions E35D / D46E / M47V / V68M / D90G / K93E. [This invention 1075] 1072. The method of any of claims 1001 to 1071, wherein the one or more amino acid modifications comprise amino acid substitutions E35D / D46V / M47L / V68M / L85Q / E88D. [This invention 1076] The method of any of claims 1001 to 1075, wherein the unmodified CD80 is human CD80. [This invention 1077] Any of the methods of claims 1001 to 1076, wherein the extracellular domain of unmodified CD80 or a portion thereof (i) comprises the amino acid sequence set forth in SEQ ID NO:2, (ii) comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO:2; or (iii) is a portion of (i) or (ii) comprising an IgV domain or a specific binding fragment thereof. [This invention 1078] 1078. The method of claim 1077, wherein the extracellular domain of unmodified CD80 or a portion thereof is an extracellular domain portion that is or comprises an IgV domain or a specific binding fragment thereof. [This invention 1079] 1078. The method of claim 1078, wherein the extracellular domain portion of unmodified CD80 comprises an IgV domain but does not comprise an IgC domain or a portion of an IgC domain. [The present invention 1080] The method of claim 1078 or claim 1079, wherein the extracellular domain portion of unmodified CD80 is set forth as the sequence of amino acids 35 to 135 of SEQ ID NO:2 (SEQ ID NO:76) or 35 to 141 of SEQ ID NO:2 (SEQ ID NO:150). [This invention 1081] The method of any of claims 1001 to 1080, wherein the variant CD80 extracellular domain or a portion thereof is an extracellular domain portion that does not include an IgC domain or a portion of an IgC domain. [This invention 1082] 10. The method of any of claims 1001 to 1081, wherein the variant CD80 extracellular domain comprises the sequence of amino acids 35 to 135 of SEQ ID NO:2 (SEQ ID NO:76) or 35 to 141 of SEQ ID NO:2 (SEQ ID NO:150), wherein the variant CD80 extracellular domain contains one or more amino acid substitutions. [This invention 1083] 10. The method of any of claims 1001 to 1081, wherein the variant CD80 extracellular domain is the sequence of amino acids 35 to 135 of SEQ ID NO:2 (SEQ ID NO:76) or 35 to 141 of SEQ ID NO:2 (SEQ ID NO:150), containing one or more amino acid substitutions. [This invention 1084] 1084. The method of any of claims 1001 to 1083, wherein the variant CD80 extracellular domain has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acid modifications, optionally wherein the amino acid modifications are amino acid substitutions. [This invention 1085] 10. The method of any of claims 1001 to 1084, wherein the variant CD80 extracellular domain or portion thereof comprises no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13 amino acid modifications, and optionally, the amino acid modifications are amino acid substitutions. [This invention 1086] 10. The method of any of claims 1001 to 1085, wherein the amino acid sequence of the variant CD80 extracellular domain has at least, or at least about, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the sequence of amino acids 35 to 135 of SEQ ID NO:2 (SEQ ID NO:76) or 35 to 141 of SEQ ID NO:2 (SEQ ID NO:150). [This invention 1087] The method of any one of claims 1001 to 1086, wherein the multimerization domain is an Fc region. [This invention 1088] 1087. The method of claim 1087, wherein the Fc region is that of an immunoglobulin G1 (IgG1) or immunoglobulin G2 (IgG2) protein. [This invention 1089] The method of claim 1087 or claim 1088, wherein the Fc region exhibits one or more effector functions. [The present invention 1090] The method of invention 1087 or invention 1088, wherein the Fc region is a variant Fc region comprising one or more amino acid substitutions in a wild-type Fc region, said variant Fc region exhibiting one or more reduced effector functions compared to the wild-type Fc region, and optionally the wild-type human Fc is that of human IgG1. [This invention 1091] 1090. The method of claim 1090, wherein the Fc region comprises the amino acid substitution N297G, this residue being numbered according to the EU index of Kabat. [This invention 1092] 1090. The method of claim 1090, wherein the Fc region comprises the amino acid substitutions R292C / N297G / V302C, said residues being numbered according to the EU index of Kabat. [This invention 1093] 1090. The method of claim 1090, wherein the Fc region comprises the amino acid substitutions L234A / L235E / G237A, said residues being numbered according to the EU index of Kabat. [This invention 1094] 1093. The method of any of claims 1087 to 1093, wherein the Fc region further comprises the amino acid substitution C220S, this residue being numbered according to the EU index of Kabat. [This invention 1095] 10. The method of any of claims 1087 to 1094, wherein the Fc region comprises K447del, this residue being numbered according to the EU index of Kabat. [This invention 1096] The method of any of claims 1001 to 1095, wherein the variant CD80 fusion protein antagonizes the activity of CTLA-4. [This invention 1097] The method of any of claims 1001 to 1096, wherein the variant CD80 fusion protein blocks PD-1 / PD-L1 interaction. [This invention 1098] The method of any of claims 1001 to 1097, wherein the variant CD80 fusion protein binds to CD28 and mediates CD28 agonism. [This invention 1099] The method of claim 1098, wherein CD28 agonism is PD-L1 dependent. [The present invention 1100] The method of any one of claims 1001 to 1099, wherein the subject is a human. [The present invention 1101] (a) a variant CD80 fusion protein that specifically binds to PD-L1, the variant CD80 fusion protein comprising a variant CD80 extracellular domain or portion thereof comprising an IgV domain or a specific-binding fragment thereof, and a multimerization domain, wherein the variant CD80 extracellular domain or portion thereof comprises one or more amino acid modifications at one or more positions within the amino acid sequence of the extracellular domain or portion thereof of an unmodified CD80 polypeptide; and (b) Anticancer drugs Includes a kit. [The present invention 1102] The kit of the present invention 1101, wherein the anticancer drug is an immune checkpoint inhibitor or a chemotherapeutic agent. [The present invention 1103] The kit of the present invention 1101 or 1102, wherein the anticancer agent is a chemotherapeutic agent that is a platinum-based chemotherapeutic agent. [The present invention 1104] The kit of the present invention 1103, wherein the chemotherapeutic agent is oxilaplatin. [This invention 1105] The kit of invention 1101 or invention 1102, wherein the anti-cancer agent is an immune checkpoint inhibitor of CTLA-4, and optionally the checkpoint inhibitor is an anti-CTLA-4 antibody or an antigen-binding fragment thereof. [The present invention 1106] 1105. The kit of the present invention, wherein said immune checkpoint inhibitor is ipilimumab or tremelimumab, or an antigen-binding fragment thereof. [This invention 1107] The kit of invention 1101 or invention 1102, wherein the anticancer agent is an immune checkpoint inhibitor of PD-1 (PD-1 inhibitor), and optionally, the PD-1 inhibitor is an anti-PD-1 antibody or an antigen-binding fragment thereof. [This invention 1108] (a) a variant CD80 fusion protein that specifically binds to PD-L1, the variant CD80 fusion protein comprising a variant CD80 extracellular domain or portion thereof comprising an IgV domain or a specific-binding fragment thereof, and a multimerization domain, wherein the variant CD80 extracellular domain or portion thereof comprises one or more amino acid modifications at one or more positions within the amino acid sequence of the extracellular domain or portion thereof of an unmodified CD80 polypeptide; and (b) Programmed death-1 (PD-1) inhibitors that disrupt the interaction between PD-1 and its ligands Includes a kit. [This invention 1109] 1108. The kit of claim 1108, wherein said ligand is programmed death-ligand-1 (PD-L1) or PD-L2. [The present invention 1110] The kit of any one of 1107 to 1109, wherein the PD-1 inhibitor specifically binds to PD-1. [The present invention 1111] The kit of any of claims 1107 to 1110, wherein the PD-1 inhibitor does not compete with the variant CD80 fusion protein for binding to PD-L1. [The present invention 1112] The kit of claim 1107 or 1108, wherein the PD-1 inhibitor is a peptide, a protein, an antibody or an antigen-binding fragment thereof, or a small molecule. [The present invention 1113] The kit of any one of 1107 to 1112, wherein the PD-1 inhibitor is an antibody that specifically binds to PD-1 or an antigen-binding fragment thereof. [This invention 1114] The kit of invention 1107 or invention 1113, wherein the antibody or antigen-binding portion thereof is selected from nivolumab, pembrolizumab, MEDI0680 (AMP514), PDR001, cemiplimab (REGN2810), pidilizumab (CT011), or an antigen-binding portion thereof. [This invention 1115] The kit of any one of 1107 to 1112, wherein the PD-1 inhibitor comprises the extracellular domain of PD-L2 that binds to PD-1 or a part thereof, and an Fc region. [The present invention 1116] The kit of the present invention 1115, wherein the PD-1 inhibitor is AMP-224. [This invention 1117] 1107. The kit of any of claims 1107 to 1116, wherein the variant CD80 fusion protein exhibits increased binding to at least one binding partner selected from among CD28, PD-L1, and CTLA-4 compared to a fusion protein comprising the extracellular domain of unmodified CD80 or a portion thereof for said at least one binding partner. [This invention 1118] 1107. The kit of any of claims 1107 to 1117, wherein the variant CD80 fusion protein exhibits increased binding to PD-L1 compared to a fusion protein comprising the extracellular domain of unmodified CD80 to PD-L1 or a portion thereof. [This invention 1119] 1107. The kit of any of claims 1107 to 1118, wherein the variant CD80 fusion protein exhibits increased binding to at least one binding partner selected from among CD28 and CTLA-4 compared to a fusion protein comprising the extracellular domain of unmodified CD80 or a portion thereof for said at least one binding partner. [The present invention 1120] 1107-1119. The kit of any of claims 1107-1119, wherein the binding affinity is increased by more than 1.2-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 60-fold, 80-fold, 100-fold, 150-fold, 200-fold, 250-fold, 300-fold, 400-fold, or 450-fold compared to the binding affinity of unmodified CD80 for the ectodomain of the binding partner. [This invention 1121] The kit of any one of claims 1107 to 1120, wherein the one or more amino acid modifications are amino acid substitutions. [This invention 1122] The kit of any of claims 1107 to 1121, wherein the one or more amino acid modifications include one or more amino acid substitutions selected from H18Y, A26E, E35D, D46E, D46V, M47I, M47L, M47V, V68M, A71D, A71G, L85M, L85Q or D90G, or conservative amino acid substitutions thereof, with reference to the numbering of SEQ ID NO:2. [This invention 1123] The kit of any of claims 1107 to 1122, wherein the one or more amino acid modifications include two or more amino acid substitutions selected from H18Y, A26E, E35D, D46E, D46V, M47I, M47L, M47V, V68M, A71D, A71G, L85M, L85Q or D90G, or conservative amino acid substitutions thereof, with reference to the numbering of SEQ ID NO:2. [This invention 1124] The one or more amino acid modifications may be selected from the group consisting of amino acid substitutions H18Y / E35D, E35D / D46E, E35D / D46V, E35D / M47I, E35D / M47L, E35D / M47V, E35D / V68M, E35D / L85M, E35D / L85Q, D46E / M47I, D46E / M47L, D46E / M47V, D46V / M47I, D46V / M47L, D46V / M47L , D46E / V68M, D46V / V68M, H18Y / M47I, H18Y / M47L, H18Y / M47V, M47I / V68M, M47L / V68M or M47V / V68M, M47I / E85M, M47L / E85M, M47V / E85M, M47I / E85Q, M47L / E85Q or M47V / E85Q. [Invention 1125] The kit of any of claims 1107 to 1124, wherein the one or more amino acid modifications comprise the amino acid substitutions E35D / M47L / V68M, E35D / M47V / V68M or E35D / M47I / L70M. [The present invention 1126] The kit of any of claims 1107 to 1125, wherein the one or more amino acid modifications comprise amino acid substitutions E35D / M47V / N48K / V68M / K89N, H18Y / A26E / E35D / M47L / V68M / A71G / D90G, E35D / D46E / M47V / V68M / D90G / K93E or E35D / D46V / M47L / V68M / L85Q / E88D. [This invention 1127] The kit of any one of claims 1107 to 1126, wherein the unmodified CD80 is human CD80. [This invention 1128] Any of the kits of the present inventions 1107 to 1127, wherein the extracellular domain of unmodified CD80 or a portion thereof (i) comprises the amino acid sequence set forth in SEQ ID NO:2, (ii) comprises an amino acid sequence having at least 95% sequence identity with SEQ ID NO:2; or (iii) is a portion of (i) or (ii) comprising an IgV domain or a specific binding fragment thereof. [This invention 1129] 1128. The kit of the present invention, wherein the extracellular domain of unmodified CD80 or a portion thereof is an extracellular domain portion that is or comprises an IgV domain or a specific binding fragment thereof. [The present invention 1130] 1129. The kit of the present invention, wherein the portion of the extracellular domain of unmodified CD80 comprises an IgV domain but does not comprise an IgC domain or a portion of an IgC domain. [This invention 1131] The kit of invention 1129 or invention 1130, wherein the extracellular domain portion of unmodified CD80 is set forth as the sequence of amino acids 35 to 135 of SEQ ID NO:2 (SEQ ID NO:76) or 35 to 141 of SEQ ID NO:2 (SEQ ID NO:150). [This invention 1132] The kit of any one of claims 1101 to 1131, wherein the variant CD80 extracellular domain or a portion thereof is an extracellular domain portion that does not include an IgC domain or a portion of an IgC domain. [This invention 1133] The kit of any of claims 1101 to 1132, wherein the variant CD80 extracellular domain comprises the sequence of amino acids 35 to 135 of SEQ ID NO:2 (SEQ ID NO:76) or 35 to 141 of SEQ ID NO:2 (SEQ ID NO:150), containing one or more amino acid substitutions. [This invention 1134] The kit of any of claims 1101 to 1133, wherein the variant CD80 extracellular domain is the sequence of amino acids 35 to 135 of SEQ ID NO:2 (SEQ ID NO:76) or 35 to 141 of SEQ ID NO:2 (SEQ ID NO:150), containing one or more amino acid substitutions. [This invention 1135] The kit of any of claims 1101 to 1134, wherein the variant CD80 extracellular domain has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acid modifications, optionally wherein the amino acid modifications are amino acid substitutions. [This invention 1136] 6. The kit of any one of claims 1101 to 1135, wherein the variant CD80 extracellular domain comprises no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13 amino acid modifications, and optionally the amino acid modifications are amino acid substitutions. [This invention 1137] 11. The kit of any of claims 1101-1136, wherein the variant CD80 extracellular domain has at least, or at least about, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the sequence of amino acids 35-135 of SEQ ID NO:2 (SEQ ID NO:76) or 35-141 of SEQ ID NO:2 (SEQ ID NO:150). [This invention 1138] The kit of any one of 1101 to 1137, wherein the multimerization domain is an Fc region. [This invention 1139] 1138. The kit of the present invention, wherein the Fc region is that of an immunoglobulin G1 (IgG1) or immunoglobulin G2 (IgG2) protein. [This invention 1140] The kit of invention 1138 or invention 1139, wherein the Fc region exhibits one or more effector functions. [This invention 1141] The kit of any of claims 1138 to 1140, wherein the Fc region is a variant Fc region comprising one or more amino acid substitutions in a wild-type Fc region, and the variant Fc region exhibits one or more reduced effector functions compared to the wild-type Fc region, and optionally the wild-type human Fc is that of human IgG1. [This invention 1142] An article of manufacture comprising a kit according to any one of inventions 1101 to 1141 and instructions for use. [This invention 1143] The article of manufacture of claim 1142, wherein said instructions provide information for administration of a variant CD80 Fc fusion protein or a PD-1 inhibitor according to the method of any of claims 1001-1020, 1022-1031 and 1034-1100. [This invention 1144] 1. A multivalent CD80 polypeptide comprising two copies of a fusion protein, said fusion protein comprising: (1) at least two variant CD80 extracellular domains or portions thereof (vCD80s) comprising an IgV domain or a specific binding fragment thereof, wherein the vCD80s comprise one or more amino acid modifications at one or more positions in the amino acid sequence of the extracellular domain or portions thereof of an unmodified CD80 polypeptide; and (2) Fc region polypeptide. [Invention 1145] 1144. A multivalent CD80 polypeptide of the present invention, wherein said polypeptide is tetravalent. [Invention 1146] 1144. The multivalent CD80 polypeptide of claim 1145, wherein said fusion protein comprises the structure: (vCD80)-linker-Fc-linker-(vCD80). [This invention 1147] 1144. The multivalent CD80 polypeptide of claim 1145, wherein said fusion protein comprises the structure: (vCD80)-linker-(vCD80)-linker-Fc. [This invention 1148] 1148. The multivalent CD80 polypeptide of any of claims 1144 to 1147, wherein vCD80 exhibits increased binding to at least one binding partner selected from among CD28, PD-L1, and CTLA-4, compared to the extracellular domain of unmodified CD80 or a portion thereof to said at least one binding partner. [This invention 1149] 1149. The multivalent CD80 polypeptide of any of claims 1144 to 1148, wherein vCD80 exhibits increased binding to PD-L1 compared to the extracellular domain of unmodified CD80 or a portion thereof to PD-L1. [This invention 1150] 1148 or 1149, wherein the affinity is increased by more than 1.2-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 60-fold, 80-fold, 100-fold, 150-fold, 200-fold, 250-fold, 300-fold, 400-fold, or 450-fold compared to the binding affinity of unmodified CD80 for the ectodomain of the binding partner. [This invention 1151] 1144-1150. The multivalent CD80 polypeptide of any of claims 1144-1150, wherein the one or more amino acid modifications are amino acid substitutions. [This invention 1152] 1144-1151. The multivalent CD80 polypeptide of any of claims 1144 to 1151, wherein the one or more amino acid modifications comprise one or more amino acid substitutions selected from among H18Y, A26E, E35D, D46E, D46V, M47I, M47L, M47V, V68M, A71D, A71G, L85M, L85Q or D90G, with reference to the numbering of SEQ ID NO:2, or conservative amino acid substitutions thereof. [This invention 1153] 1144 to 1152. The multivalent CD80 polypeptide of any of claims 1144 to 1152, wherein the one or more amino acid modifications comprise two or more amino acid substitutions selected from among H18Y, A26E, E35D, D46E, D46V, M47I, M47L, M47V, V68M, A71D, A71G, L85M, L85Q, or D90G, with reference to the numbering of SEQ ID NO:2, or conservative amino acid substitutions thereof. [This invention 1154] The one or more amino acid modifications may be selected from the group consisting of amino acid substitutions H18Y / E35D, E35D / D46E, E35D / D46V, E35D / M47I, E35D / M47L, E35D / M47V, E35D / V68M, E35D / L85M, E35D / L85Q, D46E / M47I, D46E / M47L, D46E / M47V, D46V / M47I, D46V / M47L ... 1144 to 1153. The multivalent CD80 polypeptide of any of claims 1144 to 1153, comprising E / V68M, D46V / V68M, H18Y / M47I, H18Y / M47L, H18Y / M47V, M47I / V68M, M47L / V68M or M47V / V68M, M47I / E85M, M47L / E85M, M47V / E85M, M47I / E85Q, M47L / E85Q or M47V / E85Q. [This invention 1155] 1155. The multivalent CD80 polypeptide of any of claims 1144 to 1154, wherein the one or more amino acid modifications comprise the amino acid substitutions E35D / M47L / V68M, E35D / M47V / V68M or E35D / M47I / L70M. [Invention 1156] 1144-1155. The multivalent CD80 polypeptide of any of claims 1144-1155, wherein the one or more amino acid modifications comprise the amino acid substitutions E35D / M47V / N48K / V68M / K89N, H18Y / A26E / E35D / M47L / V68M / A71G / D90G, E35D / D46E / M47V / V68M / D90G / K93E or E35D / D46V / M47L / V68M / L85Q / E88D. [This invention 1157] The multivalent CD80 polypeptide of any of claims 1144 to 1156, wherein the unmodified CD80 is human CD80. [This invention 1158] The multivalent CD80 polypeptide of any of claims 1144 to 1157, wherein the extracellular domain of unmodified CD80, or a portion thereof, (i) comprises the amino acid sequence set forth in SEQ ID NO:2, or (ii) comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO:2; or (iii) is a portion of (i) or (ii) comprising an IgV domain or a specific binding fragment thereof. [This invention 1159] The multivalent CD80 polypeptide of the invention 1158, wherein the extracellular domain of unmodified CD80 or a portion thereof is an extracellular domain portion that is or comprises an IgV domain or a specific binding fragment thereof. [The present invention 1160] 1159. A multivalent CD80 polypeptide of the invention, wherein the extracellular domain portion of unmodified CD80 comprises an IgV domain but does not comprise an IgC domain or a portion of an IgC domain. [This invention 1161] The multivalent CD80 polypeptide of the present invention 1159 or 1160, wherein the extracellular domain portion of unmodified CD80 is set forth as amino acids 35 to 135 of SEQ ID NO:2 (SEQ ID NO:76) or 35 to 141 of SEQ ID NO:2 (SEQ ID NO:150). [This invention 1162] The multivalent CD80 polypeptide of any of claims 1144 to 1161, wherein vCD80 is an extracellular domain portion that does not include an IgC domain or a portion of an IgC domain. [This invention 1163] 1144-1162. The multivalent CD80 polypeptide of any of claims 1144-1162, wherein vCD80 comprises the sequence of amino acids 35 to 135 of SEQ ID NO:2 (SEQ ID NO:76) or 35 to 141 of SEQ ID NO:2 (SEQ ID NO:150), wherein the vCD80 contains one or more amino acid substitutions. [This invention 1164] 1144-1163. The multivalent CD80 polypeptide of any of claims 1144-1163, wherein vCD80 has the sequence of amino acids 35 to 135 of SEQ ID NO:2 (SEQ ID NO:76) or 35 to 141 of SEQ ID NO:2 (SEQ ID NO:150), wherein the vCD80 contains one or more amino acid substitutions. [Invention 1165] 1144. The multivalent CD80 polypeptide of any of claims 1144 to 1164, wherein vCD80 comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acid modifications, optionally wherein the amino acid modifications are amino acid substitutions. [Invention 1166] 1166. The multivalent CD80 polypeptide of any of claims 1144 to 1165, wherein vCD80 comprises no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13 amino acid modifications, optionally wherein the amino acid modifications are amino acid substitutions. [This invention 1167] 11. The multivalent CD80 polypeptide of any of claims 1144 to 1166, wherein vCD80 has at least, or at least about, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the sequence of amino acids 35 to 135 of SEQ ID NO:2 (SEQ ID NO:76) or 35 to 141 of SEQ ID NO:2 (SEQ ID NO:150). [Invention 1168] 1144 to 1167. The multivalent CD80 polypeptide of any of claims 1144 to 1167, wherein the Fc region is that of an immunoglobulin G1 (IgG1) or immunoglobulin G2 (IgG2) protein. [This invention 1169] 1169. The multivalent CD80 polypeptide of any of claims 1144 to 1168, wherein the Fc region exhibits one or more effector functions. [This invention 1170] 1144 to 1168. The multivalent CD80 polypeptide of any of claims 1144 to 1168, wherein the Fc region is a variant Fc region comprising one or more amino acid substitutions in a wild-type Fc region, and wherein the variant Fc region exhibits one or more reduced effector functions compared to the wild-type Fc region, and optionally the wild-type human Fc is that of human IgG1. [This invention 1171] The multivalent CD80 polypeptide of any of claims 1144 to 1170, wherein each vCD80 is the same. [This invention 1172] 1144 to 1171. The multivalent CD80 polypeptide of any one of claims 1144 to 1171, wherein the linker is a flexible linker. [This invention 1173] 1144 to 1172. The multivalent CD80 polypeptide of any one of claims 1144 to 1172, wherein the linker is a peptide linker. [This invention 1174] 1173. A multivalent CD80 polypeptide of the invention, wherein the linker is GSGGGGS (SEQ ID NO: 1522) or 3xGGGGS (SEQ ID NO: 1504). [This invention 1175] A nucleic acid molecule encoding a fusion protein of any one of the multivalent CD80 polypeptides of the present invention 1144 to 1174. [Invention 1176] A vector comprising the nucleic acid of the present invention. [This invention 1177] 1176. A vector of the present invention which is an expression vector. [This invention 1178] A host cell comprising the nucleic acid of the present invention 1175 or the vector of the present invention 1176 or 1177. [This invention 1179] A method for producing a multivalent CD80 polypeptide of any of the present inventions 1144 to 1174, comprising the step of introducing the nucleic acid of the present invention 1175 or the vector of the present invention 1176 or 1177 into a host cell under conditions that allow the protein to be expressed in the cell. [This invention 1180] 1179. The method of claim 1179, further comprising the step of isolating or purifying a protein comprising said multivalent CD80 polypeptide. [This invention 1181] An engineered cell comprising a multivalent CD80 polypeptide according to any one of claims 1144 to 1174. [This invention 1182] 1181. The engineered cell of claim 1181, wherein said multivalent CD80 polypeptide comprises a fusion protein encoded by a nucleic acid molecule operably linked to a sequence encoding a secretory signal peptide. [This invention 1183] 1181 or 1182, wherein said multivalent CD80 polypeptide, when expressed, is capable of being secreted from the engineered cell. [This invention 1184] An engineered cell comprising a nucleic acid molecule of the invention 1175 or a vector of the invention 1176 or 1177. [This invention 1185] 1184. The engineered cell of claim 1184, wherein said nucleic acid molecule comprises a sequence encoding a secretory signal peptide operably linked to a sequence encoding said fusion protein. [Invention 1186] 1184 or 1185, wherein the nucleic acid molecule encodes a fusion protein of a multivalent CD80 polypeptide, and the multivalent CD80 polypeptide, when expressed, is capable of being secreted from the engineered cell. [This invention 1187] The engineered cell of any of claims 1182 and 1184 to 1186, wherein the signal peptide is a non-naturally occurring signal sequence. [This invention 1188] The engineered cell of any of claims 1182 and 1184 to 1186, wherein the signal peptide is an IgGκ signal peptide, an IL-2 signal peptide, a CD33 signal peptide, or a VH signal peptide. [This invention 1189] 1189. The engineered cell of any of claims 1182 to 1188, wherein said nucleic acid molecule further comprises at least one promoter operably linked to control expression of said fusion protein. [This invention 1190] 1189. The engineered cell of claim 1189, wherein said promoter is a constitutively active promoter. [This invention 1191] 1189. The engineered cell of claim 1189, wherein said promoter is an inducible promoter. [This invention 1192] 1189 or 1191, wherein the promoter is responsive to an element that responds to T cell activation signaling, and optionally the promoter comprises a binding site for NFAT or a binding site for NF-κB. [This invention 1193] The engineered cell of any of claims 1181 to 1192, which is an immune cell, optionally an antigen-presenting cell (APC) or a lymphocyte. [This invention 1194] 4. The engineered cell of any of claims 1181 to 1193, wherein said cell is a lymphocyte that is a T cell, a B cell or a NK cell, and optionally said lymphocyte is a T cell that is CD4+ or CD8+. [This invention 1195] The engineered cell of any of claims 1181 to 1193, wherein said cell is a primary cell obtained from a subject, and optionally, the subject is a human subject. [Invention 1196] 1181-1195. The engineered cell of any of claims 1181-1195, further comprising a chimeric antigen receptor (CAR) or an engineered T cell receptor (TCR). [This invention 1197] A pharmaceutical composition comprising a multivalent CD80 polypeptide according to any one of claims 1144 to 1174 of the present invention. [This invention 1198] A pharmaceutical composition comprising the engineered cells of any of the present inventions 1181 to 1196. [This invention 1199] (i) a variant extracellular domain comprising one or more amino acid substitutions at one or more positions in the amino acid sequence set forth as amino acid residues 35-230 of the wild-type human CD80 extracellular domain corresponding to the residues set forth in SEQ ID NO:1; and (ii) an Fc region having effector activity wherein the extracellular domain of the variant CD80 fusion protein specifically binds to the ectodomain of human CD28 and does not bind to the ectodomain of human PD-L1, or binds to the ectodomain of PD-L1 with a binding affinity similar to that of the extracellular domain of wild-type human CD80 for the ectodomain of PD-L1. [The present invention 1200] A variant CD80 fusion protein of the present invention, wherein the extracellular domain of the variant CD80 fusion protein exhibits increased binding affinity to the ectodomain of human CTLA-4 compared to the binding affinity of the extracellular domain of wild-type CD80 to the ectodomain of human CTLA-4. [The present invention 1201] A variant CD80 fusion protein of the invention 1199 or the invention 1200, wherein the extracellular domain of the variant CD80 fusion protein exhibits increased binding affinity to the ectodomain of human CD28 compared to the binding affinity of the extracellular domain of wild-type CD80 to the ectodomain of human CD28. [This invention 1202] A variant CD80 fusion protein of any of claims 1199 to 1201, wherein the wild-type human CD80 extracellular domain has the amino acid sequence set forth in SEQ ID NO:2, or a sequence having at least 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:2. [This invention 1203] 12. The variant CD80 fusion protein of any of claims 1199 to 1202, wherein said one or more amino acid substitutions comprise one or more amino acid substitutions selected from L70Q, K89R, D90G, D90K, A91G, F92Y, K93R, I118V, T120S, or T130A, with reference to the numbering set forth in SEQ ID NO:2, or conservative amino acid substitutions thereof. [The present invention 1204] The one or more amino acid substitutions are selected from the group consisting of amino acid modifications L70Q / K89R, L70Q / D90G, L70Q / D90K, L70Q / A91G, L70Q / F92Y, L70Q / K93R, L70Q / I118V, L70Q / T120S, L70Q / T130A, K89R / D90G, K89R / D90K, K89R / A91G, K89R / F92Y, K89R / K93R, K89R / I118V, K89R / T120S, K89R / T130A, D90G / A91G, D90G / F92Y, D90G / K93R, D90G / I118
[0033] The variant CD80 fusion protein of any of claims 1199 to 1203, comprising: V, D90G / T120S, D90G / T130A, D90K / A91G, D90K / F92Y, D90K / K93R, D90K / I118V, D90K / T120S, D90K / T130A, F92Y / K93R, F92Y / I118V, F92Y / T120S, F92Y / T130A, K93R / I118V, K93R / T120S, K93R / T130A, I118V / T120S, I118V / T130A or T120S / T130A. [This invention 1205] 12. The variant CD80 fusion protein of any of claims 1199 to 1202, wherein said one or more amino acid substitutions comprise one or more amino acid substitutions selected from among H18Y, A26E, E35D, D46E, D46V, M47I, M47L, M47V, V68M, A71D, A71G, L85M, L85Q or D90G, with reference to the numbering of SEQ ID NO:2, or conservative amino acid substitutions thereof. [This invention 1206] The one or more amino acid substitutions are selected from the group consisting of amino acid substitutions H18Y / E35D, E35D / D46E, E35D / D46V, E35D / M47I, E35D / M47L, E35D / M47V, E35D / V68M, E35D / L85M, E35D / L85Q, D46E / M47I, D46E / M47L, D46E / M47V, D46V / M47I, D46V / M47L, D46V / M47L, D46E / V68M , D46V / V68M, H18Y / M47I, H18Y / M47L, H18Y / M47V, M47I / V68M, M47L / V68M or M47V / V68M, M47I / E85M, M47L / E85M, M47V / E85M, M47I / E85Q, M47L / E85Q or M47V / E85Q. [This invention 1207] 1199 to 1206, a variant CD80 fusion protein of any of claims 1199 to 1206, wherein the Fc region is that of immunoglobulin G1 (IgG1). [This invention 1208] A nucleic acid molecule encoding any one of the variant CD80 fusion proteins of the present invention 1199 to 1207. [This invention 1209] A vector comprising a nucleic acid of the invention 1208, which is optionally an expression vector. [The present invention 1210] A host cell comprising a nucleic acid of the invention 1208 or a vector of the invention 1209. [The present invention 1211] 12. A method for producing a variant CD80 fusion protein of any of claims 1199 to 1210, comprising introducing a nucleic acid of claim 1208 or a vector of claim 1209 into a host cell under conditions for expression of the protein in said cell, and optionally further comprising isolating or purifying a protein comprising the variant CD80 fusion protein. [The present invention 1212] A pharmaceutical composition comprising any one of the variant CD80 fusion proteins of the present invention. [This invention 1213] The pharmaceutical composition of any of claims 1197, 1198, and 1212, comprising a pharmaceutically acceptable excipient. [This invention 1214] Any of the pharmaceutical compositions of inventions 1197, 1198, 1212, and 1213, which are sterile. [This invention 1215] An article of manufacture comprising any one of the pharmaceutical compositions of 1197, 1198, and 1212-1214 in a container, optionally the container being a vial. [This invention 1216] 1215. An article of manufacture of claim 1215, wherein the container is sealed. [This invention 1217] A method for regulating an immune response in a subject, comprising administering to the subject any one of the pharmaceutical compositions of the present inventions 1197, 1198, and 1212 to 1214. [This invention 1218] A method for regulating an immune response in a subject, comprising the step of administering to the subject a multivalent CD80 polypeptide according to any one of claims 1144 to 1174 of the present invention. [This invention 1219] A method for modulating an immune response in a subject, comprising administering to the subject an engineered cell of any of claims 1181 to 1196. [The present invention 1220] The method of claim 1219, wherein said engineered cells are autologous to the subject. [This invention 1221] The method of any of claims 1217 to 1220, wherein modulating the immune response treats a disease or condition in a subject. [This invention 1222] The method of claim 1221, wherein the disease or condition is a tumor or cancer. [This invention 1223] A method of treating cancer in a subject, comprising administering to the subject a pharmaceutical composition of any of claims 1197, 1198, and 1212-1214, administering to the subject a multivalent CD80 polypeptide of any of claims 1144-1174, or administering to the subject an engineered cell of any of claims 1181-1196. [Brief explanation of the drawings]
[0122] [Figure 1A] Figure 1A depicts an exemplary schematic diagram of the activity of CD80 variant IgSF domain (vIgD) conjugated to Fc, showing that CD80-Fc blocks PD-1 / PD-L1 inhibitory activity. As shown, CD80 vIgD-Fc binds to PD-L1, antagonizing the binding of PD-L1 to its cognate binding partner PD-1, blocking PD-1 inhibitory signaling, lowering the TCR signaling threshold, and promoting T cell activation. [Figure 1B] Figure IB depicts an exemplary schematic diagram of the activity of a variant IgSF domain (vIgD) conjugated to Fc, where CD80-Fc confers PD-L1-dependent CD28 agonist activity. As shown, binding of CD80-Fc to PD-L1 expressed on the surface of tumor cells can prevent the association of PD-L1 on tumor cells with the inhibitory PD-1 receptor expressed on the surface of T cells. In addition, CD80-Fc is available to bind to the costimulatory CD28 receptor on the surface of T cells, thereby localizing T cells to tumors while promoting T cell activation via CD28 costimulation of TCR signals. [Figure 2A] 2A depicts an exemplary schematic of the activity of a variant IgSF domain (vIgD) fused to Fc (vIgD-Fc), where vIgD is a variant of the IgSF domain of CD80. As shown, soluble vIgD of CD80 interacts with its cognate binding partner and blocks the interaction of CD80 with CTLA-4, thereby blocking the CTLA-4 inhibitory receptor and potentially allowing T cells to differentiate toward an effector phenotype. [Figure 2B] 2B depicts an exemplary schematic diagram of the activity of CD80 variant IgSF domain (vIgD) conjugated to Fc, in which CD80-Fc blocks CTLA-4 inhibitory activity. As shown, binding of CD80 vIgD-Fc to CTLA-4 expressed on the surface of T cells (e.g., Treg and Teff cells) antagonizes the binding of CTLA-4 to its cognate binding partners, CD80 (B7-1) and CD86 (B7-2), designated B7, blocking CTLA-4 inhibitory signaling, lowering the TCR signaling threshold, and promoting T cell activation. [Figure 3] Figure 3 depicts various exemplary shapes of multivalent molecules containing a first CD80 vIgD and a second CD80 vIgD. As shown, the first CD80 vIgD and the second CD80 vIgD are independently linked, directly or indirectly, to the N- or C-terminus of the Fc region. To generate homodimeric Fc molecules, the Fc region is capable of forming homodimers with a compatible Fc region upon coexpression of the individual Fc regions in a cell. To generate heterodimeric Fc molecules, the individual Fc regions contain mutations (e.g., "knob-into-hole" mutations in the CH3 domain) that favor heterodimer formation over homodimers when the individual Fc regions are coexpressed in a cell. In some embodiments, the first CD80 vIgD and the second CD80 vIgD are the same or different. The shapes shown result in the protein being bivalent, tetravalent or hexavalent with respect to one or more of its cognate binding partners. [Figure 4] Figure 4 depicts the binding of exemplary CD80 IgV-Fc variants to cell surface-expressed PD-L1, CD28, and CTL44 ligands. [Figure 5] Figure 5 depicts dose-dependent PD-L1-dependent CD28 costimulation in the Jurkat / IL-2 reporter line induced by exemplary CD80 IgV-Fc variants. [Figure 6] FIG. 6 depicts human primary T cell cytokine production following PD-L1-dependent costimulation induced by exemplary CD80 IgV-Fc variants. [Figure 7] Figure 7 depicts the ability of exemplary CD80 IgV-Fc candidates to bind PD-L1 and block fluorescently conjugated PD-1 binding. [Figure 8] Figure 8 depicts the antagonism activity of exemplary variant CD80-Fc variants, PD-1 / PD-L1 interaction and subsequent functional activity. [Figure 9] FIG. 9 depicts the in vivo anti-tumor activity of exemplary variant CD80 polypeptides fused to wild-type IgG1 Fc (WT Fc) or inactive IgG1 Fc (inactive Fc). [Figure 10] Figure 10 depicts the median (left panel) and mean (right panel) tumor volumes in mouse models after treatment with an inactive Fc control; 50 μg, 100 μg, or 500 μg of an exemplary variant CD80 IgV-Fc (inactive); or 100 μg of an anti-PD-L1 antibody (durvalumab). All animals were treated on days 8, 10, and 12 (three arrows to the left of each of the left and right panels). Only animals that initially received the inactive Fc control then also received 100 μg of an exemplary variant CD80 IgV-Fc on days 26, 28, and 31 (three arrows to the right of each of the left and right panels). [Figure 11] Figure 11 depicts the concentration of IFNγ in hPD-L1MC38 tumor lysates following in vivo treatment with 50μg, 100μg, and 500μg of exemplary variant CD80 IgV-Fc (inactive) and 100μg of anti-PD-L1 antibody (durvalumab). [Figure 12] Figure 12 depicts the median (left panel) and mean (right panel) tumor volumes in mouse models after treatment with several exemplary CD80 IgV-Fc (inactive) variants and an anti-PD-L1 antibody (durvalumab). [Figure 13]Figure 13 depicts the median (left panel) and mean (right panel) tumor volumes after re-challenge with huPD-L1 / MC38 tumor cells in mice that showed tumor clearance after treatment with an exemplary CD80 IgV-Fc (inactive) variant and an anti-PD-L1 antibody (durvalumab). [Figure 14] Figure 14 depicts the detection of bound negative control Fc, CD80 variant-Fc and anti-PD-L1 antibody by flow cytometry on single-cell suspensions of viable CD45-negative (CD45 neg.; CD45-) tumor cells. [Figure 15] Figure 15 depicts the median (top panel) and mean (bottom panel) tumor volumes in a mouse model after treatment with an exemplary variant CD80 IgV-Fc (inactive) and an anti-PD-L1 antibody (durvalumab). [Figure 16] Figures 16A and 16B depict the percentage of CD8 cells detected by flow cytometry in tumor-draining lymph nodes (Figure 16A) and tumors (Figure 16B) of mice treated with negative control Fc, CD80 variant-Fc, and anti-PD-L1 antibody. Figure 16C shows the percentage of CD8 cells detected with anti-human Fc on CD45-negative tumors treated in vivo with negative control Fc, CD80 IgV-Fc, and human anti-PD-L1 antibody. [Figure 17] Figure 17 depicts the in vitro cytotoxic activity of CD80 IgV-Fc variants specific for huPD-L1-transduced MC38 tumor cells, but not for untransduced parental MC38, demonstrating huPDL1-specific killing. [Figure 18] Figures 18 and 19 depict the binding of CD80 IgV-Fc variants to primary human T cells (Figure 18) and primary human monocytes (Figure 19). [Figure 19] Figures 18 and 19 depict the binding of CD80 IgV-Fc variants to primary human T cells (Figure 18) and primary human monocytes (Figure 19). [Figure 20]Figure 20 depicts CD80 IgV-Fc variant antagonism of PD-L1-mediated SHP-2 recruitment to PD-1 using an enzyme complementation assay. [Figure 21] FIG. 21 depicts CD80 IgV-Fc variant antagonism of CD80 / CTLA-4 binding. [Figure 22A] Figure 22A shows the median tumor volumes from an evaluation of the anti-tumor activity of an exemplary test variant CD80 IgV-Fc alone and in combination with an anti-mouse PD-1 monoclonal antibody in a syngeneic mouse melanoma model. [Figure 22B] FIG. 22B shows the antitumor activity measured by TGI. [Figure 23] Figure 23 shows IL-2 production in an assessment of T cell responses with an exemplary test variant CD80 IgV-Fc combination alone and in combination with an anti-PD-1 antibody. [Figure 24-1] FIG. 24A shows the median tumor volumes from the evaluation of antitumor activity from treatment with variant CD80 IgV-Fc either IP (intraperitoneal injection) or IT (intratumoral injection). [Figure 24-2] Figure 24B shows the percentage of cells detected using huIgG among the CD45-negative cell subset from mice treated IP (intraperitoneal injection) or IT (intratumoral injection) with variant CD80 IgV-Fc. *, **, **** indicate p<0.05, 0.001, and 0.0001, respectively, relative to the Fc control group by one-way ANOVA. Figure 24C shows the percentage of cells detected using huIgG among the PD-L1+CD45- cell subset from mice treated IP (intraperitoneal injection) or IT (intratumoral injection) with variant CD80 IgV-Fc. *, **** indicate p<0.05 and 0.0001, respectively, relative to the Fc control group by one-way ANOVA. [Figure 25]Figure 25 shows the estimated percentage of p15e tetramer+CD8+ T cells among total cells in tumors from mice treated IP (intraperitoneal injection) or IT (intratumoral injection) with variant CD80 IgV-Fc. *, *** indicate p<0.05 or 0.001, respectively (vs. Fc control group by one-way ANOVA). [Figure 26] Figures 26A-26B show results from an assessment of blockade of PD-L1 / PD-1 and CTLA-4 / CD80 interactions by exemplary multivalent variant CD80 IgSF domain fusion proteins. [Figure 27] FIG. 27 shows IL-2 production in assessing cytomegalovirus (CMV) antigen-specific T cell responses with exemplary multivalent variant CD80 IgSF domain fusion proteins. [Figure 28A] FIG. 28A shows the observed (circles) and predicted (mouse PK model; solid line) serum concentrations over time in control mice (non-tumor bearing) by dose group. [Figure 28B] Figure 28B shows the goodness of fit for the mouse PK model. The upper left scatter plot compares measured serum concentrations to predicted values at the population level. The upper right scatter plot compares measured serum concentrations to predicted values at the individual level. In both plots, the dotted line represents identity. The lower left and right plots show the distribution of weighted residuals versus population predictions and time. [Figure 29A]Figures 29A-29F show the model-predicted serum concentration values (median and confidence interval (CI)) compared to the observed serum concentration values in a mouse tumor model (murine colon adenocarcinoma MC38 cells expressing human PD-L1) in which animals were treated. Data and projections for the group of mice treated with CD80 IgV-Fc (H18Y / A26E / E35D / M47L / V68M / A71G / D90G) are shown for the following doses: a single dose of 100 μg (FIG. 29A; median and CI 80%), a single dose of 33 μg every 7 days (Q7D) for a total of three doses (FIG. 29B; median and CI 90%), a single dose of 100 μg (FIG. 29C; median and CI 90%), a single dose of 500 μg (FIG. 29D; median and CI 90%), a single dose of 1500 μg (FIG. 29E; median and CI 90%), and a single dose of 167 μg every 3 days (Q3D) for a total of three doses (FIG. 29F; median and CI 90%). All treatments were administered intraperitoneally (IP). [Figure 29B] See legend to Figure 29A. [Figure 29C] See legend to Figure 29A. [Figure 29D] See legend to Figure 29A. [Figure 29E] See legend to Figure 29A. [Figure 29F] See legend to Figure 29A. [Figure 30A] FIG. 30A shows the observed (circles) and predicted (monkey PK model; solid line) serum concentrations over time in cynomolgus monkeys by dose group. [Figure 30B] Figure 30B shows the goodness of fit for the monkey PK model. The upper left scatterplot compares measured serum concentrations to predicted values at the population level. The upper right scatterplot compares measured serum concentrations to predicted values at the individual level. In both plots, the dotted line represents identity. The lower left and lower right plots show the distribution of weighted residuals versus population predictions and time. [Figure 31A]Figures 31A-31B show the observed tumor volumes (triangles and line fits) and predicted tumor volumes (mouse PD model; solid line; PRED) in hPD-L1-MC38 tumor-bearing mice over time in different treatment groups. Figure 31A shows Study #1 treatment groups in which tumor-bearing mice were untreated (CTRL), received 33 μg of the exemplary test CD80 IgV-Fc (H18Y / A26E / E35D / M47L / V68M / A71G / D90G) every 7 days for a total of three doses (Q7D×3), or received a single dose of 100 μg of CD80 IgV-Fc (H18Y / A26E / E35D / M47L / V68M / A71G / D90G). Figure 31B shows Study #2, in which tumor-bearing mice were untreated (CTRL), received a single dose of 100 μg of CD80 IgV-Fc (H18Y / A26E / E35D / M47L / V68M / A71G / D90G), received 167 μg of CD80 IgV-Fc (H18Y / A26E / E35D / M47L / V68M / A71G / D90G) every three days for a total of three doses (Q3D x 3), received a single dose of 500 μg of CD80 IgV-Fc (H18Y / A26E / E35D / M47L / V68M / A71G / D90G), or received a single dose of 1500 μg of the test CD80 variant. [Figure 31B] See legend to Figure 31A. [Figure 32A] Figure 32A shows predicted target (CD28) saturation in humans given a single dose of CD80 IgV-Fc (H18Y / A26E / E35D / M47L / V68M / A71G / D90G) at different concentrations administered once weekly (Q1W) (intravenous injection (IV)). [Figure 32B] Figure 32B shows predicted human serum concentration levels of a single dose of CD80 IgV-Fc (H18Y / A26E / E35D / M47L / V68M / A71G / D90G) administered IV to humans at different concentrations once weekly (Q1W). [Figure 32C] Figure 32C shows predicted human serum concentration levels of a single dose of CD80 IgV-Fc (H18Y / A26E / E35D / M47L / V68M / A71G / D90G) administered IV to humans at different concentrations once every three weeks (Q3W). [Figure 33] Figure 33 shows the change in tumor volume for huPD-L1+MC38 tumor-bearing mice after treatment with CD80 IgV-Fc variants, oxaliplatin, or a combination of both. [Figure 34] Figure 34 shows the change in tumor volume for huPD-L1+MC38 tumor-bearing mice after treatment with CD80 IgV-Fc variants, anti-mouse checkpoint antibodies against CTLA-4, or a combination of both. [Figure 35] Figure 35 shows the crystal structure of the binding interface between the CD80 IgV domain of a CD80 IgV-Fc variant and wild-type PD-L1. [Figure 36] Figure 36A shows the change in tumor volume for huPD-L1+MC38 tumor-bearing mice after treatment with CD80 IgV-Fc variants, anti-CD28 blocking antibodies, or a combination of both. Figure 36B shows the change in tumor volume for huPD-L1+MC38 tumor-bearing mice after treatment with CD80 IgV-Fc variants, anti-PD-L1 blocking antibodies, or a combination of both. [Figure 37] FIG. 37 shows CD80 IgV-Fc secreted immunomodulatory protein (SIP) concentration levels over time in supernatants collected from SIP-transduced donor Pan T cells. [Figure 38] FIG. 38 shows dose-dependent CD28 costimulation induced by an exemplary CD80 IgV-Fc SIP in the Jurkat / IL-2 reporter line. [Figure 39] Figure 39 shows CD80 IgV-Fc SIP binding to PD-L1-expressing artificial antigen-presenting cells. [Figure 40] FIG. 40 depicts dose-dependent FcR-dependent CD28 agonism in the Jurkat / IL-2 reporter line induced by exemplary CD80 ECD-Fc variants. DETAILED DESCRIPTION OF THE INVENTION
[0123] Detailed Description Provided herein are immunomodulatory proteins that are or contain variants or mutants of CD80 and its specific-binding fragments that exhibit altered binding activity or affinity for at least one target ligand cognate binding partner (also referred to as a counter-structure ligand protein). In some embodiments, the variant CD80 polypeptides contain one or more amino acid modifications (e.g., amino acid substitutions, deletions, or additions) compared to unmodified or wild-type CD80 polypeptides. In some embodiments, the variant CD80 polypeptides contain one or more amino acid modifications (e.g., substitutions) compared to unmodified or wild-type CD80 polypeptides. In some embodiments, the one or more amino acid substitutions are in the IgSF domain (e.g., IgV) of the unmodified or wild-type CD80 polypeptide.
[0124] Also provided herein are immunomodulatory proteins that are fusion proteins containing variants or mutants of the extracellular domain of CD80 and a multimerization domain. In some aspects, the provided variant CD80 fusion proteins contain a CD80 extracellular domain polypeptide with one or more amino acid modifications (e.g., substitutions) that confer altered binding activity or affinity with at least one target ligand cognate binding partner (also referred to as a counter-structure ligand protein). In some embodiments, the variant CD80 polypeptide contains one or more amino acid modifications (e.g., amino acid substitutions, deletions, or additions) compared to the extracellular domain of an unmodified or wild-type CD80 polypeptide. Methods of making and using these variant CD80s are also provided.
[0125] In some embodiments, the altered binding activity, e.g., binding affinity and / or binding selectivity, e.g., increased or decreased binding affinity or selectivity, is for at least one binding partner protein CD28, PD-L1, or CTLA-4. In some embodiments, the variant CD80 polypeptides exhibit altered, e.g., increased or decreased, binding activity or affinity to one or more of CD28, PD-L1, or CTLA-4 compared to unmodified or wild-type CD80 that does not contain one or more modifications.
[0126] In some embodiments, the variant CD80 polypeptides exhibit increased binding affinity to one or more of CD28, PD-L1, and CTLA-4 compared to unmodified or wild-type CD80 that does not contain one or more modifications. In some embodiments, the variant CD80 polypeptides exhibit increased binding affinity to CD28 compared to unmodified or wild-type CD80 that does not contain one or more modifications. In some embodiments, the variant CD80 polypeptides exhibit increased binding affinity to PD-L1 compared to unmodified or wild-type CD80 that does not contain one or more modifications. In some embodiments, the variant CD80 polypeptides exhibit increased binding affinity to CTLA-4 compared to unmodified or wild-type CD80 that does not contain one or more modifications.
[0127] In some embodiments, the variant CD80 polypeptides exhibit increased binding affinity to one or both of CD28 and PD-L1 compared to unmodified or wild-type CD80 that does not contain one or more modifications. In some embodiments, the variant CD80 polypeptides exhibit increased binding affinity to one or both of CD28 and CTLA-4 compared to unmodified or wild-type CD80 that does not contain one or more modifications. In some embodiments, the variant CD80 polypeptides exhibit increased binding affinity to one or both of PD-L1 and CTLA-4 compared to unmodified or wild-type CD80 that does not contain one or more modifications. In some embodiments, the variant CD80 polypeptides exhibit increased binding affinity to CD28, PD-L1, and CTLA-4 compared to unmodified or wild-type CD80 that does not contain one or more modifications.
[0128] In some embodiments, the variant CD80 polypeptides provided herein exhibit increased selectivity for binding to CD28, PD-L1 and / or CTLA-4 compared to the selectivity of unmodified or wild-type CD80 that does not contain one or more modifications for binding to CD28, PD-L1 and / or CTLA-4. In some embodiments, the ratio increases by more than 1.2x, 1.5x, 2.0x, 3.0x, 4.0x, 5.0x, 6.0x, 7.0x, 8.0x, 9.0x, 10.0x, 15.0x, 20x, 30x, 40x, 50x, 100x or more, or by more than about 1.2x, 1.5x, 2.0x, 3.0x, 4.0x, 5.0x, 6.0x, 7.0x, 8.0x, 9.0x, 10.0x, 15.0x, 20x, 30x, 40x, 50x, 100x or more.
[0129] In some embodiments, the variant CD80 polypeptides and immunomodulatory proteins regulate immunological immune responses, e.g., increase immune responses. In some embodiments, the provided variant CD80 polypeptides regulate T cell activation, expansion, differentiation, and survival through interaction with costimulatory signaling molecules. Generally, two distinct signals are required for antigen-specific T cell activation. The first signal is provided by the interaction of the T cell receptor (TCR) with major histocompatibility complex (MHC)-associated antigens present on antigen-presenting cells (APCs). The second signal, costimulatory upon TCR engagement, e.g., a CD28 costimulatory signal, is required to avoid T cell apoptosis or anergy.
[0130] In some embodiments, under normal physiological conditions, T cell-mediated immune responses are initiated by antigen recognition by T cell receptors (TCRs) and regulated by a balance of costimulatory and inhibitory signals (e.g., immune checkpoint proteins). The immune system relies on immune checkpoints to prevent autoimmunity (i.e., self-tolerance) and protect tissues from excessive damage during an immune response, for example, during an attack against a pathogenic infection. However, in some cases, these immunoregulatory proteins can become dysregulated in diseases and conditions, including tumors, as a mechanism to escape the immune system.
[0131] In some embodiments, among the known T cell costimulatory receptors is CD28, which is the T cell costimulatory receptor for the ligands B7-1 (CD80) and B7-2 (CD86), both of which are present on APCs. These ligands, in particular, can also bind to the inhibitory T cell receptor CTLA4 (cytotoxic T lymphocyte-associated protein 4) with higher affinity than CD28; binding to CTLA4 acts to downregulate immune responses. In some embodiments, CD80 can bind to programmed death-ligand 1 (PD-L1). CD80 has affinity for PD-L1 similar to that of CD28. PD-L1 is one of the two ligands for the inhibitory immune receptor, programmed death 1 (PD-1). The interaction between PD-L1 and PD-1 negatively regulates immunological activity by promoting T cell inactivation and downregulating T cell activity. PD-1 expression on T cells can be induced after T cell activation as a strategy to prevent T cell hyperactivity. Many tumor cells express PD-L1 on their surface, potentially leading to inhibition of PD-1 / PD-L1 interaction and T cell responses against tumors. Binding of CD80 to PD-L1 can block the interaction between PD-L1 and PD-1, thereby preventing inhibition of T cell responses, for example, at tumor sites, effectively enhancing or boosting immune responses. In some embodiments, provided CD80 polypeptides, e.g., soluble forms of the variant CD80 polypeptides provided herein, can antagonize B7 / CTLA-4 binding, prevent CTLA-4 inhibitory signaling, and lower the TCR signaling threshold, thereby promoting T cell activation and immune responses.
[0132] In some embodiments, CD80 may aid in binding to the CD28 receptor and may be involved in inducing T cell responses. In some embodiments, CD80 may bind to PD-L1, blocking the interaction of PD-L1 with PD-1 and preventing inhibition of T cell responses, or may bind to CTLA-4 and preventing CTLA-4 inhibitory signaling. Thus, in some cases, the interaction of CD80 with PD-L1, CD28, and / or CTLA-4 can have overlapping and complementary effects. In some embodiments, CD28 and PD-L1 may play complementary roles in modeling immune responses.
[0133] In some embodiments, provided variant CD80 polypeptides or immunomodulatory proteins modulate (e.g., increase or decrease) immunological activity induced by or associated with the inhibitory receptor CTLA-4, the PD-L1 / PD-1 negative regulatory complex, and / or the costimulatory receptor CD28. For example, in some embodiments, provided CD80 polypeptides, e.g., soluble forms of variant CD80 polypeptides provided herein, bind to and costimulate CD28 receptors on local T cells, thereby promoting the immune response. In some embodiments, provided CD80 polypeptides, e.g., soluble forms of variant CD80 polypeptides provided herein, can bind to PD-L1 on tumor cells or APCs, as shown in Figure 1A, thereby blocking the interaction of PD-L1 with the PD-1 inhibitory receptor, thereby preventing the negative regulatory signaling that would otherwise result from the PD-L1 / PD-1 interaction. In some embodiments, provided CD80 polypeptides, e.g., soluble forms of variant CD80 polypeptides provided herein, bind to the CTLA-4 inhibitory receptor and block its interaction with CD80 expressed on APCs, as shown in Figure 2A, thereby preventing negative regulatory signaling of the CD80-bound CTLA-4 receptor. In some embodiments, provided CD80 polypeptides, e.g., soluble forms of variant CD80 polypeptides provided herein, can bind to and costimulate CD28 receptors on localized T cells while blocking the PD-L1 / PD-1 interaction, thereby promoting an immune response (Figure 1B). In some specific embodiments, provided CD80 polypeptides, e.g., soluble forms of variant CD80 polypeptides provided herein, also bind to the CTLA-4 inhibitory receptor and block its interaction with CD80, preventing negative regulatory signaling of the CD80-bound CTLA-4 receptor.
[0134] Thus, in some embodiments, the provided polypeptides have independent binding affinity for both CD28 and / or PD-L1, and optionally CTLA-4, thereby agonizing or antagonizing the complementary effects of costimulation by the receptors. Methods of making and using these variant CD80s are also provided.
[0135] In some embodiments, the variant CD80 polypeptides specifically bind to CD28 and / or CTLA-4, e.g., human CD28 or human CTLA-4. In some embodiments, the variant CD80 polypeptides exhibit altered, e.g., increased, binding activity or affinity to one or both of CD28 or CTLA-4 compared to unmodified or wild-type CD80 that does not contain one or more modifications. In some embodiments, the variant CD80 polypeptides exhibit increased binding to CTLA-4, e.g., human CTLA-4, compared to wild-type human CD80 extracellular domain polypeptides. In some embodiments, the variant CD80 polypeptides exhibit increased binding to CD28, e.g., human CD28, compared to wild-type human CD80 extracellular domain polypeptides.
[0136] In some embodiments, the variant CD80 IgSF domain fusion protein is soluble. Based on the same increased binding and activity of the variant CD80 to its binding partner, the ability to format the variant polypeptide in various configurations to antagonize or agonize the immune response, depending on the context, provides flexibility for therapeutic applications. For example, delivery of an enhanced CD80 protein in a soluble format with increased affinity for CD28, PD-L1, and / or CTLA-4 can antagonize inhibitory receptor signaling, such as blocking intracellular inhibitory signals that can reduce responses to activating stimuli, e.g., CD3 and / or CD28 costimulatory or mitogenic signals. In some cases, this can result in an increased immune response.
[0137] Additionally, certain formats can optionally mediate CD28 agonism. Among the embodiments provided are those that modulate, e.g., agonize, costimulatory signals via CD28.
[0138] In some cases, CD28 agonism is mediated by certain variant CD80 polypeptides that exhibit increased binding to PD-L1, thereby tethering or bridging the variant CD80 molecule to the surface of the immune synapse for interaction with CD28, thereby providing a costimulatory signal and thereby activating T cells. This activity, referred to herein as PD-L1-dependent CD28 costimulation, is due in some aspects to the ability of the variant CD80 polypeptide to bind to both PD-L1 and CD80 in a non-competitive manner and / or by providing a dimeric format for the variant CD80 polypeptide (see, e.g., Figure 1B). In some cases, such PD-L1-dependent costimulation does not require an Fc with effector function and can be mediated by Fc fusion proteins containing effector-less or inactive Fc molecules. In some aspects, tethering or cross-linking can also or alternatively be achieved via Fc receptors when the variant CD80 polypeptide is provided as a fusion protein with a wild-type Fc region of an immunoglobulin that retains or exhibits effector function, referred to herein as Fc receptor-dependent CD28 costimulation.
[0139] In some embodiments, it has been found herein that certain formats of variant complete extracellular domains of CD80 polypeptides can mediate CD28 agonism when formatted as fusion proteins with immunoglobulin Fc having effector activity. In such instances, binding of the variant CD80 fusion to FcR via Fc binding may localize or tether the molecule to the immune synapse for association with CD28 on T cells. In some aspects, such activity is believed to be particularly effective in embodiments in which the CD80 polypeptide does not bind to programmed death-ligand 1 (PD-L1). CD80 has been reported to be able to bind to PD-L1. Certain variants, and variants in certain formats, such as those formatted with the complete extracellular domain of wild-type CD80, have been found to exhibit substantially lower or no PD-L1 binding. In some embodiments, molecules that do not bind to PD-L1 exhibit background or only slightly above background binding to PD-L1 as detected in binding assays, e.g., flow cytometry-based assays.
[0140] In some embodiments, the provided variant CD80 polypeptides exhibit increased binding to CD28. In some embodiments, increased binding to CD28 can result in increased CD28 costimulatory signaling, thereby promoting T cell activation and immune responses. In some aspects, increased CD28 costimulatory signaling is dependent on an effector Fc capable of binding to an FcR. In contrast, CD80 variants that bind to PD-L1 can exhibit PD-L1-dependent CD28 agonism in formats that do not require an Fc with effector function, e.g., formats in which the Fc fusion protein is an effector-less or inactive Fc molecule.
[0141] In some aspects, cross-linking Fc receptors, e.g., via their effector activity, can initiate antibody-dependent cellular cytotoxicity (ADCC)-mediated effector function, thereby promoting the expression of CTLA-4-expressing cells (e.g., CTLA-4-expressing regulatory T cells) or PD-L1-expressing cells (e.g., PD-L1 hi This results in the depletion of target cells expressing the cognate binding partner, such as tumor cells.
[0142] In some embodiments, provided CD80 polypeptides, e.g., soluble forms of variant CD80 polypeptides provided herein, can also antagonize B7 / CTLA-4 binding, prevent CTLA-4 inhibitory signaling, and lower the TCR signaling threshold, thereby promoting T cell activation and immune responses (Figure 2B). In some embodiments, provided CD80 polypeptides, e.g., soluble forms of variant CD80 polypeptides provided herein, bind to the CTLA-4 inhibitory receptor and block its interaction with CD80 expressed on APCs, as shown in Figures 2A and 2B, thereby preventing negative regulatory signaling of the CD80-bound CTLA-4 receptor.
[0143] In some embodiments, provided variant CD80 polypeptides, such as variant CD80 fusion proteins, modulate, e.g., increase, immunological activity induced by or associated with the inhibitory receptor CTLA-4, and / or the costimulatory receptor CD28.
[0144] Enhancement or inhibition of the activity of these receptors has clinical implications for cancer treatment. However, in some cases, therapeutics that intervene in and alter the costimulatory effects of both receptors are constrained by size limitations imposed by the extent of the immunological synapse, in addition to spatial orientation requirements. In some cases, existing therapeutics, including antibody drugs, may not be able to simultaneously interact with multiple target proteins involved in regulating these interactions. In addition, in some cases, existing therapeutics may only antagonize immune responses, without the ability to agonize them. In addition, pharmacokinetic differences between drugs that independently target one or the other of these two receptors can make it difficult to adequately maintain the desired blood levels of such drug combinations throughout the course of treatment. The provided variant CD80 polypeptides and immunomodulatory proteins, as well as other formats described, address such issues.
[0145] All publications, including patents, patent applications, scientific articles, and databases, referred to herein are incorporated by reference in their entirety for all purposes to the same extent as if each individual publication, including a patent, patent application, scientific article, or database, were specifically and individually indicated to be incorporated by reference. To the extent that a definition set forth herein contradicts or otherwise conflicts with a definition set forth in a patent, application, published application, or other publication incorporated herein by reference, the definition set forth herein shall take precedence over the definition incorporated herein by reference.
[0146] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
[0147] definition Unless otherwise defined, all technical terms, notations, and other technical and scientific terms or terms used herein are intended to have the same meaning as commonly understood by one of ordinary skill in the art to which the claimed subject matter belongs. In some cases, terms having commonly understood meanings are defined herein for clarity and / or ready reference, and the inclusion of such definitions herein should not necessarily be construed as making a significant difference from what is commonly understood in the art.
[0148] Terms used throughout this specification are defined as follows, unless otherwise limited in specific instances. As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Unless otherwise defined, all technical and scientific terms, acronyms, and abbreviations used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Unless otherwise specified, abbreviations and symbols for chemical and biochemical names are in accordance with IUPAC-IUB nomenclature. Unless otherwise specified, all numerical ranges include not only the values defining the range but also all integer values therebetween.
[0149] The term "affinity-modified," when used in the context of immunoglobulin superfamily domains, refers to a mammalian immunoglobulin superfamily (IgSF) domain having an amino acid sequence (relative to a corresponding wild-type parent or unmodified IgSF domain) that has been altered to increase or decrease binding affinity or avidity for at least one of its cognate binding partners (or "counterstructures") relative to a parent wild-type or unmodified (i.e., non-affinity-modified) IgSF control domain. In this context, affinity-modified CD80 IgSF domains are included. In some embodiments, affinity-modified IgSF domains can contain 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or more amino acid differences, e.g., amino acid substitutions, in a wild-type or unmodified IgSF domain. Increased or decreased binding affinity or avidity can be determined using well-known binding assays such as flow cytometry. Larsen et al., American Journal of Transplantation, Vol 5: 443-453 (2005). See also Linsley et al., Immunity, Vol 1(9:793-801 (1994). The increase in binding affinity or avidity of a protein for its cognate binding partner will be at least 10% greater than the wild-type IgSF domain control, and in some embodiments will be at least 20%, 30%, 40%, 50%, 100%, 200%, 300%, 500%, 1000%, 5000%, or 10000% greater than the wild-type IgSF domain control value. The decrease in binding affinity or avidity of a protein for at least one of its cognate binding partners will be 90% or less of the control but 10% or more of the wild-type IgSF domain control value, and in some embodiments will be 80%, 70%, 60%, 50%, 40%, 30%, or 20% or less of the wild-type IgSF domain control value but 10% or more.Affinity-modified proteins have altered primary amino acid sequence due to substitution, addition, or deletion of amino acid residues. The term "affinity-modified IgSF domain" should not be construed as imposing any requirement on any particular starting composition or method by which the affinity-modified IgSF domain is generated. Thus, affinity-modified IgSF domains of the present invention are not limited to wild-type IgSF domains that have been subsequently converted into affinity-modified IgSF domains by any particular affinity modification process. Affinity-modified IgSF domain polypeptides can be generated, for example, starting from wild-type mammalian IgSF domain sequence information, then modeled in silico for binding to their cognate binding partners, and finally recombinantly or chemically synthesized to obtain the subject affinity-modified IgSF domain composition. However, in another example, affinity-modified IgSF domains can be generated by site-directed mutagenesis of wild-type IgSF domains. Thus, affinity-modified IgSF domain refers to a product, but not necessarily the product produced by any given process. A wide variety of techniques may be used, including recombinant methods, chemical synthesis, or a combination thereof.
[0150] The term "antibody" as used herein is used in the broadest sense and includes polyclonal and monoclonal antibodies, including intact antibodies, as well as functional (antigen-binding) antibody fragments, including fragment antigen-binding (Fab) fragments, F(ab')2 fragments, Fab' fragments, Fv fragments, recombinant IgG (rIgG) fragments, single-chain antibody fragments, including single-chain variable fragments (scFv), and single-domain antibody (e.g., sdAb, sdFv, nanobody) fragments. The term also encompasses genetically engineered and / or otherwise modified forms of immunoglobulins, such as intrabodies, peptibodies, chimeric antibodies, fully human antibodies, humanized antibodies, and heteroconjugate antibodies, multispecific (e.g., bispecific) antibodies, diabodies, triabodies, and tetrabodies, tandem di-scFvs, and tandem tri-scFvs. Unless otherwise specified, the term "antibody" should be understood to encompass functional antibody fragments thereof. The term also encompasses intact or full-length antibodies, including antibodies of any class or subclass, including IgG and its subclasses, IgM, IgE, IgA, and IgD.
[0151] An "antibody fragment" or "antigen-binding fragment," in reference to an antibody, refers to a molecule other than an intact antibody that contains a portion of the intact antibody that binds to the antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2; diabodies; linear antibodies; single-chain antibody molecules (e.g., scFv); and multispecific antibodies formed from antibody fragments. Antibody fragments can be produced by a variety of techniques, including, but not limited to, proteolytic digestion of intact antibodies as well as production by recombinant host cells. In some embodiments, the antibody is a recombinantly produced fragment, e.g., a fragment containing a non-naturally occurring arrangement, e.g., a fragment having two or more antibody regions or chains connected by a synthetic linker, e.g., a peptide linker, and / or a fragment that cannot be produced by enzymatic digestion of a naturally occurring intact antibody.
[0152] As used herein, the terms "binding affinity" and "binding activity" refer to the specific binding affinity and specific binding activity of a protein to its counterstructure under specific binding conditions, respectively. In biochemical dynamics, binding activity refers to the cumulative strength of the affinities of multiple individual non-covalent interactions, such as between CD80 and its counterstructures PD-L1, CD28, and / or CTLA-4. Thus, binding activity differs from affinity, which describes the strength of a single interaction. The increased or decreased binding affinity of a variant CD80 containing an affinity-modified CD80 IgSF domain to its counterstructure is determined compared to the binding affinity of an unmodified CD80, such as an unmodified CD80 containing a native or wild-type IgSF domain, e.g., an IgV domain. Methods for determining binding affinity or binding activity are known in the art. See, for example, Larsen et al., American Journal of Transplantation, Vol. 5: 443-453 (2005). In some embodiments, such variant CD80 containing an affinity-modified IgSF domain specifically binds CD28, PD-L1 and / or CTLA-4 with a binding affinity that results in a mean fluorescence intensity (MFI) value that is at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% greater than an unmodified CD80 control in a binding assay such as that described in Example 6, as measured by flow cytometry.
[0153] The term "biological half-life" refers to the time required for a substance (e.g., an immunomodulatory polypeptide containing a variant CD80 polypeptide of the invention) to lose half of its pharmacological or physiological activity or concentration. Biological half-life can be affected by the substance's elimination, excretion, degradation (e.g., enzymatic), or absorption and concentration in specific organs or tissues of the body. In some embodiments, biological half-life can be assessed by determining the time required for the plasma concentration of the substance to reach half of its steady-state level ("plasma half-life"). Conjugates that can be used to derivatize the polypeptides of the invention to extend their biological half-life are known in the art and include, but are not limited to, polyethylene glycol (PEG), hydroxyethyl starch (HES), XTEN (extended recombinant peptides; see WO2013130683), human serum albumin (HSA), bovine serum albumin (BSA), lipids (acylated), and poly-Pro-Ala-Ser (PAS), polyglutamic acid (glutamylated).
[0154] The term "blocks binding," and grammatical variations thereof, in the context of PD-1 inhibitors, such as anti-PD-1 antibodies, refers to the ability of such inhibitors to inhibit, disrupt, or reduce the interaction of PD-1 with a PD-1 ligand, such as PD-L1 or PD-L2. Such inhibition may occur by any mechanism, including direct interference with ligand binding due to, for example, overlapping binding sites on PD-1 and / or antibody-induced conformational changes in PD-1 that alter ligand affinity.
[0155] The term "cancer" is used herein to refer to a group of cells that exhibits abnormally high levels of proliferation and growth. Cancers can be benign (also called benign tumors), pre-malignant, or malignant. Cancer cells can be solid cancer cells or leukemia cancer cells. Examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia. More specific examples of such cancers include, but are not limited to, squamous cell carcinoma, small cell lung cancer, pituitary cancer, esophageal cancer, astrocytoma, soft tissue sarcoma, non-small cell lung cancer (including squamous cell non-small cell lung cancer), lung adenocarcinoma, lung squamous cell carcinoma, peritoneal cancer, hepatocellular carcinoma, gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine cancer, salivary gland cancer, kidney cancer, renal cell carcinoma, liver cancer, prostate cancer, vulvar cancer, thyroid cancer, hepatic carcinoma, brain cancer, endometrial cancer, testicular cancer, cholangiocarcinoma, gallbladder cancer, gastric cancer, melanoma, and various types of head and neck cancer (including head and neck squamous cell carcinoma).
[0156] As used herein, the term "chimeric antigen receptor" or "CAR" refers to an artificial (i.e., man-made) transmembrane protein expressed on mammalian cells, containing at least an ectodomain, a transmembrane, and an endodomain. CAR proteins optionally include a "spacer" that covalently links the ectodomain to the transmembrane domain. The spacer is often a polypeptide that links the ectodomain to the transmembrane domain via a peptide bond. CARs are typically expressed on mammalian lymphocytes. In some embodiments, CARs are expressed on mammalian cells such as T cells or tumor-infiltrating lymphocytes (TILs). CARs expressed on T cells are referred to herein as "CAR T cells" or "CAR-T." In some embodiments, CAR-Ts are helper T cells, cytotoxic T cells, natural killer T cells, memory T cells, regulatory T cells, or γδ T cells. When used clinically, for example, in adoptive cell transfer, CAR-Ts with antigen-binding specificity for a patient's tumor are typically engineered to be expressed on natural T cells obtained from the patient. The engineered T cells expressing the CAR are then infused back into the patient. Thus, while CAR-Ts are often autologous, allogeneic CAR-Ts are also within the scope of the present invention. The ectodomain of the CAR contains an antigen-binding region (e.g., an antibody or its antigen-binding fragment (e.g., scFv)) that specifically binds to a target antigen (e.g., a tumor-specific antigen) under physiological conditions. Upon specific binding, a series of biochemical events (i.e., signal transduction) results in the modulation of the immunological activity of the CAR-T. Thus, for example, specific binding of the antigen-binding region of the CAR-T to its target antigen can lead to changes in the immunological activity of T cell activity, as reflected by changes in cytotoxicity, proliferation, or cytokine production. In some embodiments, signal transduction upon CAR-T activation is achieved by the CD3 zeta chain ("CD3-z"), which is involved in signal transduction in natural mammalian T cells.CAR-T can further contain multiple signaling domains (e.g., CD28, 41BB, or OX40) to further modulate the immunoregulatory response of T cells. CD3-z contains a conserved motif known as an immunoreceptor tyrosine-based activation motif (ITAM), which is involved in T cell receptor signal transduction.
[0157] The terms "collectively" or "total," when used in reference to cytokine production induced by the presence of two or more variant CD80 polypeptides in an in vitro assay, refer to the overall cytokine expression level, regardless of cytokine production induced by individual variant CD80 polypeptides. In some embodiments, the cytokine assayed is IFN-γ, e.g., in the in vitro primary T cell assay described in Example 7.
[0158] The term "cognate binding partner" (used interchangeably with "counterstructure"), with respect to a polypeptide (e.g., an IgSF domain of a variant CD80), refers to at least one molecule (typically a native mammalian protein) to which the referenced polypeptide specifically binds under specific binding conditions. In some aspects, a variant CD80 containing an affinity-modified IgSF domain specifically binds to the counterstructure of the corresponding native or wild-type CD80, but with increased or diminished affinity. A species of ligand that is recognized and specifically binds to its cognate receptor under specific binding conditions is an example of a counterstructure or cognate binding partner of that receptor. A "cell surface cognate binding partner" is a cognate binding partner expressed on the surface of a mammalian cell. A "cell surface molecular species" is a cognate binding partner of a ligand of an immunological synapse (IS) that is expressed on and by cells (e.g., mammalian cells) that form the IS.
[0159] As used herein, "conjugate," "conjugation," or grammatical variations thereof, refers to the connection or linking of two or more compounds together by any connection or linking method known in the art, resulting in the formation of another compound. It can also refer to a compound produced by connecting or linking two or more compounds together. For example, a variant CD80 polypeptide directly or indirectly linked to one or more chemical moieties or polypeptides is an exemplary conjugate. Such conjugates include fusion proteins, those produced by chemical conjugation, and those produced by any other method.
[0160] The term "competitive binding," as used herein, means that a protein can specifically bind to at least two cognate binding partners, but the specific binding of one cognate binding partner inhibits (e.g., prevents or hinders) the simultaneous binding of a second cognate binding partner. Thus, in some cases, a protein cannot simultaneously bind to two cognate binding partners. Generally, competitive binders contain identical or overlapping binding sites for specific binding, although this is not a requirement. In some embodiments, competitive binding causes measurable (partial or complete) inhibition of the specific binding of a protein to one of its cognate binding partners due to the specific binding of a second cognate binding partner. A wide variety of methods for quantifying competitive binding are known, such as ELISA (enzyme-linked immunosorbent assay) assays.
[0161] As used herein, a composition refers to any mixture of two or more products, substances, or compounds, including cells. The composition may be a solution, suspension, liquid, powder, paste, aqueous, non-aqueous, or any combination thereof.
[0162] The term "conservative amino acid substitution," as used herein, refers to an amino acid substitution in which one amino acid residue is replaced with another amino acid residue having a side chain R group with similar chemical properties (e.g., charge or hydrophobicity). Examples of groups of amino acids with side chains with similar chemical properties include: 1) aliphatic side chains: glycine, alanine, valine, leucine, and isoleucine, 2) aliphatic-hydroxyl side chains: serine and threonine, 3) amide-containing side chains: asparagine and glutamine, 4) aromatic side chains: phenylalanine, tyrosine, and tryptophan, 5) basic side chains: lysine, arginine, and histidine, 6) acidic side chains: aspartic acid and glutamic acid, and 7) sulfur-containing side chains: cysteine and methionine. Conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamate-aspartate, and asparagine-glutamine.
[0163] The term "corresponding to" with respect to a protein position, e.g., a statement that a nucleotide or amino acid position "corresponds to" a nucleotide or amino acid position in a disclosed sequence, e.g., as set forth in the sequence listing, refers to the nucleotide or amino acid position as identified by alignment with the disclosed sequence based on a structural sequence alignment or using a standard alignment algorithm (e.g., the GAP algorithm). For example, corresponding residues can be determined by aligning a reference sequence with the sequence of wild-type CD80 as set forth in SEQ ID NO:2 (ECD domain) or as set forth in SEQ ID NO:76, 150, or 1245 (IgV domain) according to the structural alignment methods described herein. By aligning the sequences, one skilled in the art can identify corresponding residues, e.g., using conserved and identical amino acid residues as a guide.
[0164] The terms "reduce" or "attenuate" or "inhibit," as used herein, refer to a statistically significant decrease. The decrease can be at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%.
[0165] The term "derivative" or "derivatized" refers to the modification of a protein by directly or indirectly covalently linking the protein to a composition to alter properties such as biological half-life, bioavailability, immunogenicity, solubility, toxicity, potency, or efficacy, while retaining or enhancing its therapeutic effect. Derivatives of the immunomodulatory polypeptides of the invention are within the scope of the invention and can be made, for example, by glycosylation, PEGylation, lipidation, or Fc fusion.
[0166] As used herein, detection includes the method that allows protein to be visualized (visually or by instrument).Protein can be visualized using the antibody specific to that protein.Protein detection can also be promoted by fusing the tag that comprises detectable label with protein, or by contacting with the second reagent that is specific to that protein, such as the second antibody that comprises detectable label.
[0167] As used herein, a domain (typically a sequence of three or more, generally five or seven or more amino acids, e.g., 10-200 amino acid residues) refers to a portion of a molecule (e.g., a protein or coding nucleic acid) that is structurally and / or functionally distinct from and identifiable with the rest of the molecule. For example, a domain includes a portion of a polypeptide chain that can independently fold within a protein composed of one or more structural motifs and / or is recognized by a functional activity, such as binding activity. A protein can have one or more distinct domains. For example, a domain can be identified, defined, or distinguished by primary sequence or structural homology to related family members, e.g., homology to a motif. In another example, a domain can be distinguished by its function (e.g., ability to interact with a biomolecule, such as a cognate binding partner). A domain can exhibit independent biological function or activity, such that a domain can function (e.g., bind) independently or fused to another molecule. A domain can be a linear or nonlinear amino acid sequence. Many polypeptides contain multiple domains. Such domains are known and can be identified by those skilled in the art. For purposes of illustration herein, definitions are provided, but it is understood that it is well within the skill of the art to recognize a particular domain by name. If necessary, appropriate software can be used to identify the domain.
[0168] The term "ectodomain," as used herein, refers to the region of a membrane protein (e.g., a transmembrane protein) that is outside the vesicle membrane. Ectodomains often contain a binding domain that specifically binds to a ligand or cell surface receptor, e.g., via a binding domain that specifically binds to the ligand or cell surface receptor. The ectodomain of a cellular transmembrane protein is alternatively referred to as the extracellular domain.
[0169] The term "effective amount" or "therapeutically effective amount" refers to an amount and / or concentration of a therapeutic composition (including a protein or cell composition) of the invention that, when administered ex vivo (by contact with cells from a patient) or in vivo (by administration to a patient), either alone (i.e., as monotherapy) or in combination with an additional therapeutic agent, results in a statistically significant reduction in disease progression, e.g., by ameliorating or eliminating the symptoms and / or pathogenesis of the disease. An effective amount can be an amount that alleviates, reduces, or relieves at least one symptom or biological response or effect associated with a disease or disorder, prevents the progression of the disease or disorder, or improves the physical function of the patient. In certain embodiments, the patient is a mammal, e.g., a non-human primate or a human patient.
[0170] The term "endodomain," as used herein, refers to a region found in some membrane proteins (e.g., transmembrane proteins) that extends into the internal space defined by the cell surface membrane. In mammalian cells, the endodomain is the cytoplasmic region of the membrane protein. In cells, the endodomain can interact with intracellular components and play a role in signal transduction, and thus, in some cases, can be an intracellular signaling domain. The endodomain of a cellular transmembrane protein is alternatively referred to as a cytoplasmic domain, which in some cases can be a cytoplasmic signaling domain.
[0171] The terms "enhanced" or "increased (improved)," as used herein in the context of increasing the immunological activity of a mammalian lymphocyte, refer to an increase in one or more activities of the lymphocyte. An increase in activity can be an increase in one or more of cell survival, cell proliferation, cytokine production, or T-cell cytotoxicity, e.g., by a statistically significant amount. In some embodiments, reference to increased immunological activity refers to an increase in interferon-gamma (IFN-γ) production, e.g., by a statistically significant amount. In some embodiments, immunological activity can be assessed in a mixed lymphocyte reaction (MLR) assay. Methods for performing MLR assays are known in the art. Wang et al., Cancer Immunol Res. 2014 Sep: 2(9):846-56. Other methods for assessing lymphocyte activity are known in the art, including any of the assays described herein. In certain embodiments, an enhancement can be an increase of at least 10%, 20%, 30%, 40%, 50%, 75%, 100%, 200%, 300%, 400%, or 500% greater than a non-zero control value.
[0172] The term "engineered cell," as used herein, refers to a mammalian cell that has been genetically modified by human intervention (e.g., recombinant DNA or viral transduction). In some embodiments, the cell is an immune cell, such as a lymphocyte (e.g., T cell, B cell, NK cell) or an antigen-presenting cell (e.g., dendritic cell). The cell can be a primary cell derived from a patient or can be a cell line. In some embodiments, the engineered cell of the invention contains a variant CD80 of the invention that has been engineered to modulate the immunological activity of a T cell expressing CD28, PD-L1, and / or CTLA-4, to which the variant CD80 polypeptide specifically binds, or an APC expressing PD-L1.
[0173] The term "engineered T cells," as used herein, refers to T cells (e.g., helper T cells, cytotoxic T cells (or cytotoxic T lymphocytes or CTLs), natural killer T cells, regulatory T cells, memory T cells, or γδ T cells) that have been genetically modified by human intervention (e.g., recombinant DNA or viral transduction methods).
[0174] The term "engineered T cell receptor" or "engineered TCR" refers to a T cell receptor (TCR) that has been engineered to specifically bind a major histocompatibility complex (MHC) / peptide target antigen with a desired affinity, which is then selected, cloned, and / or introduced into a population of T cells (often used in adoptive immunotherapy). In contrast to engineered TCRs, CARs are engineered to bind target antigens in an MHC-independent manner.
[0175] The term "expressed on," as used herein, is used in reference to a protein expressed on the surface of a cell (e.g., a mammalian cell). Thus, the protein is expressed as a membrane protein. In some embodiments, the expressed protein is a transmembrane protein. In some embodiments, the protein is conjugated to a small molecule moiety (e.g., a drug or a detectable label). A protein expressed on the surface of a cell can include a cell surface protein (e.g., a cell surface receptor) expressed on a mammalian cell.
[0176] The term "half-life extending moiety" refers to a portion of a polypeptide fusion or chemical conjugate that extends the half-life of a protein circulating in mammalian serum compared to the half-life of the protein not so conjugated to the moiety. In some embodiments, the half-life is extended by more than or about 1.2-fold, 1.5-fold, 2.0-fold, 3.0-fold, 4.0-fold, 5.0-fold, or 6.0-fold. In some embodiments, the half-life is extended by more than 6 hours, more than 12 hours, more than 24 hours, more than 48 hours, more than 72 hours, more than 96 hours, or more than 1 week after in vivo administration compared to the protein without the half-life extending moiety. Half-life refers to the time required for a protein to lose half of its concentration, amount, or activity. Half-life can be determined, for example, by using an ELISA assay or activity assay. Exemplary half-life extending moieties include an Fc domain, a multimerization domain, polyethylene glycol (PEG), hydroxyethyl starch (HES), XTEN (extended recombinant peptides; see WO2013130683), human serum albumin (HSA), bovine serum albumin (BSA), lipids (acylated), and poly-Pro-Ala-Ser (PAS), and polyglutamic acid (glutamylated).
[0177] The term "immunological synapse" or "immune synapse," as used herein, refers to the interface between a mammalian cell (e.g., an antigen-presenting cell or tumor cell) that expresses MHC I (major histocompatibility complex) or MHC II, and a mammalian lymphocyte (e.g., an effector T cell or natural killer (NK) cell).
[0178] The Fc (fragment crystallizable) region or domain (also referred to as an Fc polypeptide) of an immunoglobulin molecule primarily corresponds to the constant region of an immunoglobulin heavy chain and is responsible for various functions, including antibody effector functions. The Fc domain contains part or all of the hinge domain and the CH2 and CH3 domains of an immunoglobulin molecule. The Fc domain can form a dimer of two polypeptide chains connected by one or more disulfide bonds. An exemplary dimerization polypeptide is shown in FIG. 3. In some embodiments, the Fc is a variant Fc with reduced activity (e.g., greater than 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more) in promoting effector function. In some embodiments, references to amino acid substitutions in the Fc region are by the EU numbering system, unless otherwise noted based on a specific SEQ ID NO. EU numbering is known and follows the EU index reported in the recently updated IMGT Scientific Chart (IMGT®, i.e., international ImMunoGeneTics information system®, http: / / www.imgt.org / IMGTScientificChart / Numbering / Hu_IGHGnber.html (created May 17, 2001, last updated January 10, 2013) and Kabat, EA et al. Sequences of Proteins of Immunological interest. 5th ed. US Department of Health and Human Services, NIH publication No. 91-3242 (1991).
[0179] Immunoglobulin Fc fusions ("Fc fusions"), e.g., immunomodulatory Fc fusion proteins, are molecules comprising one or more polypeptides (or one or more small molecules) operably linked to the Fc region of an immunoglobulin. An Fc fusion can comprise, for example, the Fc region of an antibody (to facilitate pharmacokinetics) and a variant CD80 polypeptide. The immunoglobulin Fc region can be indirectly or directly linked to one or more variant CD80 polypeptides or small molecules (fusion partners). A variety of linkers are known in the art and can optionally be used to link the Fc to the fusion partner to generate the Fc fusion. Fc fusions of the same species can be dimerized to form Fc fusion homodimers, or non-identical species can be used to form Fc fusion heterodimers. In some embodiments, the Fc is a mammalian Fc, e.g., a murine, rabbit, or human Fc.
[0180] The term "host cell" refers to a cell that can be used to express a protein encoded by a recombinant expression vector. Host cells can be prokaryotic, such as Escherichia coli (E. coli), or eukaryotic, such as a unicellular eukaryote (e.g., yeast or other fungi), a plant cell (e.g., tobacco or tomato plant cell), an animal cell (e.g., a human cell, a monkey cell, a hamster cell, a rat cell, a mouse cell, or an insect cell), or a hybridoma. Examples of host cells include Chinese hamster ovary (CHO) cells or their derivatives, such as Veggie CHO, DG44, Expi CHO, or CHOZN and related cell lines grown in serum-free medium, or the DHFR-deficient CHO line DX-B11. In some embodiments, host cells can be mammalian cells (e.g., human cells, monkey cells, hamster cells, rat cells, mouse cells, or insect cells).
[0181] The term "immunoglobulin" (abbreviated "Ig"), as used herein, refers to mammalian immunoglobulin proteins including any of the five human classes of antibodies: IgA (including subclasses IgA1 and IgA2), IgD, IgE, IgG (including subclasses IgG1, IgG2, IgG3, and IgG4), and IgM. The term also refers to immunoglobulins that are less than full-length, whether fully or partially synthetic (e.g., recombinantly or chemically synthesized) or naturally produced, such as antigen-binding fragments (Fab), V, and VI. H and V L variable fragment (Fv) containing V linked together as a single chain H and V L and other antibody V region fragments such as Fab', F(ab)2, F(ab')2, dsFv diabodies, Fc, and Fd polypeptide fragments. Homobispecific and heterobispecific bispecific antibodies are included within the meaning of the term.
[0182] The term "immunoglobulin superfamily" or "IgSF" as used herein refers to a group of cell surface and soluble proteins involved in cellular recognition, binding, or adhesion processes. Molecules are classified as members of this superfamily based on structural features shared with immunoglobulins (i.e., antibodies), all of which possess domains known as immunoglobulin domains or folds. IgSF members include cell surface antigen receptors, coreceptors, and costimulatory molecules of the immune system, molecules involved in antigen presentation to lymphocytes, cell adhesion molecules, certain cytokine receptors, and intracellular muscle proteins. These are typically associated with roles in the immune system. Proteins in the immunological synapse are often members of IgSF. IgSF can also be divided into "subfamilies" based on shared characteristics, such as function. Such subfamilies typically consist of 4 to 30 IgSF members.
[0183] The terms "IgSF domain" or "immunoglobulin domain" or "Ig domain" as used herein refer to the structural domain of an IgSF protein. Ig domains are named after immunoglobulin molecules. They contain approximately 70 to 110 amino acids and are classified according to their size and function. Ig domains possess a characteristic Ig fold, a sandwich-like structure formed by two sheets of antiparallel beta strands. Interactions between hydrophobic amino acids within the sandwich and highly conserved disulfide bonds formed between cysteine residues in the B and F strands stabilize the Ig fold. One end of an Ig domain contains a region called the complementarity-determining region, which is important for the specificity of antibodies for their ligands. Ig-like domains can be classified as IgV, IgC1, IgC2, or IgI. Most Ig domains are either variable (IgV) or constant (IgC) domains. IgV domains, which have nine β-strands, are generally longer than IgC domains, which have seven β-strands. The Ig domains of some members of the IgSF are similar in amino acid sequence to IgV domains but similar in size to IgC domains. These are called IgC2 domains, while standard IgC domains are called IgC1 domains. T cell receptor (TCR) chains contain two Ig domains in their extracellular portions: one IgV domain at the N-terminus and one IgC1 domain adjacent to the cell membrane. CD80 contains two Ig domains, IgV and IgC.
[0184] The term "IgSF species," as used herein, refers to a group of IgSF member proteins that have identical or substantially identical primary amino acid sequences. Each mammalian immunoglobulin superfamily (IgSF) member defines a unique identity for all IgSF species belonging to that IgSF family. Thus, each IgSF family member is unique from other IgSF family members, and therefore, each species of a particular IgSF family member is unique from another IgSF family member species. Nevertheless, differences between molecules of the same IgSF species can arise due to differences in post-translational modifications, such as glycosylation, phosphorylation, ubiquitination, nitrosylation, methylation, acetylation, and lipidation. In addition, minor sequence differences within a single IgSF species due to genetic polymorphisms, as well as wild-type truncated forms of an IgSF species due to, for example, proteolytic cleavage, can result in distinct morphological differences within a single IgSF species. A "cell surface IgSF species" is an IgSF species expressed on the surface of a cell (typically a mammalian cell).
[0185] The term "immunological activity," as used herein in the context of mammalian lymphocytes such as T cells, refers to one or more of cell survival, cell proliferation, cytokine production (e.g., interferon-γ), or T-cytotoxic activity. In some cases, immunological activity can refer to their expression of cytokines such as chemokines or interleukins. Assays for determining enhanced or suppressed immunological activity include the MLR (mixed lymphocyte reaction) assay, which measures interferon-γ cytokine levels in culture supernatants (Wang et al., Cancer Immunol Res. 2014 Sep: 2(9):846-56), the SEB (staphylococcal enterotoxin B) T-cell stimulation assay (Wang et al., Cancer Immunol Res. 2014 Sep: 2(9):846-56), and the anti-CD3 T-cell stimulation assay (Li and Kurlander, J Transl Med. 2010: 8: 104). Because T cell activation is associated with the secretion of IFN-γ cytokines, detection of IFN-γ levels in culture supernatants from these in vitro human T cell assays can be assayed using commercially available ELISA kits (Wu et al., Immunol Lett 2008 Apr 15; 117(1): 57-62). Induction of an immune response results in increased immunological activity compared to resting lymphocytes. Immunomodulatory proteins (e.g., variant CD80 polypeptides containing affinity-engineered IgSF domains) as provided herein can increase, in some embodiments, or decrease, IFN-γ (interferon-γ) expression in primary T cell assays compared to wild-type IgSF members or IgSF domain controls. Those skilled in the art will recognize that the format of a primary T cell assay used to determine increased IFN-γ expression differs from the format used to assay for decreased IFN-γ expression.When assaying for the ability of an immunomodulating protein or affinity-modified IgSF domain of the invention to reduce IFN-γ expression in a primary T cell assay, a mixed lymphocyte reaction (MLR) assay can be used, as described in Example 6. Conveniently, a soluble form of an affinity-modified IgSF domain of the invention can be used to determine its ability to reduce IFN-γ expression by antagonizing it in an MLR, also as described in Example 6. Alternatively, when assaying for the ability of an immunomodulating protein or affinity-modified IgSF domain of the invention to increase IFN-γ expression in a primary T cell assay, a co-immobilization assay can be used, in which a T cell receptor signal (provided in some embodiments by an anti-CD3 antibody) is used in combination with a co-immobilized affinity-modified IgSF domain, such as a variant CD80, to determine its ability to increase IFN-γ expression compared to a wild-type IgSF domain control. Methods for assaying the immunological activity of engineered cells, including assessing the activity of variant CD80 transmembrane immunomodulatory proteins, are known in the art and include, but are not limited to, the ability to expand T cells after antigen stimulation, the ability to sustain T cell expansion in the absence of restimulation, and anti-cancer activity in appropriate animal models. Assays are also standard. 51 Assays to assess cytotoxicity include Cr release assays (see, e.g., Milone et al., (2009) Molecular Therapy 17: 1453-1464) or flow-based cytotoxicity assays, or impedance-based cytotoxicity assays (Peper et al. (2014) Journal of Immunological Methods, 405:192-198).
[0186] An "immunomodulating polypeptide" or "immunomodulating protein" is a polypeptide or protein molecule that modulates immunological activity. "Modulation" or "modulating" an immune response refers to either increasing or decreasing immunological activity. An immunomodulating protein can be a single polypeptide chain or a multimer (dimer or higher order multimer) of at least two polypeptide chains covalently linked to each other (e.g., by an interchain disulfide bond). Thus, monomeric, dimeric, and higher order multimeric polypeptides are within the scope of the defined term. Multimeric polypeptides can be homomultimers (of identical polypeptide chains) or heteromultimers (of non-identical polypeptide chains). An immunomodulating protein can include a variant CD80 polypeptide.
[0187] The term "increase" as used herein means to increase by a statistically significant amount. The increase can be at least 5%, 10%, 20%, 30%, 40%, 50%, 75%, 100%, or more over a non-zero control value.
[0188] An "isoform" of CD80 is one of multiple naturally occurring CD80 polypeptides that differ in amino acid sequence. Isoforms can be the product of splice variants of an RNA transcript expressed by a single gene, or can be the expression product of highly similar but different genes that produce functionally similar proteins, such as can result from gene duplication. As used herein, the term "isoform" of CD80 also refers to the product of different alleles of the CD80 gene.
[0189] As used herein, a "kit" refers to a combination of components, e.g., a composition herein with another item, including, but not limited to, instruments / devices for reconstitution, activation, and delivery, administration, diagnosis, and evaluation of biological activity or properties. The kit optionally includes instructions for use.
[0190] The term "label" refers to a compound or composition that can be directly or indirectly bound or linked to provide a detectable signal, or that can interact with a second label to modify the detectable signal. A label can be directly or indirectly conjugated to a polypeptide to produce a labeled polypeptide. The label can itself be detectable (e.g., a radioisotope label or a fluorescent label), or, in the case of an enzymatic label, can catalyze a chemical change in a substrate compound composition that is detectable. Non-limiting examples of labels include a fluorogenic moiety, green fluorescent protein, or luciferase.
[0191] The term "lymphocyte," as used herein, refers to any of three subtypes of white blood cells in the mammalian immune system. These include natural killer cells (NK cells), which function in cell-mediated cytotoxic innate immunity, T cells, which are involved in cell-mediated cytotoxic adaptive immunity, and B cells, which are involved in humoral antibody-mediated adaptive immunity. T cells include helper T cells, cytotoxic T cells, natural killer T cells, memory T cells, regulatory T cells, or γδ T cells. Also included within the definition of lymphocyte are innate lymphocytes (ILCs).
[0192] The term "subject," sometimes used interchangeably with patient or individual, refers to a mammal, such as a human or other animal, typically a human. The term "mammal" includes reference to at least one of a human, chimpanzee, rhesus monkey, cynomolgus monkey, dog, cat, mouse, or rat.
[0193] The term "mammal" or "patient" specifically includes reference to at least one of a human, chimpanzee, rhesus monkey, cynomolgus monkey, dog, cat, mouse, or rat.
[0194] The term "membrane protein" as used herein refers to a protein that is directly or indirectly bound to a lipid bilayer under physiological conditions. The lipid bilayer that forms the membrane can be a biological membrane, such as a cell membrane of a eukaryote (e.g., a mammal), or an artificial (i.e., man-made) membrane, such as a membrane found on a liposome. The binding of a membrane protein to a lipid bilayer can be by covalent bonding or by non-covalent interactions (e.g., hydrophobic or electrostatic interactions). The membrane protein can be an integral membrane protein or a peripheral membrane protein. A membrane protein that is a peripheral membrane protein is non-covalently bound to the lipid bilayer or non-covalently bound to an integral membrane protein. The peripheral membrane protein forms a transient bond to the lipid bilayer so that the peripheral membrane protein can associate with and / or dissociate from the lipid bilayer under physiological conditions in mammals. In contrast to peripheral membrane proteins, integral membrane proteins form virtually permanent bonds to the lipid bilayer of the membrane, such that they do not dissociate from the lipid bilayer under physiological conditions in mammals. Membrane proteins can form bonds to the membrane through one layer of the lipid bilayer (monotopic) or through both layers of the membrane (polytopic). Integral membrane proteins that interact with only one lipid bilayer are "integral monotopic proteins." Integral membrane proteins that interact with both lipid bilayers are "integral polytopic proteins," or are referred to herein as "transmembrane proteins."
[0195] The terms "modulating" or "modulate," as used herein in the context of an immune response (e.g., a mammalian immune response), refer to any change (e.g., an increase or decrease) in an existing or potential immune response that occurs as a result of administration of an immunomodulatory polypeptide comprising a variant CD80 of the invention. Thus, modulation refers to a change (e.g., an increase or decrease) in an immune response compared to an immune response that occurs or exists in the absence of administration of an immunomodulatory protein comprising a variant CD80. Such modulation includes any induction, activation, suppression, or change in the degree or extent of immunological activity of immune cells. Immune cells include B cells, T cells, NK (natural killer) cells, NK T cells, professional antigen-presenting cells (APCs), and non-professional antigen-presenting cells, as well as inflammatory cells (neutrophils, macrophages, monocytes, eosinophils, and basophils). Modulation includes any change imparted to an existing, developing, or potential immune response, or to the ability to induce, regulate, affect, or respond to an immune response. Modulation includes any change in the expression and / or function of genes, proteins, and / or other molecules in immune cells as part of an immune response. Modulation of immune response or modulation of immunological activity includes, for example, the disappearance, deletion, or sequestration of immune cells; the induction or generation of immune cells that can regulate the functional capabilities of other cells, such as autoreactive lymphocytes, antigen-presenting cells, or inflammatory cells; the induction of an unresponsive state (i.e., anergy) in immune cells; enhancing or suppressing the activity or function of immune cells (including, but not limited to, changing the pattern of proteins expressed by these cells). Examples include changes in the production and / or secretion of specific classes of molecules, such as cytokines, chemokines, growth factors, transcription factors, kinases, costimulatory molecules, or other cell surface receptors, or any combination of these regulatory events. Modulation can be assessed, for example, by changes in IFN-γ (interferon gamma) expression compared to wild-type or unmodified CD80 controls in primary T cell assays (see Zhao and Ji, Exp Cell Res. 2016 Jan1;340(1):132-138).Modulation can be assessed, for example, by a change in the immunological activity of the engineered cells compared to cells engineered with wild-type CD80 transmembrane protein, such as a change in the cytotoxic activity of the engineered cells or a change in cytokine secretion of the engineered cells.
[0196] The term "multimerization domain" refers to an amino acid sequence that promotes stable interaction between a polypeptide molecule and one or more additional polypeptide molecules, containing complementary multimerization domains (e.g., a first multimerization domain and a second multimerization domain), each of which can be the same or different. The interaction between the complementary multimerization domains, for example, the interaction between the first multimerization domain and the second multimerization domain, forms a stable protein-protein interaction to produce a multimer of the polypeptide molecule and the additional polypeptide molecule. In some cases, the multimerization domain is the same and interacts with itself to form a stable protein-protein interaction between the two polypeptide chains. Generally, the polypeptide is directly or indirectly connected to the multimerization domain. Exemplary multimerization domains include immunoglobulin sequences or portions thereof, leucine zippers, hydrophobic regions, hydrophilic regions, and compatible protein-protein interaction domains. The multimerization domain can be, for example, an immunoglobulin constant region or domain, such as an Fc domain or portion thereof, from IgG (including IgG1, IgG2, IgG3 or IgG4 subtypes), IgA, IgE, IgD and IgM and modified forms thereof.
[0197] The terms "nucleic acid" and "polynucleotide" are used interchangeably and refer to a polymer of nucleic acid residues (e.g., deoxyribonucleotides or ribonucleotides) in either single-stranded or double-stranded form. Unless otherwise specified, the terms encompass nucleic acids containing known natural nucleotide analogs and nucleic acids that have similar binding properties and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise specified, a particular nucleic acid sequence also implicitly encompasses not only the sequence explicitly set forth ("reference sequence"), but also conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary nucleotide sequences. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and / or deoxyinosine residues. The term nucleic acid or polynucleotide encompasses cDNA or mRNA encoded by a gene.
[0198] The term "molecular species" as used herein refers to a population of proteins with identical or substantially identical primary amino acid sequences. Each mammalian immunoglobulin superfamily (IgSF) member defines a collection of identical or substantially identical molecular species. Thus, for example, human CD80 is an IgSF member, and each human CD80 molecule is a molecular species of CD80. Differences between molecules of the same molecular species can occur due to differences in post-translational modifications, such as glycosylation, phosphorylation, ubiquitination, nitrosylation, methylation, acetylation, and lipidation. In addition, small sequence differences within a single molecular species due to genetic polymorphisms constitute other forms of differences within a single molecular species, as do wild-type truncated forms of a single molecular species due to, for example, proteolytic cleavage. A "cell surface molecular species" is a molecular species expressed on the surface of a mammalian cell. Two or more different protein species, each present in only one or only the other (but not both) of two mammalian cells forming an IS, are said to be in "cis" or "cis configuration" with each other. Two different protein species, the first of which is present only in the first of two mammalian cells that form an IS and the second of which is present only in the second of two mammalian cells that form an IS, are said to be in "trans" or in a "trans configuration." Two different protein species, each of which is present in both two mammalian cells that form an IS, are in both cis and trans configurations on those cells.
[0199] The term "non-competitive binding," as used herein, refers to the ability of a protein to specifically bind to at least two cognate binding partners simultaneously. Thus, a protein can simultaneously bind to at least two different cognate binding partners, although the binding interactions need not be of the same duration; in some cases, the protein specifically binds to only one of the cognate binding partners. In some embodiments, binding occurs under specific binding conditions. In some embodiments, simultaneous binding is such that binding of one cognate binding partner does not substantially inhibit simultaneous binding with a second cognate binding partner. In some embodiments, non-competitive binding means that binding of a second cognate binding partner to its binding site on the protein does not displace binding of a first cognate binding partner to its binding site on the protein. Methods for assessing non-competitive binding are well known in the art, such as those described in Perez de La Lastra et al., Immunology, 1999 Apr: 96(4): 663-670. In some cases, in a non-competitive interaction, a first cognate binding partner specifically binds to a non-overlapping interaction site with a second cognate binding partner, such that the binding of the second cognate binding partner does not directly interfere with the binding of the first cognate binding partner. Thus, any effect of the binding of the second cognate binding partner on the binding of the cognate binding partner is via a mechanism other than direct interference with the binding of the first cognate binding partner. For example, in an enzyme-substrate interaction, a non-competitive inhibitor binds to a site other than the active site of the enzyme. Non-competitive binding encompasses a non-competitive binding interaction in which a second cognate binding partner specifically binds to a non-overlapping interaction site with the binding of the first cognate binding partner, but only binds to the second interaction site when the first interaction site is occupied by the first cognate binding partner.
[0200] The term "package insert" is conventionally used to refer to instructions included in commercial packaging of a therapeutic product that contain information about the indications, uses, dosage, administration, concomitant therapy, contraindications and / or warnings concerning the use of such therapeutic product.
[0201] The term "pharmaceutical composition" refers to a composition suitable for pharmaceutical use in a mammalian subject, often a human. Pharmaceutical compositions typically comprise an effective amount of an active agent (e.g., an immunomodulatory polypeptide comprising a variant CD80 or engineered cells expressing a variant CD80 transmembrane immunomodulatory protein) and a carrier, excipient, or diluent. The carrier, excipient, or diluent is typically a pharmaceutically acceptable carrier, excipient, or diluent, respectively.
[0202] The terms "polypeptide" and "protein" are used interchangeably herein and refer to a molecular chain of two or more amino acids linked via peptide bonds. The term does not refer to a specific length of the product. Thus, "peptide" and "oligopeptide" are included within the definition of polypeptide. The term includes post-translational modifications of polypeptides, such as glycosylation, acetylation, phosphorylation, etc. The term also includes molecules of one or more amino acid analogs or non-standard or unnatural amino acids, which can be synthesized or recombinantly expressed using known protein engineering techniques. In addition, proteins can be derivatized.
[0203] The term "primary T cell assay," as used herein, refers to an in vitro assay for measuring interferon-γ ("IFN-γ") expression. A wide variety of such primary T cell assays are known in the art, such as the assay described in Example 6. In a preferred embodiment, the assay used is an anti-CD3 co-immobilization assay. In this assay, primary T cells are stimulated with immobilized anti-CD3, with or without additional recombinant proteins. Culture supernatants are collected at a time point (usually 24-72 hours). In another embodiment, the assay used is a mixed lymphocyte reaction (MLR). In this assay, primary T cells are stimulated with allogeneic APCs. Culture supernatants are collected at a time point (usually 24-72 hours). Human IFN-γ levels in the culture supernatants are measured by standard ELISA techniques. Commercial kits are available from suppliers, and the assay is performed according to the manufacturer's recommendations.
[0204] The term "purified," when applied to nucleic acids (e.g., encoding immunomodulatory proteins of the invention), generally refers to a nucleic acid or polypeptide that is substantially free from other components as determined by analytical techniques well known in the art (e.g., a purified polypeptide or polynucleotide will form a distinct band in an electrophoretic gel, a chromatographic eluate, and / or a medium subjected to density gradient centrifugation). For example, a nucleic acid or polypeptide that gives rise to essentially one band in an electrophoretic gel is "purified." Purified nucleic acids or proteins of the invention are at least about 50% pure, typically at least about 75%, 80%, 85%, 90%, 95%, 96%, 99% or more pure (e.g., on a weight percent or molar basis).
[0205] The term "recombinant" indicates that a substance (e.g., a nucleic acid or polypeptide) has been artificially (i.e., non-naturally) altered by human intervention. The alteration can be performed on a substance in or removed from its natural environment or state. For example, a "recombinant nucleic acid" is one produced by recombining nucleic acids, e.g., during cloning, affinity engineering, DNA shuffling, or other well-known molecular biological procedures. A "recombinant DNA molecule" is composed of segments of DNA joined together by such molecular biological techniques. The term "recombinant protein" or "recombinant polypeptide," as used herein, refers to a protein molecule expressed using a recombinant DNA molecule. A "recombinant host cell" is a cell that contains and / or expresses a recombinant nucleic acid or is otherwise altered by genetic engineering (e.g., by introducing into the cell a nucleic acid molecule encoding a recombinant protein (e.g., a transmembrane immunomodulatory protein provided herein)). Transcriptional control signals in eukaryotes include "promoter" and "enhancer" elements. Promoters and enhancers consist of short arrays of DNA sequences that specifically interact with cellular proteins involved in transcription. Promoter and enhancer elements have been isolated from a wide variety of eukaryotic sources, including genes in yeast, insect and mammalian cells, and viruses (analogous control elements, i.e., promoters, are also found in prokaryotes). The selection of a particular promoter and enhancer depends on the cell type to be used to express the protein of interest. The terms "in functional combination," "in functional order," and "operably linked," as used herein, refer to the linking of nucleic acid sequences in a manner or orientation that produces a nucleic acid molecule capable of directing the transcription of a given gene and / or the synthesis of a desired protein molecule.
[0206] The term "recombinant expression vector," as used herein, refers to a DNA molecule containing a desired coding sequence and appropriate nucleic acid sequences necessary for expression of the operably linked coding sequence in a particular host cell. Nucleic acid sequences necessary for expression in prokaryotes include a promoter, optionally an operator sequence, a ribosome binding site, and possibly other sequences. Eukaryotic cells are known to utilize promoters, enhancers, and termination and polyadenylation signals. If desired, a secretory signal peptide sequence can also be encoded by the recombinant expression vector operably linked to the coding sequence of the recombinant protein (e.g., a recombinant fusion protein) so that the expressed fusion protein can be secreted by the recombinant host cell for easier isolation of the fusion protein from the cell. This term includes vectors as autonomously replicating nucleic acid structures and vectors that integrate into the genome of a host cell into which they are introduced. Among vectors are viral vectors, such as lentiviral vectors.
[0207] The term "selectivity" refers to the preference of a protein or polypeptide of interest for specific binding of a substrate, such as a cognate binding partner, compared to specific binding of the protein of interest to another substrate, such as a different cognate binding partner. Selectivity can be measured by the binding activity (e.g., binding affinity) (e.g., K) of the protein of interest to a first substrate (e.g., a first cognate binding partner). d1 ) and the binding activity (e.g., binding affinity) (e.g., K d2 ) can be reflected as a ratio.
[0208] The term "sequence identity" as used herein refers to the sequence identity between genes or proteins at the nucleotide or amino acid level, respectively. "Sequence identity" is a measure of identity between proteins at the amino acid level and between nucleic acids at the nucleotide level. The sequence identity of proteins can be determined by comparing the amino acid sequence at a given position in each sequence when the sequences are aligned. Similarly, the sequence identity of nucleic acids can be determined by comparing the nucleotide sequence at a given position in each sequence when the sequences are aligned. Methods for aligning sequences for comparison are well known in the art, and include GAP, BESTFIT, BLAST, FASTA, and TFASTA. The BLAST algorithm calculates the percent sequence identity and performs a statistical analysis of the similarity between two sequences. Software for performing BLAST analysis is publicly available through the website of the National Center for Biotechnology Information (NCBI).
[0209] The term "soluble" when used herein in reference to a protein means that the protein is not a membrane protein. Generally, a soluble protein contains only the extracellular domain or a portion thereof of an IgSF family member receptor, which contains one or more IgSF domains or specific binding fragments thereof, but does not contain a transmembrane domain. In some cases, the solubility of a protein can be improved by linking or binding to an Fc domain directly or indirectly via a linker, which can also improve the stability and / or half-life of the protein in some cases. In some aspects, the soluble protein is an Fc fusion protein.
[0210] The term "species," as used herein with respect to a polypeptide or nucleic acid, refers to a group of molecules having identical or substantially identical sequences. Differences between polypeptides of the same species can occur due to differences in post-translational modifications, such as glycosylation, phosphorylation, ubiquitination, nitrosylation, methylation, acetylation, and lipidation. Slightly truncated polypeptide sequences that differ from the full-length species by (or encode differences in) only one, two, or three amino acid residues or less at the amino or carboxy terminus are considered to be sequences of a single species. Such microheterogeneity is a common feature of manufactured proteins.
[0211] The term "specific binding fragment," as used herein with reference to a full-length wild-type mammalian CD80 polypeptide or its IgV or IgC domain, refers to a polypeptide having a subsequence of the IgV and / or IgC domain and specifically binding to mammalian CD28, mammalian PD-L1, and / or mammalian CTLA-4 (e.g., human or murine CD28, PD-L1, and / or CTLA-4) in vitro and / or in vivo. In some embodiments, a specific binding fragment of CD80 IgV or CD80 IgC is at least 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of the sequence length of the full-length wild-type sequence. The sequence of the specific binding fragment can be altered to form a variant CD80.
[0212] The term "specifically binds" as used herein refers to the ability of a protein to bind to a target protein under specific binding conditions such that its affinity or avidity is at least 5 times greater than the average affinity or avidity of the same protein for a population of random peptides or polypeptides of sufficient statistical size, but optionally at least 10, 20, 30, 40, 50, 100, 250, or 500 times greater, or even at least 1000 times greater. A specifically binding protein need not bind only to a single target molecule, but may also specifically bind to non-target molecules (e.g., paralogs or orthologs) due to similarities in structural form between the target and non-target molecules. Those skilled in the art will recognize that specific binding to molecules with the same function in different animal species (i.e., orthologs) or to non-target molecules (e.g., paralogs) with substantially similar epitopes to the target molecule can occur and does not compromise the specificity of the binding determined by comparing to a statistically plausible population of unique non-targets (e.g., random polypeptides). Thus, the polypeptides of the present invention may specifically bind to more than one distinct target molecular species due to cross-reactivity. Specific binding between two proteins can be determined using solid-phase ELISA immunoassays or surface plasmon resonance (e.g., Biacore) measurements. Generally, the interaction between two binding proteins is greater than 1×10 -5 Less than M, often 1 × 10 -12 M has a low dissociation constant (K d In certain embodiments of the present disclosure, the interaction between the two binding proteins has a molecular weight of 1×10 -6 M, 1 x 10 -7 M, 1 x 10 -8 M, 1 x 10 -9 M, 1 x 10 -10 M or 1×10 -11 It has a dissociation constant of M.
[0213] The terms "surface-expressed" or "surface expression," with respect to a mammalian cell expressing a polypeptide, mean that the polypeptide is expressed as a membrane protein. In some embodiments, the membrane protein is a transmembrane protein.
[0214] "Synthetic," as used herein with respect to, for example, a synthetic nucleic acid molecule or a synthetic gene or a synthetic peptide, refers to a nucleic acid molecule or polypeptide molecule that is produced by recombinant and / or chemical synthesis methods.
[0215] The term "targeting moiety," as used herein, refers to a composition that is covalently or non-covalently attached to or physically encapsulates a polypeptide comprising a variant CD80. A targeting moiety has specific binding affinity for a desired counterstructure, such as a cell surface receptor (e.g., the B7 family member PD-L1) or a tumor antigen (e.g., a tumor-specific antigen (TSA) or tumor-associated antigen (TAA), e.g., B7-H6). Typically, the desired counterstructure is localized on a specific tissue or cell type. A targeting moiety can be an antibody, an antigen-binding fragment (Fab), a V-cell, or a mAb. H and V L variable fragment (Fv) containing V linked together as a single chain H and V L and other antibody V region fragments, such as Fab', F(ab)2, F(ab')2, dsFv diabodies, nanobodies, soluble receptors, receptor ligands, affinity matured receptors or ligands, and small molecule (less than 500 daltons) compositions (e.g., specific binding receptor compositions). Targeting moieties can also be covalently or non-covalently attached to the lipid membrane of liposomes that encapsulate the polypeptides of the invention.
[0216] The term "transmembrane protein" as used herein refers to a membrane protein that substantially or completely spans a lipid bilayer, such as those found in biological membranes, e.g., mammalian cells, or in artificial constructs, e.g., liposomes. Transmembrane proteins contain a transmembrane domain ("transmembrane domain") that is integrated into the lipid bilayer and whose integration is thermodynamically stable under physiological conditions. Transmembrane domains can generally be predicted from their amino acid sequences by any number of commercially available bioinformatics software applications based on their increased hydrophobicity compared to regions of the protein that interact with an aqueous environment (e.g., cytosol, extracellular fluid). Transmembrane domains are often hydrophobic α-helices that span the membrane. Transmembrane proteins can pass through both layers of the lipid bilayer one or more times. The transmembrane immunomodulatory proteins provided herein are included in transmembrane proteins. In addition to the transmembrane domain, the transmembrane immunomodulatory proteins of the present invention further comprise an ectodomain and, in some embodiments, an endodomain.
[0217] The terms "treating," "treatment," or "therapy" of a disease or disorder, as used herein, refer to slowing, halting, or reversing the progression of the disease or disorder, as evidenced by the reduction, arrest, or elimination of any clinical or diagnostic symptoms, by administering a therapeutic composition of the invention (e.g., containing an immunomodulatory protein), either alone or in combination with another compound described herein. As used herein in the context of cancer, the terms "treating" cancer, "inhibiting" cancer, "inhibiting" cancer, or "inhibition" of cancer refer to at least one of a statistically significant reduction in tumor growth rate, halting tumor growth, or a reduction in tumor size, mass, metabolic activity, or volume, or a statistically significant increase in progression-free survival (PFS) or overall survival (OS), as measured by standard criteria, such as, but not limited to, Response Evaluation Criteria for Solid Tumors (RECIST). "Preventing" a disease or disorder, "prophylaxis" of a disease or disorder, or "prevention" of a disease or disorder, as used in the context of this invention, refers to the administration of an immunomodulatory polypeptide, either alone or in combination with another compound, to prevent the appearance or development of a disease or disorder or some or all of the symptoms of a disease or disorder, or to reduce the likelihood of developing a disease or disorder.
[0218] The term "tumor-specific antigen" or "TSA," as used herein, refers to a counter structure that is present primarily on tumor cells of a mammalian subject but is not generally found on normal cells of the mammalian subject. A tumor-specific antigen need not be present exclusively on tumor cells, but rather the proportion of cells in a particular mammal that bear the tumor-specific antigen is sufficiently high, or the level of the tumor-specific antigen on the surface of the tumor is sufficiently high, so that it can be targeted with an anti-tumor therapeutic agent (e.g., an immunomodulatory polypeptide of the invention) and provide for the prevention or treatment of the mammal from the effects of the tumor. In some embodiments, in a statistically random sample of cells from a mammal with a tumor, at least 50% of the cells that display the TSA are cancerous. In other embodiments, at least 60%, 70%, 80%, 85%, 90%, 95%, or 99% of the cells that display the TSA are cancerous.
[0219] The term "variant" (also "modified" or "mutant"), when used with reference to variant CD80, refers to a CD80 created by human intervention, e.g., mammalian (e.g., human or murine) CD80. A variant CD80 is a polypeptide having an altered amino acid sequence compared to unmodified or wild-type CD80. A variant CD80 is a polypeptide that differs from the wild-type CD80 isoform sequence by one or more amino acid substitutions, deletions, additions, or a combination thereof. For purposes herein, a variant CD80 contains at least one affinity-modifying domain whereby one or more amino acid differences occur in the IgSF domain (e.g., the IgV domain). A variant CD80 can contain 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or more amino acid differences, e.g., amino acid substitutions. A variant CD80 polypeptide generally exhibits at least 50%, 60%, 70%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity with a corresponding wild-type or unmodified CD80, e.g., the sequence of SEQ ID NO:1, its mature sequence, or a portion thereof containing the extracellular domain or the IgSF domain. In some embodiments, the variant CD80 polypeptide exhibits at least 50%, 60%, 70%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to a corresponding wild-type or unmodified CD80, including the sequence set forth in SEQ ID NO:2, SEQ ID NO:76, or SEQ ID NO:150, or SEQ ID NO:1245.
[0220] Non-naturally occurring and naturally occurring amino acids are included within the scope of permissible substitutions or additions. The variant CD80 is not limited to any particular method of production, including, for example, de novo chemical synthesis, de novo recombinant DNA technology, or a combination thereof. The variant CD80 of the present invention specifically binds to at least one or more of CD28, PD-L1, and / or CTLA-4 of a mammalian species. In some embodiments, the altered amino acid sequence results in altered (i.e., increased or decreased) binding affinity or avidity with CD28, PD-L1, and / or CTLA-4 compared to the unmodified or wild-type CD80 protein. Increased or decreased binding affinity or avidity can be determined using well-known binding assays, such as flow cytometry. Larsen et al., American Journal of Transplantation, Vol. 5:443-453 (2005). See also Linsley et al., Immunity, Vol. 1(9): 793-801 (1994). The increase in binding affinity or avidity of the variant CD80 to CD28, PD-L1, and / or CTLA-4 can be at least 5% greater than that of unmodified or wild-type CD80, and in some embodiments can be at least 10%, 15%, 20%, 30%, 40%, 50%, or 100% greater than that of the unmodified or wild-type CD80 control value. The decrease in binding affinity or avidity of CD80 to CD28, PD-L1, and / or CTLA-4 can be to 95% or less of that of the unmodified or wild-type CD80 control value, and in some embodiments, to 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5% or less of that of the unmodified or wild-type CD80 control value, or to undetectable values. Variant CD80 polypeptides have an altered primary amino acid sequence due to the substitution, addition, or deletion of amino acid residues. The term "variant" in the context of variant CD80 polypeptides should not be construed as imposing any requirement on any particular starting composition or method by which the variant CD80 is made.A variant CD80 can be generated, for example, starting from wild-type mammalian CD80 sequence information, then modeled in silico for binding to CD28, PD-L1, and / or CTLA-4, and finally recombinantly or chemically synthesized to obtain the variant CD80. However, in another example, a variant CD80 can be made by site-directed mutagenesis of unmodified or wild-type CD80. Thus, a variant CD80 refers to a composition, but not necessarily a product produced by any given process. A wide variety of techniques may be used, including recombinant methods, chemical synthesis, or a combination thereof.
[0221] The terms "wild-type" or "native" or "naturally occurring," as used herein in reference to biological material such as nucleic acid molecules, proteins (e.g., CD80), IgSF members, host cells, etc., refer to those found in nature and unmodified by human intervention.
[0222] As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. For example, "a" or "an" means "at least one" or "one or more." It is understood that the aspects and variations described herein include "consisting of" and / or "consisting essentially of" the aspects and variations.
[0223] Throughout this disclosure, various aspects of the claimed subject matter are presented in range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the claimed subject matter. Accordingly, the description of a range should be considered to specifically disclose all possible subranges and individual numerical values within that range. For example, when a range is provided, it is understood that each intervening value between the upper and lower limits of that range, and any other stated or intervening value within that stated range, is encompassed within the claimed subject matter. The upper and lower limits of these smaller ranges may independently be included within the smaller ranges, and are also encompassed within the claimed subject matter, subject to any specifically excluded limits in the stated range. When a stated range includes one or both limits, ranges excluding either or both of those included limits are also encompassed within the claimed subject matter. This applies regardless of the breadth of the range.
[0224] The term "about," as used herein, refers to a normal error range for each value that is readily apparent to one of ordinary skill in the art. Reference herein to a value or parameter with "about" includes (and describes) aspects directed to that value or parameter itself. For example, a description that refers to "about X" includes the description of "X."
[0225] As used herein, "optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances when the event or circumstance occurs and instances when it does not occur. For example, an optionally substituted group means that the group is either unsubstituted or substituted.
[0226] As used herein, abbreviations for any protecting groups, amino acids and other compounds follow their common usage, accepted abbreviations, or those of the IUPAC-IUB Commission on Biochemical Nomenclature (see (1972) Biochem. 11:1726), unless otherwise indicated.
[0227] I. Variant CD80 IGSF Domain Fusion Proteins Provided herein are fusion proteins containing variant CD80 polypeptides that exhibit altered (e.g., increased or decreased) binding activity or affinity for one or more CD80 binding partners. In some embodiments, the CD80 binding partner is CD28, PD-L1, or CTLA-4. In some embodiments, the variant CD80 polypeptide exhibits altered (e.g., increased) binding activity or affinity for one or more CD80 binding partners. In some embodiments, the variant CD80 polypeptide exhibits altered (e.g., increased) binding activity or affinity for two or more CD80 binding partners. In some embodiments, the two or more CD80 binding partners are two or more of CD28, PD-L1, or CTLA-4. In some embodiments, the variant CD80 polypeptide exhibits altered (e.g., increased) binding activity or affinity for three CD80 binding partners. In some embodiments, the CD80 binding partners are CD28, PD-L1, and CTLA-4. In some embodiments, a variant CD80 polypeptide contains one or more amino acid modifications, e.g., one or more substitutions (or "mutations" or "exchanges"), deletions, or additions, in the immunoglobulin superfamily (IgSF) domain (IgD) compared to a wild-type or unmodified CD80 polypeptide, or a portion of wild-type or unmodified CD80 containing IgD, or a specific-binding fragment thereof. Thus, provided variant CD80 polypeptides are or comprise variant IgDs (hereinafter referred to as "vIgDs") in which one or more amino acid modifications (e.g., substitutions) are in the IgD. In some embodiments, the variant CD80 is soluble and lacks a transmembrane domain.
[0228] In some embodiments, the variant CD80 polypeptide contains an extracellular domain containing IgD, which comprises an IgV domain and an IgC domain. In some embodiments, the IgD can comprise the entire extracellular domain (ECD). In some embodiments, the IgD comprises an IgV domain or an IgC (e.g., IgC2) domain, or a specific-binding fragment of an IgV domain or an IgC (e.g., IgC2) domain, or a combination thereof. In some embodiments, the IgD can be IgV only, a combination of IgV and IgC, including the entire extracellular domain (ECD), or any combination of the Ig domains of CD80. Table 1 provides exemplary residues corresponding to the IgV or IgC regions of CD80. In some embodiments, the variant CD80 polypeptide contains an IgV or IgC domain, or a specific-binding fragment thereof, with at least one amino acid modification (e.g., substitution) in the IgV or IgC domain, or a specific-binding fragment thereof. In some embodiments, the variant CD80 polypeptide contains an IgV domain or a specific binding fragment thereof, wherein at least one amino acid modification (e.g., substitution) is in the IgV domain or specific binding fragment thereof. In some embodiments, the altered IgV domain or IgC domain is an affinity-altered IgSF domain due to altered binding activity or affinity.
[0229] Table 1. CD80 domains and sequences TIFF2024164118000003.tif67166
[0230] In some embodiments, the variant has one more IgSF domain modified relative to the sequence of the unmodified CD80 sequence. In some embodiments, the unmodified CD80 sequence is wild-type CD80. In some embodiments, the unmodified or wild-type CD80 has the sequence of a native CD80 or its ortholog. In some embodiments, the unmodified CD80 is or comprises the extracellular domain (ECD) of CD80 or a portion thereof containing one or more IgSF domains (see Table 1). For example, the unmodified CD80 polypeptide is or comprises the IgV domain set forth as amino acids 35-135 of SEQ ID NO:1, amino acids 35-138 of SEQ ID NO:1 (see SEQ ID NO:1245), or amino acids 35-141 of SEQ ID NO:1. In some embodiments, the unmodified CD80 polypeptide is or comprises the IgC domain set forth as amino acids 145-230 of SEQ ID NO:1 or amino acids 142-232 of SEQ ID NO:1. In some embodiments, the extracellular domain of an unmodified or wild-type CD80 polypeptide comprises an IgV domain and one or more IgC domains. However, a variant CD80 polypeptide need not comprise both an IgV domain and one or more IgC domains. In some embodiments, a variant CD80 polypeptide comprises or consists essentially of an IgV domain or a specific-binding fragment thereof. In some embodiments, a variant CD80 polypeptide comprises or consists essentially of an IgC domain or a specific-binding fragment thereof. In some embodiments, a variant CD80 is soluble and lacks a transmembrane domain. In some embodiments, a variant CD80 further comprises a transmembrane domain and, optionally, a cytoplasmic domain.
[0231] In some embodiments, the wild-type or unmodified CD80 polypeptide is a mammalian CD80 polypeptide, such as, but not limited to, a human, mouse, cynomolgus monkey, or rat CD80 polypeptide. In some embodiments, the wild-type or unmodified CD80 sequence is human.
[0232] In some embodiments, the wild-type or unmodified CD80 polypeptide (i) has the amino acid sequence set forth in SEQ ID NO:1 or a mature form thereof lacking the signal sequence, (ii) has an amino acid sequence or a mature form thereof that exhibits at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to SEQ ID NO:1, or (iii) is a portion of (i) or (ii) that contains an IgV domain or an IgC domain or a specific-binding fragment thereof.
[0233] In some embodiments, a wild-type or unmodified CD80 polypeptide is or comprises the extracellular domain of CD80 or a portion thereof. For example, in some embodiments, an unmodified or wild-type CD80 polypeptide comprises the amino acid sequence set forth in SEQ ID NO:2, or an ortholog thereof. For example, an unmodified or wild-type CD80 polypeptide can (i) comprise the sequence of amino acids set forth in SEQ ID NO:2, (ii) comprise an amino acid sequence having at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to SEQ ID NO:2, or (iii) is a specific-binding fragment of (i) or (ii) comprising the IgV domain or the IgC domain. In some embodiments, the wild-type or unmodified extracellular domain of CD80 is capable of binding to one or more CD80 binding proteins, such as one or more of CTLA-4, PD-L1, or CD28.
[0234] In some embodiments, a wild-type or unmodified CD80 polypeptide contains an IgV domain or an IgC domain, or a specific-binding fragment thereof. In some embodiments, the IgV domain of a wild-type or unmodified CD80 polypeptide comprises the amino acid sequence set forth in SEQ ID NO:76, 150, or 1245, or an ortholog thereof. For example, the IgV domain of an unmodified or wild-type CD80 polypeptide can (i) contain the amino acid sequence set forth in SEQ ID NO:76, 150, or 1245, (ii) contain an amino acid sequence having at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to SEQ ID NO:76, 150, or 1245, or (iii) is a specific-binding fragment of (i) or (ii). In some embodiments, the wild-type or unmodified IgV domain is capable of binding to one or more CD80 binding proteins, such as one or more of CTLA-4, PD-L1 or CD28.
[0235] In some embodiments, the IgC domain of a wild-type or unmodified CD80 polypeptide comprises the amino acid sequence set forth as residues 145-230, 154-232, or 142-232 of SEQ ID NO:1, or an ortholog thereof. For example, the IgC domain of an unmodified or wild-type CD80 polypeptide can (i) contain the amino acid sequence set forth as residues 145-230, 154-232, or 142-232 of SEQ ID NO: 1, or (ii) contain an amino acid sequence having at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to residues 145-230, 154-232, or 142-232 of SEQ ID NO: 1, or (iii) is a specific-binding fragment of (i) or (ii). In some embodiments, the wild-type or unmodified IgC domain is capable of binding to one or more CD80 binding proteins.
[0236] In some embodiments, the wild-type or unmodified CD80 polypeptide contains a specific-binding fragment of CD80, e.g., a specific-binding fragment of the IgV domain or the IgC domain. In some embodiments, the specific-binding fragment can bind to CD28, PD-L1, and / or CTLA-4. The specific-binding fragment can have an amino acid length of at least 50 amino acids, e.g., at least 60, 70, 80, 90, 100, or 110 amino acids. In some embodiments, the specific-binding fragment of the IgV domain contains an amino acid sequence that is at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the length of the IgV domain set forth as amino acids 35-135, 35-138, 37-138, or 35-141 of SEQ ID NO:1. In some embodiments, a specific binding fragment of an IgC domain comprises an amino acid sequence that is at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% of the length of the IgC domain set forth as amino acids 145-230, 154-232, or 142-232 of SEQ ID NO:1.
[0237] In some embodiments, a variant CD80 IgSF domain fusion protein contains a variant CD80 polypeptide comprising an ECD domain or a portion thereof comprising one or more affinity-modified IgSF domains. In some embodiments, the variant CD80 polypeptide can comprise an IgV domain or an IgC domain, or a specific-binding fragment of an IgV domain or a specific-binding fragment of an IgC domain, wherein at least one of the IgV domain or the IgC domain contains one or more amino acid modifications (e.g., substitutions). In some embodiments, the variant CD80 polypeptide can comprise an IgV domain and an IgC domain, or a specific-binding fragment of an IgV domain and a specific-binding fragment of an IgC domain. In some embodiments, the variant CD80 polypeptide comprises a full-length IgV domain. In some embodiments, the variant CD80 polypeptide comprises a full-length IgC domain. In some embodiments, the variant CD80 polypeptide comprises a specific-binding fragment of an IgV domain. In some embodiments, the variant CD80 polypeptide comprises a specific-binding fragment of an IgC domain. In some embodiments, the variant CD80 polypeptide comprises a full-length IgV domain and a full-length IgC domain. In some embodiments, the variant CD80 polypeptide comprises a full-length IgV domain and a specific-binding fragment of the IgC domain. In some embodiments, the variant CD80 polypeptide comprises a specific-binding fragment of the IgV domain and a full-length IgC domain. In some embodiments, the variant CD80 polypeptide comprises a specific-binding fragment of the IgV domain and a specific-binding fragment of the IgC domain.
[0238] In any of such embodiments, the one or more amino acid modifications (e.g., substitutions) of the variant CD80 polypeptide can be located in any one or more of the CD80 polypeptide domains. For example, in some embodiments, the one or more amino acid modifications (e.g., substitutions) are located in the extracellular domain of the variant CD80 polypeptide. In some embodiments, the one or more amino acid modifications (e.g., substitutions) are located in the IgV domain or a specific-binding fragment of the IgV domain. In some embodiments, the one or more amino acid modifications (e.g., substitutions) are located in the IgC domain or a specific-binding fragment of the IgC domain.
[0239] Generally, each of the various attributes of a polypeptide (e.g., affinity of CD80 for a binding partner, number of mutations per polypeptide chain, number of linked polypeptide chains, number and nature of amino acid changes per variant CD80, etc.) is disclosed separately. However, as will be apparent to one of skill in the art, any particular polypeptide can include a combination of these independent attributes. It is understood that reference to amino acids, including reference to specific sequences set forth as SEQ ID NOs, used to describe the domain organization of IgSF domains is for illustrative purposes and is not intended to limit the scope of the provided embodiments. It is understood that descriptions of polypeptides, and their domains, are theoretically derived based on homology analysis and alignment with similar molecules. Thus, the exact locus can vary and is not necessarily the same from protein to protein. Thus, a particular IgSF domain (e.g., a particular IgV or IgC domain) can be several (e.g., 1, 2, 3, or 4) amino acids longer or shorter.
[0240] Furthermore, the various aspects of the invention as discussed below are frequently provided within the meanings of the defined terms as disclosed above. Accordingly, aspects described in a particular definition should be construed as being incorporated by reference when the defined terms are utilized in the discussion of the various aspects and attributes described herein. Accordingly, the headings, the order of presentation of the various aspects and embodiments, and the separate disclosure of each independent attribute are not intended to be limitations on the scope of the present disclosure.
[0241] A. Variant CD80 Polypeptides Provided herein are variant CD80 IgSF domain fusion polypeptides that contain at least one affinity-modified IgSF domain, or a specific-binding fragment thereof, relative to the IgSF domain contained in a wild-type or unmodified CD80 polypeptide, such that the variant CD80 polypeptide exhibits altered (increased or decreased) binding activity or affinity for one or more cognate binding partners, CD28, PD-L1, or CTLA-4, relative to the wild-type or unmodified CD80 polypeptide. In some embodiments, the variant CD80 polypeptide has a binding affinity for CD28, PD-L1, or CTLA-4 that differs from that of a wild-type or unmodified CD80 polypeptide control sequence, as measured, for example, by solid-phase ELISA immunoassay, flow cytometry, or surface plasmon resonance (Biacore) assay. In some embodiments, the variant CD80 polypeptide has increased binding affinity for CD28, PD-L1, and / or CTLA-4. In some embodiments, the variant CD80 polypeptide has increased binding affinity for CD28 and / or CTLA-4. In some embodiments, the variant CD80 polypeptide has a reduced binding affinity for PD-L1. CD28, PD-L1 and / or CTLA-4 can be mammalian proteins, e.g., human proteins or murine proteins.
[0242] Altered (e.g., increased) binding activity or affinity for CD28, PD-L1, and / or CTLA-4 is conferred by one or more amino acid modifications in the IgSF domain of a wild-type or unmodified IgSF domain. A wild-type or unmodified CD80 sequence need not necessarily be used as the starting composition to generate the variant CD80 polypeptides described herein. Thus, the use of the term "substitution" does not imply that the provided embodiments are limited to a particular method of making the variant CD80 polypeptide. Variant CD80 polypeptides can be made, for example, by de novo peptide synthesis and thus do not necessarily require a "substitution" in the sense of changing the codon encoding the substitution. This principle also extends to the terms "addition" and "deletion" of amino acid residues, which also do not imply a particular method of production. The means by which variant CD80 polypeptides are designed or made is not limited to any particular method. However, in some embodiments, nucleic acids encoding wild-type or unmodified CD80 are mutagenized from wild-type or unmodified CD80 genetic material according to the methods disclosed in the Examples or other methods known to those of skill in the art, and screened for the desired specific binding affinity and / or induction of IFN-γ expression or other functional activity. In some embodiments, variant CD80 polypeptides are synthesized de novo using protein or nucleic acid sequences available in any number of publicly available databases, and then subsequently screened. The National Center for Biotechnology Information provides such information, and its website is publicly accessible via the internet, as is the UniProtKB database, as discussed above.
[0243] Unless otherwise indicated, as indicated throughout this disclosure, amino acid modifications are designated by the following amino acid position number corresponding to the position numbering of the unmodified ECD sequence set forth in SEQ ID NO:2, or, where applicable, the position numbering of the unmodified IgV sequence set forth in SEQ ID NO:76, 150, or 1245: TIFF2024164118000004.tif60165
[0244] It is within the level of ordinary skill in the art to identify the corresponding position of a modification (e.g., amino acid substitution) in a CD80 polypeptide (including a portion thereof containing its IgSF domain (e.g., IgV)) by aligning a reference sequence with, for example, SEQ ID NO:2 or SEQ ID NO:76 or SEQ ID NO:150 or SEQ ID NO:1245. In describing modifications throughout this disclosure, the amino acid position is shown centered, the corresponding unmodified (e.g., wild-type) amino acid is listed before the number, and the amino acid substitution of the identified variant is listed after the number. If the modification is a deletion at that position, it is indicated as "del," and if the modification is an insertion at that position, it is indicated as "ins." In some cases, the amino acid position is shown centered and the insertion is listed, the corresponding unmodified (e.g., wild-type) amino acid is listed before and after the number, and the amino acid insertion of the identified variant is listed after the unmodified (e.g., wild-type) amino acid.
[0245] In certain embodiments provided herein, the amino acid modifications (e.g., substitutions) are in the entire extracellular domain of wild-type CD80. In some embodiments, the variant CD80 polypeptide contains amino acid residues corresponding to amino acid residues 35-230 of the exemplary wild-type human CD80 extracellular domain set forth in SEQ ID NO:1. In some embodiments, the variant CD80 polypeptide contains one or more amino acid substitutions in the extracellular domain corresponding to amino acid residues 35-230 of the exemplary wild-type human CD80 extracellular domain set forth in SEQ ID NO:1. In some embodiments, the extracellular domain of wild-type CD80 is set forth in SEQ ID NO:2. In some embodiments, variant CD80 polypeptides containing one or more amino acid substitutions in the extracellular domain have an amino acid sequence having at least, or at least about, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the sequence set forth in SEQ ID NO:2.
[0246] In some embodiments, the variant CD80 polypeptide has one or more amino acid modifications (e.g., substitutions) in a wild-type or unmodified CD80 sequence. The one or more amino acid modifications (e.g., substitutions) can be in the ectodomain (extracellular domain) of the wild-type or unmodified CD80 sequence, e.g., the extracellular domain. In some embodiments, the one or more amino acid modifications (e.g., substitutions) are in the IgV domain or a specific-binding fragment thereof. In some embodiments of the variant CD80 polypeptide, some of the one or more amino acid modifications (e.g., substitutions) are in the IgV domain or a specific-binding fragment thereof, and some of the one or more amino acid modifications (e.g., substitutions) are in the IgC domain or a specific-binding fragment thereof.
[0247] In some embodiments, the variant CD80 polypeptide has up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid modifications (e.g., substitutions). The modifications (e.g., substitutions) can be in the IgV domain or the IgC domain. In some embodiments, the variant CD80 polypeptide has up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid modifications (e.g., substitutions) in the IgV domain or specific-binding fragment thereof. In some embodiments, the variant CD80 polypeptide has up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid modifications (e.g., substitutions) in the IgC domain or specific-binding fragment thereof. In some embodiments, the variant CD80 polypeptide has at least about 85%, 86%, 86%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to a wild-type or unmodified CD80 polypeptide or specific-binding fragment thereof (e.g., the amino acid sequence of SEQ ID NO:2, 76, 150, or 1245).
[0248] In some embodiments, the variant CD80 polypeptide is a variant CD80 polypeptide having a sequence similar to that of unmodified CD80 or a specific binding fragment thereof, as defined by SEQ ID NO: 4, 7, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 33, 34, 35, 36, 37, 38, 40, 41, 42, 43, 44, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92 , 93, 94, 95, 96, 97, 99, 102, 103, 104, 107, 108, 109, 110, 114, 115, 116, 117, 118, 120, 121, 122, 126, 127, 128, 129, 130, 133, 137, 140, 142, 143, 144, 148, 149, 152, 154, 160, 162, 164, 168, 169, 174, 175, 177, 178, 182, 183, 185, 178, 185, 188, 190, 192, 193, or 199. In some embodiments, such variant CD80 polypeptides exhibit altered binding affinity for one or more of CD28, PD-L1, or CTLA-4 compared to wild-type or unmodified CD80 polypeptides. For example, in some embodiments, variant CD80 polypeptides exhibit increased binding affinity for CD28, PD-L1, and / or CTLA-4 compared to wild-type or unmodified CD80 polypeptides.
[0249] In some embodiments, the variant CD80 polypeptide is TIFF2024164118000005.tif151165.
[0250] In some embodiments, the one or more amino acid modifications, e.g., substitutions, are: TIFF2024164118000006.tif238165TIFF2024164118000007.tif238165TIFF2024164118000008.tif238164TIFF2024164118000009.tif238163TIFF2024164118000010.tif238166TIFF2024164118000011.tif238166TIFF2024164118000012.tif238166TIFF2024164118000013.tif238166TIFF2024164118000014.tif37165
[0251] In some embodiments, the variant CD80 polypeptide has one or more amino acid modifications (e.g., substitutions) in unmodified CD80 or a specific binding fragment thereof corresponding to positions 7, 23, 26, 34, 49, 51, 55, 57, 58, 71, 73, 78, 79, 82, and / or 84 with reference to the numbering of SEQ ID NO:2. In some embodiments, the variant CD80 polypeptide has one or more amino acid modifications (e.g., substitutions) in unmodified CD80 or a specific binding fragment thereof corresponding to positions 7, 23, 26, 34, 49, 51, 55, 57, 58, 71, 73, 78, 79, 82, or 84 with reference to the numbering of SEQ ID NO:2. In some embodiments, the variant CD80 polypeptide has an alteration, e.g., an amino acid substitution, at any two or more of the aforementioned positions, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more of the positions.
[0252] In some embodiments, the variant CD80 polypeptide is TIFF2024164118000015.tif64164.
[0253] In some embodiments, the variant CD80 polypeptide comprises an amino acid modification Includes TIFF2024164118000016.tif57165TIFF2024164118000017.tif238165TIFF2024164118000018.tif238165TIFF2024164118000019.tif238164TIFF2024164118000020.tif130159.
[0254] In some embodiments, the variant CD80 polypeptide has one or more amino acid modifications (e.g., substitutions) in unmodified CD80 or a specific-binding fragment thereof corresponding to positions 7, 13, 15, 16, 20, 22, 23, 24, 25, 26, 27, 30, 31, 33, 34, 35, 36, 38, 41, 42, 43, 46, 47, 48, 51, 53, 54, 55, 57, 58, 61, 62, 65, 67, 68, 69, 70, 71, 72, 73, 74, 76, 77, 78, 79, 81, 82, 84, 85, 86, 87, 88, 92, 94, 95, and / or 97 with reference to the numbering of SEQ ID NO:2. In some embodiments, the variant CD80 polypeptide has one or more amino acid modifications (e.g., substitutions) in unmodified CD80 or a specific-binding fragment thereof corresponding to positions 7, 23, 26, 30, 34, 35, 46, 51, 55, 57, 58, 65, 71, 73, 78, 79, 82, or 84, with reference to the numbering of SEQ ID NO: 2. In some embodiments, the variant CD80 polypeptide has modifications, e.g., amino acid substitutions, at any two or more of the foregoing positions, e.g., at 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or more of the positions.
[0255] In some embodiments, the variant CD80 polypeptide is TIFF2024164118000021.tif64164. In some embodiments, the variant CD80 polypeptide has one or more amino acid substitutions selected from E7D, E23D, E23G, A26E, A26P, A26S, A26T, I30F, I30T, I30V, K34E, E35D, E35G, D46E, D46V, P51A, N55D, N55I, T57A, T57I, I58V, L65P, A71D, A71G, R73S, G78A, T79A, T79I, T79L, T79P, C82R, V84A, V84I, L85Q, or a conservative amino acid substitution thereof. In some embodiments, the variant CD80 polypeptide comprises any one or more of the foregoing amino acid substitutions, for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or more amino acid substitutions. In some embodiments, the variant CD80 polypeptide comprises only one amino acid difference compared to an unmodified or wild-type CD80 polypeptide comprising only one of the foregoing amino acid substitutions.
[0256] In some embodiments, the variant CD80 polypeptide contains one or more additional amino acid modifications (e.g., substitutions) in unmodified CD80 or a specific-binding fragment thereof corresponding to positions 12, 18, 29, 31, 37, 38, 41, 43, 44, 47, 61, 67, 68, 69, 70, 72, 77, 83, 88, 89, 90, 91, or 93 with reference to the numbering of SEQ ID NO:2. In some embodiments, the variant CD80 polypeptide has one or more additional amino acid substitutions selected from among A12T, A12V, H18L, H18Y, R29H, Y31H, K37E, M38T, T41A, M43I, S44P, M47L, M47T, I67T, V68A, V68M, I69T, L70P, L70R, L70Q, L72P, E77G, V83A, V83I, E88D, K89E, K89N, D90G, D90N, A91T, K93R.
[0257] Conservative amino acid substitutions are any amino acids that belong to the same class of amino acids as the substituted amino acid, other than wild-type or unmodified amino acids.The amino acid classes are aliphatic (glycine, alanine, valine, leucine, and isoleucine), hydroxyl or sulfur-containing (serine, cysteine, threonine, and methionine), cyclic (proline), aromatic (phenylalanine, tyrosine, tryptophan), basic (histidine, lysine, and arginine), and acidic / amide (aspartic acid, glutamic acid, asparagine, and glutamine).Thus, for example, conservative amino acid substitutions for the A26E substitution include A26D, A26N, and A26Q amino acid substitutions.
[0258] In some embodiments, the variant CD80 polypeptide has one or more amino acid substitutions, or conservative amino acid substitutions thereof, selected from among L70Q, K89R, D90G, D90K, A91G, F92Y, K93R, I118V, T120S, or T130A, with reference to the numbering set forth in SEQ ID NO: 2. In some embodiments, the variant CD80 polypeptide has two or more amino acid substitutions, or conservative amino acid substitutions thereof, selected from among L70Q, K89R, D90G, D90K, A91G, F92Y, K93R, I118V, T120S, or T130A, with reference to the numbering set forth in SEQ ID NO: 2. In some embodiments, the variant CD80 polypeptide has three or more amino acid substitutions from among L70Q, K89R, D90G, D90K, A91G, F92Y, K93R, I118V, T120S, or T130A, with reference to the numbering set forth in SEQ ID NO:2, or conservative amino acid substitutions thereof.
[0259] In some embodiments, the variant CD80 polypeptide comprises an amino acid substitution Has or contains TIFF2024164118000022.tif37156.
[0260] In some embodiments, the variant CD80 polypeptide has or comprises the amino acid substitutions A91G / I118V / T120S / T130A.
[0261] In some embodiments, the variant CD80 polypeptide has or comprises the amino acid substitutions S21P / L70Q / D90G / I118V / T120S / T130A.
[0262] In some embodiments, the variant CD80 polypeptide has or comprises the amino acid substitutions E88D / K89R / D90K / A91G / F92Y / K93R.
[0263] In some embodiments, the variant CD80 polypeptide has or comprises the amino acid substitutions I67T / L70Q / A91G / I118V / T120S / T130A.
[0264] In some embodiments, the variant CD80 polypeptide comprises an amino acid modification of unmodified CD80 or a specific-binding fragment thereof at a position corresponding to position 18 with reference to the numbering of positions set forth in SEQ ID NO:2. In some embodiments, the amino acid modification is the amino acid substitution H18Y or a conservative amino acid substitution thereof. In some embodiments, the variant CD80 polypeptide further contains one or more amino acid modifications, e.g., amino acid substitutions, at one or more positions 26, 35, 46, 47, 68, 71, 85, or 90. In some embodiments, the one or more amino acid modifications are one or more of the amino acid substitutions A26E, E35D, D46E, D46V, M47I, M47L, V68M, A71G, L85Q, or D90G, or a conservative amino acid substitution thereof. In some embodiments, the variant CD80 polypeptide comprises the amino acid modifications H18Y / A26E, H18Y / E35D, H18Y / D46E, H18Y / D46V, H18Y / M47I, H18Y / M47L, H18Y / V68M, H18Y / A71G, H18Y / L85Q, H18Y / D90G. The variant CD80 polypeptide can be provided with additional amino acid modifications according to the provided embodiments. Table 2 describes exemplary amino acid modifications and variant CD80 polypeptides that are described.
[0265] In some embodiments, the variant CD80 polypeptide comprises an amino acid modification of unmodified CD80 or a specific-binding fragment thereof at a position corresponding to position 26 with reference to the numbering of positions set forth in SEQ ID NO:2. In some embodiments, the amino acid modification is the amino acid substitution A26E, or a conservative amino acid substitution thereof. In some embodiments, the variant CD80 polypeptide further contains one or more amino acid modifications, e.g., amino acid substitutions, at one or more positions 18, 35, 46, 47, 68, 71, 85, or 90. In some embodiments, the one or more amino acid modifications are one or more of the amino acid substitutions H18Y, E35D, D46E, D46V, M47I, M47L, V68M, A71G, L85Q, or D90G, or a conservative amino acid substitution thereof. In some embodiments, the variant CD80 polypeptide comprises the amino acid modifications H18Y / A26E, A26E / E35D, A26E / D46E, A26E / D46V, A26E / M47I, A26E / M47L, A26E / V68M, A26E / A71G, A26E / L85Q, A26E / D90G. The variant CD80 polypeptide can comprise additional amino acid modifications, such as any described herein, in accordance with provided embodiments. Table 2 describes exemplary amino acid modifications and variant CD80 polypeptides that are described.
[0266] In some embodiments, the variant CD80 polypeptide comprises an amino acid modification of unmodified CD80 or a specific-binding fragment thereof at a position corresponding to position 35 with reference to the numbering of positions set forth in SEQ ID NO:2. In some embodiments, the amino acid modification is the amino acid substitution E35D, or a conservative amino acid substitution thereof. In some embodiments, the variant CD80 polypeptide further contains one or more amino acid modifications, e.g., amino acid substitutions, at one or more of positions 18, 26, 46, 47, 68, 71, 85, or 90. In some embodiments, the one or more amino acid modifications are one or more of the following amino acid substitutions: H18Y, A26E, D46E, D46V, M47I, M47L, V68M, A71G, L85Q, or D90G, or a conservative amino acid substitution thereof. In some embodiments, the variant CD80 polypeptide comprises the amino acid modifications H18Y / E35D, A26E / E35D, E35D / D46E, E35D / D46V, E35D / M47I, E35D / M47L, E35D / V68M, E35D / A71G, E35D / L85Q, or E35D / D90G. The variant CD80 polypeptide can comprise additional amino acid modifications, such as any described herein, according to provided embodiments. Table 2 describes exemplary amino acid modifications and variant CD80 polypeptides that are described. In some embodiments, the variant CD80 polypeptide comprises the amino acid modification of unmodified CD80 or a specific-binding fragment thereof at a position corresponding to position 46 with reference to the position numbering set forth in SEQ ID NO:2. In some embodiments, the amino acid modification is the amino acid substitution D46E or D46V, or a conservative amino acid substitution thereof. In some embodiments, the variant CD80 polypeptide further contains one or more amino acid modifications, e.g., amino acid substitutions, at one or more positions 18, 26, 35, 47, 68, 71, 85, or 90. In some embodiments, the one or more amino acid modifications are one or more of H18Y, A26E, E35D, M47I, M47L, V68M, A71G, L85Q, or D90G amino acid substitutions, or conservative amino acid substitutions thereof.In some embodiments, variant CD80 polypeptides comprise the amino acid modifications H18Y / D46E, A26E / D46E, E35D / D46E, D46E / M47I, D46E / M47L, D46E / V68M, D46E / A71G, D46E / L85Q, D46E / D90G. In some embodiments, variant CD80 polypeptides comprise the amino acid modifications H18Y / D46V, A26E / D46V, E35D / D46V, D46V / M47I, D46V / M47L, D46V / V68M, D46V / A71G, D46V / L85Q, D46V / D90G. Variant CD80 polypeptides can comprise additional amino acid modifications such as any described herein, according to provided embodiments. Table 2 describes exemplary amino acid modified and variant CD80 polypeptides that are described.
[0267] In some embodiments, the variant CD80 polypeptide comprises an amino acid modification of unmodified CD80 or a specific-binding fragment thereof at a position corresponding to position 47 with reference to the numbering of positions set forth in SEQ ID NO:2. In some embodiments, the amino acid modification is amino acid substitution M47I or M47L, or a conservative amino acid substitution thereof. In some embodiments, the variant CD80 polypeptide further contains one or more amino acid modifications, e.g., amino acid substitutions, at one or more positions 18, 26, 35, 46, 68, 71, 85, or 90. In some embodiments, the one or more amino acid modifications are one or more of the following amino acid substitutions: H18Y, A26E, E35D, D46E, D46V, V68M, A71G, L85Q, or D90G, or a conservative amino acid substitution thereof. In some embodiments, the variant CD80 polypeptide comprises the amino acid modifications H18Y / M47I, A26E / M47I, E35D / M47I, M47I / D46E, M47I / D46V, M47I / V68M, M47I / A71G, M47I / L85Q, or M47I / D90G. In some embodiments, the variant CD80 polypeptide comprises the amino acid modifications H18Y / M47L, A26E / M47L, E35D / M47L, M47L / D46E, M47L / D46V, M47L / V68M, M47L / A71G, M47L / L85Q, or M47L / D90G. The variant CD80 polypeptide can comprise additional amino acid modifications such as any described herein, according to provided embodiments. Table 2 describes exemplary amino acid modified and variant CD80 polypeptides that are described.
[0268] In some embodiments, the variant CD80 polypeptide comprises an amino acid modification of unmodified CD80 or a specific-binding fragment thereof at a position corresponding to position 68 with reference to the numbering of positions set forth in SEQ ID NO:2. In some embodiments, the amino acid modification is the amino acid substitution V68M, or a conservative amino acid substitution thereof. In some embodiments, the variant CD80 polypeptide further contains one or more amino acid modifications, e.g., amino acid substitutions, at one or more positions 18, 26, 35, 46, 47, 71, 85, or 90. In some embodiments, the one or more amino acid modifications are one or more of the following amino acid substitutions: H18Y, A26E, E35D, D46E, D46V, M47I, M47L, A71G, L85Q, or D90G, or a conservative amino acid substitution thereof. In some embodiments, the variant CD80 polypeptide comprises the amino acid modifications H18Y / V68M, A26E / V68M, E35D / V68M, D46E / V68M, D46V / D68M, M47I / V68M, M47L / V68M, V68M / A71G, V68M / L85Q, V68M / D90G. The variant CD80 polypeptide can comprise additional amino acid modifications, such as any described herein, in accordance with provided embodiments. Table 2 describes exemplary amino acid modifications and variant CD80 polypeptides that are described.
[0269] In some embodiments, the variant CD80 polypeptide comprises an amino acid modification of unmodified CD80 or a specific-binding fragment thereof at a position corresponding to position 71 with reference to the numbering of positions set forth in SEQ ID NO:2. In some embodiments, the amino acid modification is the amino acid substitution A71G, or a conservative amino acid substitution thereof. In some embodiments, the variant CD80 polypeptide further contains one or more amino acid modifications, e.g., amino acid substitutions, at one or more positions 18, 26, 35, 46, 47, 68, 85, or 90. In some embodiments, the one or more amino acid modifications are one or more of the following amino acid substitutions: H18Y, A26E, E35D, D46E, D46V, M47I, M47L, V68M, L85Q, or D90G, or a conservative amino acid substitution thereof. In some embodiments, the variant CD80 polypeptide comprises the amino acid modifications H18Y / A71G, A26E / A71G, E35D / A71G, D46E / A71G, D46V / D68M, M47I / A71G, M47L / A71G, V68M / A71G, A71G / L85Q, A71G / D90G. The variant CD80 polypeptide can comprise additional amino acid modifications, such as any described herein, in accordance with provided embodiments. Table 2 describes exemplary amino acid modifications and variant CD80 polypeptides that are described.
[0270] In some embodiments, the variant CD80 polypeptide comprises an amino acid modification of unmodified CD80 or a specific-binding fragment thereof at a position corresponding to position 85 with reference to the numbering of positions set forth in SEQ ID NO:2. In some embodiments, the amino acid modification is the amino acid substitution L85Q, or a conservative amino acid substitution thereof. In some embodiments, the variant CD80 polypeptide further contains one or more amino acid modifications, e.g., amino acid substitutions, at one or more positions 18, 26, 35, 46, 47, 68, 71, or 90. In some embodiments, the one or more amino acid modifications are one or more of the following amino acid substitutions: H18Y, A26E, E35D, D46E, D46V, M47I, M47L, V68M, A71G, or D90G, or a conservative amino acid substitution thereof. In some embodiments, the variant CD80 polypeptide comprises the amino acid modifications H18Y / L85Q, A26E / L85Q, E35D / L85Q, D46E / L85Q, D46V / D68M, M47I / L85Q, M47L / L85Q, V68M / L85Q, A71G / L85Q, L85Q / D90G. The variant CD80 polypeptide can comprise additional amino acid modifications, such as any described herein, in accordance with provided embodiments. Table 2 describes exemplary amino acid modifications and variant CD80 polypeptides that are described.
[0271] In some embodiments, the variant CD80 polypeptide comprises an amino acid modification of unmodified CD80 or a specific-binding fragment thereof at a position corresponding to position 90 with reference to the numbering of positions set forth in SEQ ID NO:2. In some embodiments, the amino acid modification is the amino acid substitution D90G, or a conservative amino acid substitution thereof. In some embodiments, the variant CD80 polypeptide further contains one or more amino acid modifications, e.g., amino acid substitutions, at one or more of positions 18, 26, 35, 46, 47, 68, 71, or 85. In some embodiments, the one or more amino acid modifications are one or more of the amino acid substitutions H18Y, A26E, E35D, D46E, D46V, M47I, M47L, V68M, A71G, or L85Q, or a conservative amino acid substitution thereof. In some embodiments, the variant CD80 polypeptide comprises the amino acid modifications H18Y / D90G, A26E / D90G, E35D / D90G, D46E / D90G, D46V / D68M, M47I / D90G, M47L / D90G, V68M / D90G, A71G / D90G, L85Q / D90G. The variant CD80 polypeptide can comprise additional amino acid modifications, such as any described herein, in accordance with provided embodiments. Table 2 describes exemplary amino acid modifications and variant CD80 polypeptides that are described.
[0272] In some embodiments, the variant CD80 polypeptide comprises an amino acid modification of unmodified CD80 or a specific binding fragment thereof at a position corresponding to positions 18, 26, 35, 46, 47, 48, 68, 70, 71, 85, 88, 89, 90, or 93 with reference to the numbering set forth in SEQ ID NO:2. In some embodiments, the amino acid modification is the amino acid substitution H18Y, A26E, E35D, D46E, D46V, M47I, M47L, M47V, N48K, V68M, L70M, A71G, L85Q, E88D, K89N, D90G, K93E, or a conservative amino acid substitution thereof. In some embodiments, the variant CD80 polypeptide comprises the amino acid modifications E35D / M47I / L70M, E35D / M47L E35D / M47V / N48K / V68M / K89N, H18Y / A26E / E35D / M47L / V68M / A71G / D90G, E35D / D46E / M47V / V68M / D90G / K93E, or E35D / D46V / M47L / V68M / L85Q / E88D.
[0273] In some embodiments, the variant CD80 polypeptide does not contain amino acid modifications relative to the unmodified CD80 polypeptide set forth in SEQ ID NO:2, 76, or 150, and the amino acid modifications are only H18Y / M47I / T57I / A71G, H18Y / A26T / E35D / A71D / L85Q, or H18Y / A71D / L72P / E88V. In some embodiments, the variant CD80 polypeptide is not a polypeptide set forth in SEQ ID NO:41, 59, 66, 115, 133, 140, 189, 207, or 214.
[0274] In some embodiments, the variant CD80 polypeptide does not contain the amino acid modifications in the unmodified CD80 polypeptide set forth in SEQ ID NO:2, 76, or 150, and the only amino acid modifications are A26E / E35D / M47L / L85Q. In some embodiments, the variant CD80 polypeptide is not the polypeptide set forth in SEQ ID NO:73, 147, or 221.
[0275] In some embodiments, the variant CD80 polypeptide does not contain an amino acid modification to the unmodified CD80 polypeptide set forth in SEQ ID NO:2, 76, or 150, and the amino acid modifications are selected from the group consisting of E35D / M47I / L65P / D90N, L25S / E35D / M47I / D90N, E35D / A71D, E35D / M47I, E35D / T57I / L70Q / A71D, E35D / A71D, E35D / I67L / A71D, E35D, E35D / M47I / L70M, E35D / A71D / L72V, E35D / M43L / L70M, A26P / E35D / M43I / L85Q / E88D, E35D / D46V / L85Q, Q2 7L / E35D / M47I / T57I / L70Q / E88D, E35D / T57A / A71D / L85Q, H18Y / A26T / E35D / A71D / L85Q, E35D / M47L, E35D / M43I / A71D, E23G / A26S / E35D / T62N / A71D / L 72V / L85M, A12T / E24D / E35D / D46V / I61V / L72P / E95V, V22L / E35D / M43L / A71G / D76H, A26E / E35D / M47L / L85Q, Y31H / E35D / T41S / V68L / K93R / R94W. In some embodiments, the variant CD80 polypeptide is selected from the group consisting of SEQ ID NOs: 72V / L85M, A12T / E24D / E35D / D46V / I61V / L72P / E95V, V22L / E35D / M43L / A71G / D76H, A26E / E35D / M47L / L85Q, Y31H / E35D / T41S / V68L / K93R / R94W. NO:19, 20, 28, 29, 37, 46, 47, 50, 51, 52, 53, 54, 55, 56, 58, 59, 60, 64, 68, 69, 70, 7 3, 75, 93, 94, 102, 103, 111, 120, 121, 124, 125, 126, 127, 128, 129, 130, 132, 133, 1 34, 138, 142, 143, 144, 147, 149, 167, 168, 176, 177, 185, 194, 195, 198, 199, 200, 201, 202, 203, 204, 206, 207, 208, 212, 216, 217, 218, 221, or 223.
[0276] In some embodiments, the variant CD80 polypeptide does not contain amino acid modifications to the unmodified CD80 polypeptide set forth in SEQ ID NO:2, 76, or 150, and the amino acid modifications are only E35D / D46V / L85Q, A12T / E24D / E35D / D46V / I61V / L72P / E95V, or D46E / A71D. In some embodiments, the variant CD80 polypeptide is not a polypeptide set forth in SEQ ID NO:55, 69, 74, 129, 143, 148, 203, 217, or 222.
[0277] In some embodiments, the variant CD80 polypeptide does not contain amino acid modifications to the unmodified CD80 polypeptide set forth in SEQ ID NO:2, 76, or 150, and the only amino acid modifications are E35D / M47I / L65P / D90N, L25S / E35D / M47I / D90N, E35D / M47I, M47L / V68A, M47I / E88D, H18Y / M47I / T57I / A71G, T13R / M42V / M47I / A71D, E35D / M47I / L70M, Q27L / E35D / M47I / T57I / L70Q / E88D, E35D / M47L, A26E / E35D / M47L / L85Q. In some embodiments, the variant CD80 polypeptide is not a polypeptide set forth in SEQ ID NOs: 19, 20, 29, 33, 38, 41, 49, 51, 56, 60, 73, 93, 94, 103, 107, 112, 115, 123, 125, 130, 134, 147, 167, 168, 177, 181, 186, 189, 197, 199, 204, 208, 221.
[0278] In some embodiments, the variant CD80 polypeptide does not contain the amino acid modifications in the unmodified CD80 polypeptide set forth in SEQ ID NO:2, 76, or 150, and the only amino acid modifications are A26E / E35D / M47L / L85Q. In some embodiments, the variant CD80 polypeptide is not a polypeptide set forth in SEQ ID NO:62, 136, 210.
[0279] In some embodiments, the variant CD80 polypeptide does not contain the amino acid modifications in the unmodified CD80 polypeptide set forth in SEQ ID NO:2, 76, or 150, and the amino acid modifications are only H18Y / M47I / T57I / A71G or V22L / E35D / M43L / A71G / D76H. In some embodiments, the variant CD80 polypeptide is not a polypeptide set forth in SEQ ID NO:41, 70, 115, 144, 189, or 218.
[0280] In some embodiments, the variant CD80 polypeptide does not contain amino acid modifications to the unmodified CD80 polypeptide set forth in SEQ ID NO:2, 76, or 150, and the amino acid modifications are only A26P / E35D / M43I / L85Q / E88D, E35D / D46V / L85Q, E35D / T57A / A71D / L85Q, H18Y / A26T / E35D / A71D / L85Q, or A26E / E35D / M47L / L85Q. In some embodiments, the variant CD80 polypeptide is not a polypeptide set forth in SEQ ID NO:54, 55, 58, 59, 73, 128, 129, 132, 133, 147, 202, 203, 206, 207, or 221.
[0281] In some embodiments, the variant CD80 polypeptide comprises amino acid modifications of unmodified CD80, or a specific-binding fragment thereof, at positions corresponding to E35D and M47L. In some embodiments, the variant CD80 polypeptide comprises amino acid modifications corresponding to E35D and M47I in unmodified CD80, or a specific-binding fragment thereof. In some embodiments, the variant CD80 polypeptide comprises amino acid modifications corresponding to E35D and A71G in unmodified CD80, or a specific-binding fragment thereof. In some embodiments, the variant CD80 polypeptide comprises amino acid modifications corresponding to E35D and M47V in unmodified CD80, or a specific-binding fragment thereof. In some embodiments, the variant CD80 polypeptide comprises amino acid modifications corresponding to E35D and V68M in unmodified CD80, or a specific-binding fragment thereof. In some embodiments, the variant CD80 polypeptide comprises amino acid modifications corresponding to H18Y and E35D in unmodified CD80, or a specific-binding fragment thereof.
[0282] In some embodiments, the variant CD80 polypeptide comprises at least three amino acid modifications, including modifications at three or more positions corresponding to 18, 26, 35, 46, 47, 68, 71, 85, or 90 with reference to the numbering of positions set forth in SEQ ID NO:2. In some embodiments, the at least three amino acid modifications comprise amino acid modifications corresponding to H18Y, A26E, E35D, D46E, D46V, M47I, M47L, V68M, A71G, L85Q, or D90G, or conservative amino acid substitutions thereof, in unmodified CD80 or a specific-binding fragment thereof.
[0283] In some embodiments, the variant CD80 polypeptide comprises amino acid modifications corresponding to E35D / M47L / V68M in unmodified CD80 or a specific-binding fragment thereof.
[0284] In some embodiments, the variant CD80 polypeptide comprises amino acid modifications corresponding to E35D / M47V / V68M in unmodified CD80 or a specific-binding fragment thereof.
[0285] In some embodiments, the variant CD80 polypeptide comprises amino acid modifications corresponding to E35D / M47L / L85Q in unmodified CD80 or a specific-binding fragment thereof.
[0286] In some embodiments, the variant CD80 polypeptide comprises amino acid modifications corresponding to H18Y / E35D / M47I in unmodified CD80 or a specific-binding fragment thereof.
[0287] In some embodiments, a variant CD80 polypeptide comprises any of the substitutions (mutations) listed in Table 2. Table 2 also provides exemplary sequences by reference to SEQ ID NOs for the extracellular domain (ECD) or IgV domain of wild-type CD80 or exemplary variant CD80 polypeptides. As indicated, the exact locus or residues corresponding to a given domain can vary, depending, for example, on the method used to identify or classify the domain. Furthermore, in some cases, adjacent N- and / or C-terminal amino acids of a given domain (e.g., IgV) can also be included in the sequence of the variant IgSF polypeptide, e.g., to ensure proper folding of the domain when expressed. Thus, it is understood that the exemplary SEQ ID NOs in Table 2 should not be construed as limiting. For example, a particular domain (e.g., IgV domain) of a variant CD80 polypeptide can be several amino acids longer or shorter, e.g., 1 to 10 amino acids, e.g., 1, 2, 3, 4, 5, 6, or 7 amino acids longer or shorter, than the amino acid sequence set forth in the respective SEQ ID NO.
[0288] In some embodiments, the variant CD80 polypeptide comprises any of the extracellular domain (ECD) sequences listed in Table 2 (i.e., any one of SEQ ID NOs: 3-75, 224-319, 512-722, 1145-1175, 1299-1365, 1383-1444, 1447-1500, 1537, or 1541). In some embodiments, the variant CD80 polypeptide comprises a polypeptide sequence exhibiting at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, e.g., at least 96% identity, 97% identity, 98% identity, or 99% identity to any of the extracellular domain (ECD) sequences listed in Table 2 (i.e., any one of SEQ ID NOs: 3-75, 224-319, 512-722, 1145-1175, 1299-1365, 1383-1444, 1447-1500, 1537, or 1541), and contains an amino acid modification (e.g., a substitution) that is not present in wild-type or unmodified CD80. In some embodiments, the variant CD80 polypeptide comprises a specific binding fragment of any of the extracellular domain (ECD) sequences listed in Table 2 (i.e., any one of SEQ ID NOs: 3-75, 224-319, 512-722, 1145-1175, 1299-1365, 1383-1444, 1447-1500, 1537, or 1541) and contains an amino acid modification (e.g., a substitution) that is not present in wild-type or unmodified CD80. In some embodiments, the variant CD80 polypeptide comprises any of the IgV sequences listed in Table 2 (i.e., any one of SEQ ID NOs:77-149, 151-223, 320-511, 723-1144, 1176-1237, 1256-1298, 1366-1368, 1370-1380, 1381-1382, 1445-1446, 1538, 1540, 1542, or 1544).In some embodiments, the variant CD80 polypeptide is any of the IgV sequences listed in Table 2 (i.e., SEQ ID NO: 1). and (e.g., any one of SEQ ID NOs: 77-149, 151-223, 320-511, 723-1144, 1176-1237, 1256-1298, 1366-1368, 1370-1380, 1381-1382, 1445-1446, 1538, 1540, 1542, or 1544), and contains an amino acid modification (e.g., a substitution) that is not present in wild-type or unmodified CD80. In some embodiments, the variant CD80 polypeptide comprises a specific binding fragment of any of the IgV sequences listed in Table 2 (i.e., any one of SEQ ID NOs:77-149, 151-223, 320-511, 723-1144, 1176-1237, 1256-1298, 1366-1368, 1370-1380, 1381-1382, 1445-1446, 1538, 1540, 1542, or 1544) and contains an amino acid modification (e.g., a substitution) that is not present in wild-type or unmodified CD80.
[0289] Table 2 also provides exemplary sequences by reference to SEQ ID NOs for the extracellular domain (ECD) or IgV domain of wild-type CD80 or exemplary variant CD80 polypeptides. As indicated, the exact locus or residues corresponding to a given domain can vary, depending, for example, on the method used to identify or classify the domain. Furthermore, in some cases, the adjacent N- and / or C-terminal amino acids of a given domain (e.g., ECD) can also be included in the sequence of the variant IgSF polypeptide, for example, to ensure proper folding of the domain when expressed. Thus, it is understood that the exemplary SEQ ID NOs in Table 2 should not be construed as limiting. For example, a particular domain (e.g., IgV domain) of a variant CD80 polypeptide can be several amino acids longer or shorter, e.g., 1 to 10 amino acids, e.g., 1, 2, 3, 4, 5, 6, or 7 amino acids longer or shorter, than the amino acid sequence set forth in the respective SEQ ID NO.
[0290] Table 2: Exemplary variant CD80 polypeptides TIFF2024164118000023.tif98169TIFF2024164118000024.tif237169TIFF2024164118000025.tif237169TIFF2024164118000026.tif237169TIFF2024164118000027.tif237169TIFF2024164118000028.tif237169TIFF2024164118000029.tif237169TIFF2024164118000030.tif237169TIFF2024164118000031.tif237169TIFF2024164118000032.tif241169TIFF2024164118000033.tif233169TIFF2024164118000034.tif232169TIFF2024164118000035.tif233169TIFF2024164118000036.tif235169TIFF2024164118000037.tif237169TIFF2024164118000038.tif210169
[0291] In some embodiments, one or more amino acid modifications of the variant CD80 polypeptides provided herein produce at least one IgSF domain (e.g., IgV or IgC) or specific binding fragment thereof that is affinity-modified relative to the IgSF domain contained in the wild-type or unmodified CD80 polypeptide, such that the variant CD80 polypeptide exhibits altered (increased or decreased) binding activity or affinity for one or more binding partners, CTLA-4, PD-L1, or CD28, compared to the wild-type or unmodified CD80 polypeptide. Provided variant CD80 polypeptides that contain at least one affinity-modified IgSF domain (e.g., IgV or IgC) or specific binding fragment thereof exhibit altered (increased or decreased) binding activity or affinity for one or more cognate binding partners, CTLA-4, PD-L1, or CD28, compared to the wild-type or unmodified CD80 polypeptide. In some embodiments, the variant CD80 polypeptide has a binding affinity for CD28, PD-L1, or CTLA-4 that differs from that of a wild-type or unmodified CD80 polypeptide control sequence, as determined, for example, by solid-phase ELISA immunoassay, flow cytometry, or surface plasmon resonance (Biacore) assay. In some embodiments, the variant CD80 polypeptide has an increased binding affinity for CD28, PD-L1, and / or CTLA-4. In some embodiments, the variant CD80 polypeptide has an increased binding affinity for CTLA-4 and / or CD28. In some embodiments, the variant CD80 polypeptide has a decreased binding affinity for PD-L1 compared to the wild-type or unmodified CD80 polypeptide. CD28, PD-L1, and / or CTLA-4 can be mammalian proteins, e.g., human proteins or murine proteins.
[0292] The binding affinity for each of the binding partners is independent, i.e., in some embodiments, the variant CD80 polypeptide has an altered binding affinity for one, two, or three of CD28, PD-L1, and CTLA-4 compared to a wild-type or unmodified CD80 polypeptide. In some embodiments, the variant CD80 polypeptide has an increased binding affinity for one, two, or three of CD28, PD-L1, and CTLA-4 compared to a wild-type or unmodified CD80 polypeptide. In some embodiments, the variant CD80 polypeptide has an increased binding affinity for one, two, or three of CD28, PD-L1, and CTLA-4, and / or a decreased binding affinity for one, two, or three of CD28, PD-L1, and CTLA-4 compared to a wild-type or unmodified CD80 polypeptide.
[0293] In some embodiments, the variant CD80 polypeptide has increased binding affinity for CD28 compared to wild-type or unmodified CD80 polypeptides. In some embodiments, the variant CD80 polypeptide has increased binding affinity for PD-L1 compared to wild-type or unmodified CD80 polypeptides. In some embodiments, the variant CD80 polypeptide has increased binding affinity for CTLA-4 compared to wild-type or unmodified CD80 polypeptides.
[0294] In some embodiments, the variant CD80 polypeptides have increased binding affinity for PD-L1 and increased binding affinity for CD28 compared to wild-type or unmodified CD80 polypeptides. In some embodiments, the variant CD80 polypeptides have increased binding affinity for CTLA-4 and increased binding affinity for PD-L1 compared to wild-type or unmodified CD80 polypeptides. In some embodiments, the variant CD80 polypeptides have increased binding affinity for CD28 and increased binding affinity for CTLA-4 compared to wild-type or unmodified CD80 polypeptides. In some embodiments, the variant CD80 polypeptides have increased binding affinity for CD28, PD-L1, and CTLA-4 compared to wild-type or unmodified CD80 polypeptides.
[0295] In some embodiments, the variant CD80 polypeptide has a reduced binding affinity for PD-L1 compared to a wild-type or unmodified CD80 polypeptide.
[0296] In some embodiments, the variant CD80 polypeptide has increased binding affinity for CTLA-4 and CD28 compared to wild-type or unmodified CD80 polypeptide. In some embodiments, the variant CD80 polypeptide has increased binding affinity for CTLA-4 and decreased binding affinity for CD28 compared to wild-type or unmodified CD80 polypeptide. In any of such embodiments, the variant CD80 polypeptide has decreased binding affinity for PD-L1 and / or does not bind, or does not substantially bind, PD-L1.
[0297] In some embodiments, variant CD80 polypeptides with increased or greater binding affinity to CD28, PD-L1, and / or CTLA-4 have at least about a 5%, e.g., at least about a 10%, 15%, 20%, 25%, 35%, or 50% increase in binding affinity to a CD28, PD-L1, and / or CTLA-4 binding partner relative to a wild-type or unmodified CD80 polypeptide control. In some embodiments, the increase in binding affinity relative to a wild-type or unmodified CD80 polypeptide is greater than 1.2-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 100-fold, 150-fold, 200-fold, 250-fold, 300-fold, 350-fold, 400-fold, or more. In such examples, the wild-type or unmodified CD80 polypeptide has the same sequence as the variant CD80 polypeptide, except that it does not contain the one or more amino acid modifications (eg, substitutions).
[0298] In some embodiments, a variant CD80 polypeptide with reduced or decreased binding affinity to its cognate binding partner has at least a 5%, e.g., at least about a 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more decrease in binding affinity to the binding partner compared to a wild-type or unmodified CD80 polypeptide control. In some embodiments, the decrease in binding affinity compared to a wild-type or unmodified CD80 polypeptide is greater than 1.2-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 30-fold, 40-fold, or 50-fold. In such examples, the wild-type or unmodified CD80 polypeptide has the same sequence as the variant CD80 polypeptide, except that it does not contain one or more amino acid modifications (e.g., substitutions).
[0299] In some embodiments, the equilibrium dissociation constant (K) with CD28, PD-L1, and / or CTLA-4 of any of the preceding embodiments. d ) is at least 1 × 10 -5 M, 1 x 10 -6 M, 1 x 10-7 M, 1 x 10 -8 M, 1 x 10 -9 M, 1 x 10 -10 M or 1 x 10 -11 M, or 1 x 10 -12 M or less, or about 1 x 10 -5 M, 1 x 10 -6 M, 1 x 10 -7 M, 1 x 10 -8 M, 1 x 10 -9 M, 1 x 10 -10 M or 1 x 10 -11 M, or 1 x 10 -12 It can be M or less.
[0300] Non-limiting examples of CD80 variant polypeptides with altered (e.g., increased or decreased) binding to binding partners are described in the Examples, including those containing mutations in the complete extracellular domain containing the IgV and IgC domains. Exemplary avidity for binding to a cognate binding partner is shown in a flow cytometry-based assay based on mean fluorescence intensity (MFI) and comparison of binding to the corresponding unmodified or wild-type CD80 polypeptide. Among such variant polypeptides are polypeptides that exhibit increased or decreased binding to a cognate binding partner, such as CD28, CTLA-4, and / or PD-L1, as described.
[0301] In some embodiments, provided variant CD80 polypeptides containing at least one affinity-modified IgSF domain (e.g., IgV or IgC) or a specific-binding fragment thereof relative to the IgSF domain contained in a wild-type or unmodified CD80 polypeptide exhibit altered (increased / stimulated or decreased / inhibited) signaling induced by one or more functional binding partners, such as CD28, PD-L1, and / or CTLA-4 expressed on the surface of a signal-transducing cell, such as a T cell, that is capable of releasing cytokines in response to an intracellular signal, compared to the wild-type or unmodified CD80 polypeptide upon binding to one or more binding partners. In some embodiments, the altered signaling is different from that produced by, e.g., a wild-type or unmodified CD80 polypeptide control sequence of the same format (e.g., soluble), as determined, e.g., by an assay measuring cytokine release (e.g., IL-2 release or IFN-γ release) after incubation with a particular variant and / or wild-type or unmodified CD80 polypeptide. Exemplary assays are described in Examples 8-9. In an exemplary assay, cytokine release is a function of the sum of the signaling activities of functional binding partners expressed on the surface of cytokine-releasing cells.
[0302] Because CTLA-4 induces inhibitory signaling, increased CTLA-4 signaling results in decreased cytokine release in some exemplary assays. Conversely, decreased CTLA-4 signaling results in decreased inhibitory signaling, which may not decrease cytokine release but may result in increased cytokine release in some assays. Because CD28 signaling stimulates cytokine release, increased CD28 signaling results in increased cytokine release in some exemplary assays. Conversely, decreased CD28 signaling results in decreased cytokine release in some exemplary assays. Because PD-L1 induces inhibitory signaling, when bound to PD-1, increased PD-L1 signaling results in decreased cytokine release in some exemplary assays. Conversely, decreased PD-L1 signaling results in decreased inhibitory signaling, which may not decrease cytokine release but may result in increased cytokine release in some assays.
[0303] In some embodiments, the variant CD80 polypeptides increase CD28-mediated signaling compared to wild-type or unmodified CD80 polypeptides. In some embodiments, the variant CD80 polypeptides decrease PD-L1- and / or CTLA-4-mediated signaling compared to wild-type or unmodified CD80 polypeptides. In some embodiments, the variant CD80 polypeptides increase CD28-mediated signaling and decrease PD-L1- and / or CTLA-4-mediated signaling compared to wild-type or unmodified CD80 polypeptides.
[0304] The binding affinity for each of the cognate binding partners is independent, and thus, in some embodiments, a variant CD80 polypeptide can increase signaling induced by one, two, or three of CD28, PD-L1, and CTLA-4, and / or decrease signaling induced by one, two, or three of CD28, PD-L1, and CTLA-4, compared to a wild-type or unmodified CD80 polypeptide.
[0305] In some embodiments, the variant CD80 polypeptide, upon binding, increases CD28-induced signaling compared to wild-type or unmodified CD80 polypeptides. In some embodiments, the variant CD80 polypeptide decreases PD-L1 / PD-1-induced signaling compared to wild-type or unmodified CD80 polypeptides. In some embodiments, the variant CD80 polypeptide decreases CTLA-4-induced signaling compared to wild-type or unmodified CD80 polypeptides.
[0306] In some embodiments, the variant CD80 polypeptides decrease CTLA-4-induced signaling and increase CD28-induced signaling compared to wild-type or unmodified CD80 polypeptides. In some embodiments, the variant CD80 polypeptides decrease PD-L1-induced signaling and increase CD28-induced signaling compared to wild-type or unmodified CD80 polypeptides.
[0307] In some embodiments, variant CD80 polypeptides that stimulate or increase CD28-induced signaling generate a signal that is at least 105%, 110%, 120%, 150%, 200%, 300%, 400%, or 500%, or more, of the signal induced by a wild-type or unmodified CD80 polypeptide. In some embodiments, the increase in CD28-mediated signaling compared to a wild-type or unmodified CD80 polypeptide is greater than 1.2-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 100-fold, 150-fold, 200-fold, 250-fold, 300-fold, 350-fold, 400-fold, or more. In such examples, the wild-type or unmodified CD80 polypeptide has the same sequence as the variant CD80 polypeptide, except that it does not contain one or more amino acid modifications (e.g., substitutions).
[0308] In some embodiments, a variant CD80 polypeptide that inhibits or reduces inhibitory signaling induced by CTLA-4 or PD-1 / PD-L1 generates a signal that is 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, or less of the signal induced by a wild-type or unmodified CD80 polypeptide. In such examples, the wild-type or unmodified CD80 polypeptide has the same sequence as the variant CD80 polypeptide, except that it does not contain the one or more amino acid modifications (e.g., substitutions).
[0309] In some embodiments, variant CD80 polypeptides that affect inhibitory signaling induced by CTLA-4 and / or PD-L1 and / or affect signaling by CD28 result in a sum of PD-L1, CTLA-4, and CD28 signaling that is greater than the sum of PD-L1, CTLA-4, and CD28 signaling that is provided by the corresponding wild-type or unmodified CD80 polypeptide. In such embodiments, the sum of PD-L1, CTLA-4, and CD28 signaling is at least 105%, 110%, 120%, 150%, 200%, 300%, 400%, or 500%, or more, of the signal provided by the corresponding wild-type or unmodified CD80 polypeptide. In such examples, the corresponding wild-type or unmodified CD80 polypeptide has the same sequence as the variant CD80 polypeptide, except that it does not contain one or more amino acid modifications (e.g., substitutions).
[0310] Non-limiting examples of CD80 variant polypeptides with altered (e.g., increased or decreased) signaling induced after interaction with one or more functional binding partners, such as CD28, PD-L1, and / or CTLA-4, are described in the Examples. Among the provided CD80 variant polypeptides are those containing mutations in the complete extracellular domain, including the IgV and IgC domains. Exemplary functional activities are demonstrated in reporter-based assays based on changes in reporter fluorescence in a T cell reporter Jurkat cell line, including comparison with corresponding unmodified or wild-type CD80 polypeptides. Among such variant polypeptides are polypeptides that exhibit increased CD28 costimulation or agonism, as described.
[0311] 1. CD28 In some embodiments, the variant CD80 polypeptides exhibit increased affinity for the ectodomain of CD28 compared to wild-type or unmodified CD80 polypeptides. In some embodiments, the variant CD80 polypeptides exhibit increased affinity for the ectodomain of CD28 compared to wild-type or unmodified CD80 polypeptides comprising, e.g., a sequence set forth in SEQ ID NO:2, 76, 150, or 1245. In some embodiments, the increased affinity for the ectodomain of CD28 is greater than a 1.2-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 60-fold, 70-fold, 80-fold, 90-fold, 100-fold, 150-fold, or 200-fold increase compared to the binding affinity of unmodified CD80 for the ectodomain of CD28.
[0312] In some embodiments, the variant CD80 polypeptides exhibit increased affinity for the CD28 ectodomain and the CTLA-4 ectodomain, compared to a wild-type or unmodified CD80 polypeptide comprising, e.g., a sequence set forth in SEQ ID NO:2, 76, 150, or 1245. In some embodiments, the variant CD80 polypeptides exhibit increased affinity for the CD28 ectodomain and the PD-L1 ectodomain, compared to a wild-type or unmodified CD80 polypeptide comprising, e.g., a sequence set forth in SEQ ID NO:2, 76, 150, or 1245. In some embodiments, the variant CD80 polypeptides exhibit increased affinity for the CD28 ectodomain, the PD-L1 ectodomain, and the CTLA-4 ectodomain, compared to a wild-type or unmodified CD80 polypeptide comprising, e.g., a sequence set forth in SEQ ID NO:2, 76, 150, or 1245. In some embodiments, the increased affinity for CD28 and one or both of the ectodomains of CTLA-4 and PD-L1 is independently increased by more than 1.2-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 60-fold, 70-fold, 80-fold, 90-fold, 100-fold, 150-fold, 200-fold, 250-fold, 300-fold, 350-fold, 400-fold, or 450-fold compared to the binding affinity of unmodified CD80 for the ectodomain of CTLA-4 or PD-L1.
[0313] In some embodiments, the variant CD80 polypeptides exhibit increased affinity for the CD28 ectodomain and the CTLA-4 ectodomain, compared to a wild-type or unmodified CD80 polypeptide comprising, e.g., a sequence set forth in SEQ ID NO:2, 76, 150, or 1245. In some embodiments, the variant CD80 polypeptides exhibit increased affinity for the CD28 ectodomain and the PD-L1 ectodomain, compared to a wild-type or unmodified CD80 polypeptide comprising, e.g., a sequence set forth in SEQ ID NO:2, 76, 150, or 1245. In some embodiments, the variant CD80 polypeptides exhibit increased affinity for the CD28 ectodomain, the CTLA-4 ectodomain, and the PD-L1 ectodomain, compared to a wild-type or unmodified CD80 polypeptide comprising, e.g., a sequence set forth in SEQ ID NO:2, 76, 150, or 1245. In some embodiments, the increased affinity for the CD28 ectodomain is greater than 1.2-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, or 60-fold increased compared to the binding affinity of unmodified CD80 for the CD28 ectodomain.
[0314] Non-limiting examples of CD80 variant polypeptides with altered (e.g., increased) binding to CD28 are described in the Examples. Exemplary avidity for binding to CD28 is shown in a flow cytometry-based assay based on mean fluorescence intensity (MFI) and comparison of binding to a corresponding unmodified or wild-type CD80 polypeptide. Among such variant polypeptides are polypeptides that exhibit increased binding to CD28, e.g., human CD28, as described. Additionally, non-limiting examples of CD80 variant polypeptides with altered (e.g., increased) signaling induced following interaction with one or more functional binding partners, e.g., CD28, are described in the Examples. In some aspects, exemplary functional activity is shown in a reporter-based assay based on changes in reporter fluorescence in a mixed lymphocyte reaction and / or a T-cell reporter Jurkat cell line, including comparison to a corresponding unmodified or wild-type CD80 polypeptide. Among such variant polypeptides are polypeptides that exhibit increased CD28 costimulation or agonism, as described.
[0315] In some of these embodiments, non-limiting examples of such variant polypeptides include variant CD80 polypeptides that exhibit increased binding affinity for CD28 compared to a wild-type or unmodified CD80 polypeptide and have one or more amino acid modifications (e.g., substitutions) corresponding to positions 12, 13, 18, 20, 22, 23, 24, 26, 27, 31, 35, 41, 42, 43, 46, 47, 54, 55, 57, 58, 61, 62, 67, 68, 69, 70, 71, 72, 79, 83, 84, 85, 88, 90, 93, 94, and / or 95 of SEQ ID NO:2, 76, 150, or 1245. In some of these embodiments, the variant CD80 polypeptide that exhibits increased binding affinity for CD28 compared to a wild-type or unmodified CD80 polypeptide has one or more amino acid modifications (e.g., substitutions) corresponding to positions 23, 26, 35, 46, 55, 57, 58, 71, 79, and / or 84 of SEQ ID NO:2, 76, 150, or 1245.
[0316] In some embodiments, the variant CD80 polypeptide is TIFF2024164118000039.tif51166. In some embodiments, the variant CD80 polypeptide has one or more amino acid substitutions selected from the group consisting of: TIFF2024164118000040.tif37164.
[0317] In some embodiments, the one or more amino acid substitutions are TIFF2024164118000041.tif225166TIFF2024164118000042.tif124154.
[0318] 2. PD-L1 In some embodiments, the variant CD80 polypeptides exhibit increased affinity for PD-L1 compared to wild-type or unmodified CD80 polypeptides. In some embodiments, the variant CD80 polypeptides exhibit increased affinity for the PD-L1 ectodomain compared to wild-type or unmodified CD80 polypeptides, e.g., comprising a sequence set forth in SEQ ID NOs: 2, 76, 150, or 1245. In some embodiments, the increased affinity for the PD-L1 ectodomain is greater than a 1.2-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 60-fold, 70-fold, 80-fold, 90-fold, 100-fold, 150-fold, 200-fold, 250-fold, 300-fold, 350-fold, 400-fold, or 450-fold increase compared to the binding affinity of unmodified CD80 for the PD-L1 ectodomain.
[0319] In some embodiments, the variant CD80 polypeptides exhibit increased affinity for the ectodomain of PD-L1 and increased affinity for the ectodomain of CTLA-4 compared to a wild-type or unmodified CD80 polypeptide, e.g., comprising a sequence set forth in SEQ ID NO:2, 76, 150, or 1245. In some embodiments, the variant CD80 polypeptides exhibit increased affinity for the ectodomain of PD-L1 and increased affinity for the ectodomain of CD28 compared to a wild-type or unmodified CD80 polypeptide, e.g., comprising a sequence set forth in SEQ ID NO:2, 76, 150, or 1245. In some embodiments, the variant CD80 polypeptides exhibit increased affinity for the ectodomain of PD-L1 and increased affinity for the ectodomain of CD28 and increased affinity for the ectodomain of CTLA-4 compared to a wild-type or unmodified CD80 polypeptide, e.g., comprising a sequence set forth in SEQ ID NO:2, 76, 150, or 1245. In some embodiments, the increased affinity for the ectodomain of PD-L1 is greater than a 1.2-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, or 60-fold increase compared to the binding affinity of unmodified CD80 for the ectodomain of PD-L1.
[0320] Non-limiting examples of CD80 variant polypeptides with altered (e.g., increased) binding to PD-L1 are described in the Examples. Exemplary avidity for binding to PD-L1 is shown in a flow cytometry-based assay based on mean fluorescence intensity (MFI) and compariso...
Claims
1. 1. A method of treating cancer in a subject, comprising: (a) administering to a subject having cancer a variant CD80 fusion protein that specifically binds PD-L1, the variant CD80 fusion protein comprising a variant CD80 extracellular domain, or a portion thereof, comprising an IgV domain, or a specific binding fragment thereof, and a multimerization domain, wherein the variant CD80 extracellular domain, or portion thereof, comprises one or more amino acid modifications at one or more positions in the amino acid sequence of the extracellular domain, or portion thereof, of an unmodified CD80 polypeptide; and (b) administering to the subject a therapeutically effective amount of an anti-cancer agent.
2. 2. The method of claim 1, wherein the anti-cancer agent is an immune checkpoint inhibitor or a chemotherapeutic agent.
3. 3. The method of claim 1 or claim 2, wherein the anti-cancer agent is a chemotherapeutic agent that is a platinum-based chemotherapeutic agent.
4. 4. The method of claim 3, wherein the chemotherapeutic agent is oxilaplatin.
5. The method of claim 1 or claim 2, wherein the anti-cancer agent is an immune checkpoint inhibitor of CTLA-4, and optionally, the checkpoint inhibitor is an anti-CTLA-4 antibody or an antigen-binding fragment thereof.
6. 6. The method of claim 5, wherein the immune checkpoint inhibitor is ipilimumab or tremelimumab, or an antigen-binding fragment thereof.
7. The method of claim 1 or claim 2, wherein the anticancer agent is an immune checkpoint inhibitor of PD-1 (PD-1 inhibitor), and optionally, the PD-1 inhibitor is an anti-PD-1 antibody or an antigen-binding fragment thereof.
8. 1. A method of treating cancer in a subject, comprising: (a) administering to a subject having cancer a variant CD80 fusion protein that specifically binds PD-L1, the variant CD80 fusion protein comprising a variant CD80 extracellular domain, or a portion thereof, comprising an IgV domain, or a specific binding fragment thereof, and a multimerization domain, wherein the variant CD80 extracellular domain, or portion thereof, comprises one or more amino acid modifications at one or more positions in the amino acid sequence of the extracellular domain, or portion thereof, of an unmodified CD80 polypeptide; and (b) administering to the subject a therapeutically effective amount of a PD-1 inhibitor, wherein the PD-1 inhibitor disrupts the interaction of programmed death-1 (PD-1) with its ligand.
9. 9. The method of claim 8, wherein the ligand is programmed death-ligand-1 (PD-L1) or PD-L2.
10. The method of any one of claims 7 to 9, wherein the PD-1 inhibitor specifically binds to PD-1.
11. 10. The method of any one of claims 7 to 9, wherein the PD-1 inhibitor does not compete with the variant CD80 fusion protein for binding to PD-L1.
12. The method of any one of claims 7 to 11, wherein the PD-1 inhibitor is a peptide, a protein, an antibody or an antigen-binding fragment thereof, or a small molecule.
13. The method of any one of claims 7 to 12, wherein the PD-1 inhibitor is an antibody or an antigen-binding fragment thereof that specifically binds to PD-1.
14. The method of any one of claims 7 to 13, wherein the antibody or antigen-binding portion is selected from nivolumab, pembrolizumab, MEDI0680 (AMP514), PDR001, cemiplimab (REGN2810), pidilizumab (CT011), or an antigen-binding portion thereof.
15. The method of any one of claims 7 to 14, wherein the PD-1 inhibitor comprises the extracellular domain of PD-L2 that binds to PD-1, or a portion thereof, and an Fc region.
16. 16. The method of claim 15, wherein the PD-1 inhibitor is AMP-224.
17. 17. The method of any one of claims 7 to 16, wherein initiation of administration of the PD-1 inhibitor is performed simultaneously or sequentially with initiation of administration of the variant CD80 fusion protein.
18. 18. The method of any one of claims 7 to 17, wherein the initiation of administration of the PD-1 inhibitor follows the initiation of administration of the variant CD80 fusion protein.
19. The method of any one of claims 7 to 18, wherein the initiation of administration of the anti-PD-1 antibody follows administration of the final dose of a therapeutically effective amount of the variant CD80 fusion protein.
20. 20. The method of any one of claims 1-19, wherein the variant CD80 fusion protein is administered in a therapeutically effective amount, either as a single dose or in multiple doses of up to six.
21. 1. A method of treating cancer in a subject comprising administering to a subject having cancer a therapeutically effective amount of a variant CD80 fusion protein comprising a variant CD80 extracellular domain or portion thereof comprising an IgV domain or a specific binding fragment thereof, and a multimerization domain, wherein the variant CD80 extracellular domain or portion thereof comprises one or more amino acid modifications at one or more positions in the amino acid sequence of the extracellular domain or portion thereof of an unmodified CD80 polypeptide, and wherein the therapeutically effective amount of the variant CD80 fusion protein is administered as a single dose or in multiple doses of up to six.
22. 22. The method of any one of claims 1 to 21, wherein the variant CD80 fusion protein is administered parenterally.
23. 23. The method of any one of claims 1 to 22, wherein the variant CD80 fusion protein is administered subcutaneously.
24. 23. The method of any one of claims 1 to 22, wherein the variant CD80 fusion protein is administered intravenously.
25. 25. The method of any one of claims 1 to 24, wherein the variant CD80 fusion protein is administered by injection that is a bolus injection.
26. A therapeutically effective amount may be from about 0.5 mg / kg to about 140 mg / kg, from about 0.5 mg / kg to about 30 mg / kg, from about 0.5 mg / kg to about 20 mg / kg, from about 0.5 mg / kg to about 18 mg / kg, from about 0.5 mg / kg to about 12 mg / kg, from about 0.5 mg / kg to about 10 mg / kg, from about 0.5 mg / kg to about 6 mg / kg, from about 0.5 mg / kg to about 3 mg / kg, from about 1 mg / kg to about 40 mg / kg, from about 1 mg / kg to about 30 mg / kg, from about 1 mg / kg to about 20 mg / kg, inclusive of each of the endpoints. mg / kg to about 20 mg / kg, about 1 mg / kg to about 18 mg / kg, about 1 mg / kg to about 12 mg / kg, about 1 mg / kg to about 10 mg / kg, about 1 mg / kg to about 6 mg / kg, about 1 mg / kg to about 3 mg / kg, about 3 mg / kg to approx. 40mg / kg, approx. 3mg / kg to approx. 30mg / kg, approx. 3mg / kg to approx. 20mg / kg, approx. 3mg / kg to approx. 18mg / kg, approx. 3mg / kg to approx. 12mg / kg, approx. 3mg / kg to approx. 10mg / kg, approx. kg to about 6mg / kg, about 6mg / kg to about 40mg / kg, about 6mg / kg to about 30mg / kg, about 6mg / kg to about 20mg / kg, about 6mg / kg to about 18mg / kg, about 6mg / kg to about 12mg / kg, about 6mg / k g to about 10mg / kg, about 10mg / kg to about 40mg / kg, about 10mg / kg to about 30mg / kg, about 10mg / kg to about 20mg / kg, about 10mg / kg to about 18mg / kg, about 10mg / kg to about 12mg / kg, about 1 26. The method of any one of claims 20-25, wherein the dose is 2 mg / kg to about 40 mg / kg, about 12 mg / kg to about 30 mg / kg, about 12 mg / kg to about 20 mg / kg, about 12 mg / kg to about 18 mg / kg, about 18 mg / kg to about 40 mg / kg, about 18 mg / kg to about 30 mg / kg, about 18 mg / kg to about 20 mg / kg, about 20 mg / kg to about 40 mg / kg, about 20 mg / kg to about 30 mg / kg, or about 30 mg / kg to about 40 mg / kg.
27. 27. The method of any one of claims 20-26, wherein the therapeutically effective amount is from about 3.0 mg / kg to 18 mg / kg, inclusive.
28. 27. The method of any one of claims 20-26, wherein the therapeutically effective amount is from about 6 mg / kg to about 20 mg / kg, inclusive.
29. 27. The method of any one of claims 20-26, wherein the therapeutically effective amount is from about 1 mg / kg to about 10 mg / kg, inclusive.
30. 30. The method of any one of claims 20-26 and 29, wherein the therapeutically effective amount is from about 2.0 mg / kg to about 6.0 mg / kg, inclusive.
31. 31. The method of any one of claims 1 to 30, wherein the variant CD80 fusion protein is administered intratumorally.
32. 1. A method of treating cancer in a subject comprising intratumorally administering to a subject having cancer a therapeutically effective amount of a variant CD80 fusion protein comprising a variant CD80 extracellular domain or portion thereof comprising an IgV domain or a specific binding fragment thereof, and a multimerization domain, wherein the variant CD80 extracellular domain or portion thereof comprises one or more amino acid modifications at one or more positions in the amino acid sequence of the extracellular domain or portion thereof of an unmodified CD80 polypeptide.
33. 33. The method of claim 32, wherein the variant CD80 fusion protein is administered in a therapeutically effective amount, either as a single dose or in multiple doses of up to six.
34. The method of any one of claims 19-25 and 31-33, wherein the therapeutically effective amount is from about 0.1 mg / kg to about 1 mg / kg, inclusive.
35. The method of any one of claims 19-25 and 31-34, wherein the therapeutically effective amount is from about 0.2 mg / kg to about 0.6 mg / kg.
36. The method of any one of claims 20-31 and 33-35, wherein the therapeutically effective amount is administered in a single dose.
37. 36. The method of any one of claims 20-31 and 33-35, wherein the therapeutically effective amount is administered in no more than six multiple doses, wherein no more than six multiple doses is two doses, three doses, four doses, five doses or six doses.
38. 38. The method of claim 37, wherein the therapeutically effective amount is administered in four doses.
39. 38. The method of claim 37, wherein the therapeutically effective amount is administered in three doses.
40. 38. The method of claim 37, wherein the therapeutically effective amount is administered in two doses.
41. 41. The method of any one of claims 37-40, wherein each of the six or fewer multiple doses is administered every week, every two weeks, every three weeks, or every four weeks.
42. The method of any one of claims 37-40, wherein the interval between each multiple dose is about one week.
43. The method of any one of claims 20-26 and 36-42, wherein the single dose or each of up to six multiple doses is administered individually once a week (Q1W) in an amount of about 0.5 mg / kg to about 10 mg / kg.
44. 1. A method of treating cancer in a subject comprising administering to a subject having cancer a variant CD80 fusion protein in an amount of about 1.0 mg / kg to 10 mg / kg, inclusive, once per week (Q1W), wherein the variant CD80 fusion protein comprises a variant CD80 extracellular domain or portion thereof comprising an IgV domain or a specific binding fragment thereof, and a multimerization domain, wherein the variant CD80 extracellular domain or portion thereof comprises one or more amino acid modifications at one or more positions in the amino acid sequence of the extracellular domain or portion thereof of an unmodified CD80 polypeptide.
45. 45. The method of claim 43 or 44, wherein the amount of variant CD80 fusion protein administered Q1W is from about 1 mg / kg to about 3 mg / kg.
46. 46. The method of any one of claims 43 to 45, wherein said administering is for a period of more than one week.
47. The method of any one of claims 20-26 and 36-41, wherein a single dose or up to six multiple doses are administered, individually, in an amount of about 1.0 mg / kg to about 40 mg / kg once every three weeks (Q3W).
48. 1. A method of treating cancer in a subject comprising administering to a subject having cancer a variant CD80 fusion protein in an amount of about 1.0 mg / kg to 40 mg / kg, inclusive, once every three weeks (Q3W), wherein the variant CD80 fusion protein comprises a variant CD80 extracellular domain or portion thereof comprising an IgV domain or a specific binding fragment thereof, and a multimerization domain, wherein the variant CD80 extracellular domain or portion thereof comprises one or more amino acid modifications at one or more positions in the amino acid sequence of the extracellular domain or portion thereof of an unmodified CD80 polypeptide.
49. 48. The method of claim 46 or claim 47, wherein the amount of variant CD80 fusion protein administered Q3W is from about 3.0 mg / kg to about 10 mg / kg.
50. 50. The method of any one of claims 44-46, 48 and 49, wherein the variant CD80 fusion protein is administered parenterally, optionally subcutaneously.
51. The method of any one of claims 44-46 and 48-50, wherein the variant CD80 fusion protein is administered by injection that is a bolus injection.
52. The method of any one of claims 20-51, wherein the therapeutically effective amount is administered for a period of six weeks or less.
53. The method of any one of claims 20-51, wherein the therapeutically effective amount is administered for a period of less than or equal to about 4 weeks.
54. 52. The method of any one of claims 20-51, wherein each of the multiple doses is of equal amount.
55. The method of any one of claims 1-54, wherein prior to the administering step, a subject having a tumor comprising cells that are surface positive for PD-L1 or CD28, and / or surface negative for a cell surface ligand selected from CD80 or CD86 is selected for treatment.
56. 1. A method of treating cancer in a subject comprising administering to a subject selected as having a tumor comprising cells that are surface negative for a cell surface ligand selected from CD80 or CD86, and / or surface positive for CD28, a variant CD80 fusion protein comprising a variant CD80 extracellular domain or portion thereof comprising an IgV domain or a specific binding fragment thereof, and a multimerization domain, wherein the variant CD80 extracellular domain or portion thereof comprises one or more amino acid modifications at one or more positions in the amino acid sequence of the extracellular domain or portion thereof of an unmodified CD80 polypeptide.
57. The method of claim 55 or claim 56, wherein the cells that are surface negative for CD80 or CD86 comprise tumor cells or antigen-presenting cells.
58. The method of claim 55 or claim 56, wherein the cells surface positive for CD28 comprise tumor-infiltrating T lymphocytes.
59. The method of any one of claims 55-58, wherein the subject is further selected as having a tumor that contains cells that are surface positive for PD-L1.
60. The method of claim 55 or claim 59, wherein the cells that are surface positive for PD-L1 are tumor cells or tumor-infiltrating immune cells, optionally tumor-infiltrating T lymphocytes.
61. The method of any one of claims 55 to 60, further comprising determining an immunoscore based on the presence or density of tumor-infiltrating T lymphocytes in the subject's tumor.
62. The method of claim 61, wherein if the immune score is low, the subject is selected for treatment.
63. 63. The method of any one of claims 1-62, wherein the variant CD80 fusion protein exhibits increased binding to at least one binding partner selected from among CD28, PD-L1 and CTLA-4 compared to a fusion protein comprising the extracellular domain of unmodified CD80 or a portion thereof to said at least one binding partner.
64. The method of any one of claims 1-63, wherein the variant CD80 fusion protein exhibits increased binding to PD-L1 compared to a fusion protein comprising the extracellular domain of unmodified CD80, or a portion thereof, to PD-L1.
65. 65. The method of any one of claims 1 to 64, wherein the variant CD80 fusion protein exhibits increased binding to at least one binding partner selected from among CD28 and CTLA-4 compared to a fusion protein comprising the extracellular domain of unmodified CD80 or a portion thereof to said at least one binding partner.
66. 66. The method of any one of claims 63-65, wherein the binding affinity is increased by more than 1.2x, 1.5x, 2x, 3x, 4x, 5x, 6x, 7x, 8x, 9x, 10x, 20x, 30x, 40x, 50x, 60x, 80x, 100x, 150x, 200x, 250x, 300x, 400x, or 450x compared to the binding affinity of unmodified CD80 to the ectodomain of the binding partner.
67. The method of any one of claims 1 to 66, wherein the one or more amino acid modifications are amino acid substitutions.
68. 68. The method of any one of claims 1 to 67, wherein the one or more amino acid modifications comprise one or more amino acid substitutions selected from among H18Y, A26E, E35D, D46E, D46V, M47I, M47L, M47V, V68M, A71D, A71G, L85M, L85Q or D90G, or conservative amino acid substitutions thereof, with reference to the numbering of SEQ ID NO:
2.
69. 69. The method of any one of claims 1 to 68, wherein the one or more amino acid modifications comprise two or more amino acid substitutions selected from among H18Y, A26E, E35D, D46E, D46V, M47I, M47L, M47V, V68M, A71D, A71G, L85M, L85Q or D90G, with reference to the numbering of SEQ ID NO:2, or conservative amino acid substitutions thereof.
70. The one or more amino acid modifications may be selected from the group consisting of the amino acid substitutions H18Y / E35D, E35D / D46E, E35D / D46V, E35D / M47I, E35D / M47L, E35D / M47V, E35D / V68M, E35D / L85M, E35D / L85Q, D46E / M47I, D46E / M47L, D46E / M47V, D46V / M47I, D46V / M47L, D46V / M47V, 70. The method of any one of claims 1 to 69, comprising administering to said patient a medicament comprising one or more of said medicaments a) to said patient a) a medicament comprising one or more of said medicaments a) to said patient, said one or more of said medicaments comprising said patient a) a medicament comprising one or more of said medicaments a) to said patient, and b) a medicament comprising one or more of said medicaments a) to said patient, said one or more of said medicaments comprising said patient a) a medicament comprising one or more of said medicaments a) to said patient,
71. 71. The method of any one of claims 1 to 70, wherein the one or more amino acid modifications comprise the amino acid substitutions E35D / M47L / V68M, E35D / M47V / V68M or E35D / M47I / L70M.
72. 72. The method of any one of claims 1 to 71, wherein the one or more amino acid modifications comprise the amino acid substitutions E35D / M47V / N48K / V68M / K89N.
73. 72. The method of any one of claims 1 to 71, wherein the one or more amino acid modifications comprise amino acid substitutions H18Y / A26E / E35D / M47L / V68M / A71G / D90G.
74. 72. The method of any one of claims 1-71, wherein the one or more amino acid modifications comprise the amino acid substitutions E35D / D46E / M47V / V68M / D90G / K93E.
75. 72. The method of any one of claims 1-71, wherein the one or more amino acid modifications comprise the amino acid substitutions E35D / D46V / M47L / V68M / L85Q / E88D.
76. The method of any one of claims 1 to 75, wherein the unmodified CD80 is human CD80.
77. The method of any one of claims 1-76, wherein the extracellular domain of unmodified CD80, or a portion thereof, (i) comprises an amino acid sequence as set forth in SEQ ID NO:2, (ii) comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO:2; or (iii) is a portion of (i) or (ii) comprising an IgV domain or a specific binding fragment thereof.
78. The method of claim 77, wherein the extracellular domain of unmodified CD80 or a portion thereof is an extracellular domain portion that is or comprises an IgV domain or a specific binding fragment thereof.
79. The method of claim 78, wherein the extracellular domain portion of unmodified CD80 comprises an IgV domain but does not comprise an IgC domain or a portion of an IgC domain.
80. The method of claim 78 or claim 79, wherein the extracellular domain portion of unmodified CD80 is set forth as the sequence of amino acids 35 to 135 of SEQ ID NO:2 (SEQ ID NO:76) or 35 to 141 of SEQ ID NO:2 (SEQ ID NO:150).
81. 81. The method of any one of claims 1 to 80, wherein the variant CD80 extracellular domain or portion thereof is a portion of the extracellular domain that does not comprise the IgC domain or a portion of the IgC domain.
82. The method of any one of claims 1-81, wherein the variant CD80 extracellular domain comprises the sequence of amino acids 35 to 135 of SEQ ID NO:2 (SEQ ID NO:76) or 35 to 141 of SEQ ID NO:2 (SEQ ID NO:150), wherein said variant CD80 extracellular domain contains one or more amino acid substitutions.
83. The method of any one of claims 1 to 81, wherein the variant CD80 extracellular domain is the sequence of amino acids 35 to 135 of SEQ ID NO:2 (SEQ ID NO:76) or 35 to 141 of SEQ ID NO:2 (SEQ ID NO:150), comprising one or more amino acid substitutions.
84. 84. The method of any one of claims 1-83, wherein the variant CD80 extracellular domain comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acid modifications, optionally wherein the amino acid modifications are amino acid substitutions.
85. 85. The method of any one of claims 1-84, wherein the variant CD80 extracellular domain or portion thereof comprises no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13 amino acid modifications, optionally wherein the amino acid modifications are amino acid substitutions.
86. 86. The method of any one of claims 1-85, wherein the amino acid sequence of the variant CD80 extracellular domain has at least, or at least about, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the sequence of amino acids 35 to 135 of SEQ ID NO:2 (SEQ ID NO:76) or 35 to 141 of SEQ ID NO:2 (SEQ ID NO:150).
87. The method of any one of claims 1 to 86, wherein the multimerization domain is an Fc region.
88. The method of claim 87, wherein the Fc region is that of an immunoglobulin G1 (IgG1) or an immunoglobulin G2 (IgG2) protein.
89. The method of claim 87 or claim 88, wherein the Fc region exhibits one or more effector functions.
90. 89. The method of claim 87 or claim 88, wherein the Fc region is a variant Fc region comprising one or more amino acid substitutions in a wild-type Fc region, said variant Fc region exhibiting one or more reduced effector functions compared to the wild-type Fc region, and optionally wherein the wild-type human Fc is that of a human IgG1.
91. The method of claim 90, wherein the Fc region comprises the amino acid substitution N297G, which residues are numbered according to the EU index of Kabat.
92. The method of claim 90, wherein the Fc region comprises the amino acid substitutions R292C / N297G / V302C, which residues are numbered according to the EU index of Kabat.
93. The method of claim 90, wherein the Fc region comprises the amino acid substitutions L234A / L235E / G237A, which residues are numbered according to the EU index of Kabat.
94. The method of any one of claims 87-93, wherein the Fc region further comprises the amino acid substitution C220S, which residues are numbered according to the EU index of Kabat.
95. The method of any one of claims 87-94, wherein the Fc region comprises K447del, this residue being numbered according to the EU index of Kabat.
96. The method of any one of claims 1-95, wherein the variant CD80 fusion protein antagonizes an activity of CTLA-4.
97. The method of any one of claims 1-96, wherein the variant CD80 fusion protein blocks PD-1 / PD-L1 interaction.
98. The method of any one of claims 1-97, wherein the variant CD80 fusion protein binds to CD28 and mediates CD28 agonism.
99. The method of claim 98, wherein the CD28 agonism is PD-L1 dependent.
100. The method of any one of claims 1 to 99, wherein the subject is a human.
101. (a) a variant CD80 fusion protein that specifically binds to PD-L1, the variant CD80 fusion protein comprising a variant CD80 extracellular domain, or a portion thereof, comprising an IgV domain, or a specific binding fragment thereof, and a multimerization domain, wherein the variant CD80 extracellular domain, or portion thereof, comprises one or more amino acid modifications at one or more positions in the amino acid sequence of the extracellular domain, or portion thereof, of an unmodified CD80 polypeptide; and (b) Anticancer drugs Including the kit.
102. The kit of claim 101, wherein the anti-cancer agent is an immune checkpoint inhibitor or a chemotherapeutic agent.
103. 103. The kit of claim 101 or claim 102, wherein the anti-cancer agent is a chemotherapeutic agent that is a platinum-based chemotherapeutic agent.
104. 104. The kit of claim 103, wherein the chemotherapeutic agent is oxilaplatin.
105. The kit of claim 101 or claim 102, wherein the anti-cancer agent is an immune checkpoint inhibitor of CTLA-4, and optionally, the checkpoint inhibitor is an anti-CTLA-4 antibody or an antigen-binding fragment thereof.
106. The kit of claim 105, wherein the immune checkpoint inhibitor is ipilimumab or tremelimumab, or an antigen-binding fragment thereof.
107. The kit of claim 101 or claim 102, wherein the anticancer agent is an immune checkpoint inhibitor of PD-1 (PD-1 inhibitor), and optionally, the PD-1 inhibitor is an anti-PD-1 antibody or an antigen-binding fragment thereof.
108. (a) a variant CD80 fusion protein that specifically binds to PD-L1, the variant CD80 fusion protein comprising a variant CD80 extracellular domain, or a portion thereof, comprising an IgV domain, or a specific binding fragment thereof, and a multimerization domain, wherein the variant CD80 extracellular domain, or portion thereof, comprises one or more amino acid modifications at one or more positions in the amino acid sequence of the extracellular domain, or portion thereof, of an unmodified CD80 polypeptide; and (b) Programmed death-1 (PD-1) inhibitors that disrupt the interaction between PD-1 and its ligands Including the kit.
109. The kit of claim 108, wherein the ligand is programmed death-ligand-1 (PD-L1) or PD-L2.
110. The kit of any one of claims 107-109, wherein the PD-1 inhibitor specifically binds to PD-1.
111. The kit of any of claims 107-110, wherein the PD-1 inhibitor does not compete with the variant CD80 fusion protein for binding to PD-L1.
112. The kit of claim 107 or 108, wherein the PD-1 inhibitor is a peptide, protein, antibody or antigen-binding fragment thereof, or a small molecule.
113. The kit of any one of claims 107-112, wherein the PD-1 inhibitor is an antibody or antigen-binding fragment thereof that specifically binds to PD-1.
114. The kit of claim 107 or claim 113, wherein the antibody or antigen-binding portion is selected from nivolumab, pembrolizumab, MEDI0680 (AMP514), PDR001, cemiplimab (REGN2810), pidilizumab (CT011), or an antigen-binding portion thereof.
115. The kit of any one of claims 107-112, wherein the PD-1 inhibitor comprises the extracellular domain of PD-L2 that binds to PD-1, or a portion thereof, and an Fc region.
116. The kit of claim 115, wherein the PD-1 inhibitor is AMP-224.
117. The kit of any of claims 107-116, wherein the variant CD80 fusion protein exhibits increased binding to at least one binding partner selected from among CD28, PD-L1, and CTLA-4 compared to a fusion protein comprising the extracellular domain of unmodified CD80, or a portion thereof, to said at least one binding partner.
118. The kit of any of claims 107-117, wherein the variant CD80 fusion protein exhibits increased binding to PD-L1 compared to a fusion protein comprising the extracellular domain of unmodified CD80 to PD-1, or a portion thereof.
119. The kit of any of claims 107-118, wherein the variant CD80 fusion protein exhibits increased binding to at least one binding partner selected from among CD28 and CTLA-4 compared to a fusion protein comprising the extracellular domain of unmodified CD80 or a portion thereof to said at least one binding partner.
120. 120. The kit of any one of claims 107-119, wherein the binding affinity is increased by more than 1.2x, 1.5x, 2x, 3x, 4x, 5x, 6x, 7x, 8x, 9x, 10x, 20x, 30x, 40x, 50x, 60x, 80x, 100x, 150x, 200x, 250x, 300x, 400x, or 450x compared to the binding affinity of unmodified CD80 to the ectodomain of the binding partner.
121. The kit of any one of claims 107-120, wherein the one or more amino acid modifications are amino acid substitutions.
122. The kit of any one of claims 107-121, wherein the one or more amino acid modifications comprise one or more amino acid substitutions selected from among H18Y, A26E, E35D, D46E, D46V, M47I, M47L, M47V, V68M, A71D, A71G, L85M, L85Q or D90G, or conservative amino acid substitutions thereof, with reference to the numbering of SEQ ID NO:
2.
123. The kit of any one of claims 107-122, wherein the one or more amino acid modifications comprise two or more amino acid substitutions selected from among H18Y, A26E, E35D, D46E, D46V, M47I, M47L, M47V, V68M, A71D, A71G, L85M, L85Q or D90G, with reference to the numbering of SEQ ID NO:2, or conservative amino acid substitutions thereof.
124. The one or more amino acid modifications may be selected from the group consisting of the amino acid substitutions H18Y / E35D, E35D / D46E, E35D / D46V, E35D / M47I, E35D / M47L, E35D / M47V, E35D / V68M, E35D / L85M, E35D / L85Q, D46E / M47I, D46E / M47L, D46E / M47V, D46V / M47I, D46V / M47L, D46V / M47L, 124. The kit of any one of claims 107-123, comprising D46E / V68M, D46V / V68M, H18Y / M47I, H18Y / M47L, H18Y / M47V, M47I / V68M, M47L / V68M or M47V / V68M, M47I / E85M, M47L / E85M, M47V / E85M, M47I / E85Q, M47L / E85Q or M47V / E85Q.
125. 125. The kit of any one of claims 107-124, wherein the one or more amino acid modifications comprise the amino acid substitutions E35D / M47L / V68M, E35D / M47V / V68M or E35D / M47I / L70M.
126. 126. The kit of any one of claims 107-125, wherein the one or more amino acid modifications comprise amino acid substitutions E35D / M47V / N48K / V68M / K89N, H18Y / A26E / E35D / M47L / V68M / A71G / D90G, E35D / D46E / M47V / V68M / D90G / K93E or E35D / D46V / M47L / V68M / L85Q / E88D.
127. The kit of any one of claims 107-126, wherein the unmodified CD80 is human CD80.
128. The kit of any one of claims 107-127, wherein the extracellular domain of unmodified CD80, or a portion thereof, (i) comprises an amino acid sequence as set forth in SEQ ID NO:2, (ii) comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO:2; or (iii) is a portion of (i) or (ii) comprising an IgV domain or a specific binding fragment thereof.
129. The kit of claim 128, wherein the extracellular domain of unmodified CD80 or a portion thereof is an extracellular domain portion that is or comprises an IgV domain or a specific binding fragment thereof.
130. The kit of claim 129, wherein the extracellular domain portion of unmodified CD80 comprises an IgV domain but does not comprise an IgC domain or a portion of an IgC domain.
131. The kit of claim 129 or claim 130, wherein the extracellular domain portion of unmodified CD80 is set forth as the sequence of amino acids 35 to 135 of SEQ ID NO:2 (SEQ ID NO:76) or 35 to 141 of SEQ ID NO:2 (SEQ ID NO:150).
132. 132. The kit of any one of claims 101-131, wherein the variant CD80 extracellular domain or portion thereof is a portion of the extracellular domain that does not include the IgC domain or a portion of the IgC domain.
133. The kit of any one of claims 101-132, wherein the variant CD80 extracellular domain comprises the sequence of amino acids 35 to 135 of SEQ ID NO:2 (SEQ ID NO:76) or 35 to 141 of SEQ ID NO:2 (SEQ ID NO:150), wherein said variant CD80 extracellular domain contains one or more amino acid substitutions.
134. The kit of any one of claims 101-133, wherein the variant CD80 extracellular domain is the sequence of amino acids 35 to 135 of SEQ ID NO:2 (SEQ ID NO:76) or 35 to 141 of SEQ ID NO:2 (SEQ ID NO:150), comprising one or more amino acid substitutions.
135. 135. The kit of any one of claims 101-134, wherein the variant CD80 extracellular domain comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acid modifications, optionally wherein the amino acid modifications are amino acid substitutions.
136. The kit of any one of claims 101-135, wherein the variant CD80 extracellular domain comprises no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13 amino acid modifications, optionally wherein the amino acid modifications are amino acid substitutions.
137. 137. The kit of any one of claims 101-136, wherein the variant CD80 extracellular domain has at least or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the sequence of amino acids 35 to 135 of SEQ ID NO:2 (SEQ ID NO:76) or 35 to 141 of SEQ ID NO:2 (SEQ ID NO:150).
138. The kit of any one of claims 101 to 137, wherein the multimerization domain is an Fc region.
139. The kit of claim 138, wherein the Fc region is that of an immunoglobulin G1 (IgG1) or an immunoglobulin G2 (IgG2) protein.
140. The kit of claim 138 or claim 139, wherein the Fc region exhibits one or more effector functions.
141. The kit of any one of claims 138-140, wherein the Fc region is a variant Fc region comprising one or more amino acid substitutions in a wild-type Fc region, wherein the variant Fc region exhibits one or more reduced effector functions compared to the wild-type Fc region, and optionally wherein the wild-type human Fc is that of human IgG1.
142. 142. An article of manufacture comprising the kit of any one of claims 101-141 and instructions for use.
143. The article of manufacture of claim 142, wherein said instructions provide information for administration of a variant CD80 Fc fusion protein or a PD-1 inhibitor according to the method of any one of claims 1-20, 22-31 and 34-100.
144. 1. A multivalent CD80 polypeptide comprising two copies of a fusion protein, said fusion protein comprising: (1) at least two variant CD80 extracellular domains or portions thereof (vCD80s) comprising an IgV domain or a specific binding fragment thereof, the variant CD80 comprising one or more amino acid modifications at one or more positions in the amino acid sequence of the extracellular domain or portions thereof of an unmodified CD80 polypeptide; and (2) Fc region polypeptide.
145. The multivalent CD80 polypeptide of claim 144, wherein said polypeptide is tetravalent.
146. 146. The multivalent CD80 polypeptide of claim 144 or claim 145, wherein said fusion protein comprises the structure: (vCD80)-linker-Fc-linker-(vCD80).
147. 146. The multivalent CD80 polypeptide of claim 144 or claim 145, wherein said fusion protein comprises the structure: (vCD80)-linker-(vCD80)-linker-Fc.
148. The multivalent CD80 polypeptide of any of claims 144-147, wherein the vCD80 exhibits increased binding to at least one binding partner selected from among CD28, PD-L1 and CTLA-4 compared to the extracellular domain of unmodified CD80 or a portion thereof to said at least one binding partner.
149. The multivalent CD80 polypeptide of any of claims 144-148, wherein vCD80 exhibits increased binding to PD-L1 compared to the extracellular domain of unmodified CD80 or a portion thereof to PD-L1.
150. 150. The multivalent CD80 polypeptide of claim 148 or claim 149, wherein the affinity is increased by more than 1.2 fold, 1.5 fold, 2 fold, 3 fold, 4 fold, 5 fold, 6 fold, 7 fold, 8 fold, 9 fold, 10 fold, 20 fold, 30 fold, 40 fold, 50 fold, 60 fold, 80 fold, 100 fold, 150 fold, 200 fold, 250 fold, 300 fold, 400 fold, or 450 fold compared to the binding affinity of unmodified CD80 to the ectodomain of the binding partner.
151. The multivalent CD80 polypeptide of any of claims 144-150, wherein the one or more amino acid modifications are amino acid substitutions.
152. 152. The multivalent CD80 polypeptide of any one of claims 144-151, wherein the one or more amino acid modifications comprise one or more amino acid substitutions selected from among H18Y, A26E, E35D, D46E, D46V, M47I, M47L, M47V, V68M, A71D, A71G, L85M, L85Q or D90G, with reference to the numbering of SEQ ID NO:2, or conservative amino acid substitutions thereof.
153. 153. The multivalent CD80 polypeptide of any one of claims 144-152, wherein the one or more amino acid modifications comprise two or more amino acid substitutions selected from among H18Y, A26E, E35D, D46E, D46V, M47I, M47L, M47V, V68M, A71D, A71G, L85M, L85Q or D90G, with reference to the numbering of SEQ ID NO:2, or conservative amino acid substitutions thereof.
154. The one or more amino acid modifications may be selected from the group consisting of the amino acid substitutions H18Y / E35D, E35D / D46E, E35D / D46V, E35D / M47I, E35D / M47L, E35D / M47V, E35D / V68M, E35D / L85M, E35D / L85Q, D46E / M47I, D46E / M47L, D46E / M47V, D46V / M47I, D46V / M47L, D46V / M47L, D46E 154. The multivalent CD80 polypeptide of any one of claims 144-153, comprising: D46V / V68M, H18Y / M47I, H18Y / M47L, H18Y / M47V, M47I / V68M, M47L / V68M or M47V / V68M, M47I / E85M, M47L / E85M, M47V / E85M, M47I / E85Q, M47L / E85Q or M47V / E85Q.
155. 155. The multivalent CD80 polypeptide of any one of claims 144-154, wherein the one or more amino acid modifications comprise the amino acid substitutions E35D / M47L / V68M, E35D / M47V / V68M or E35D / M47I / L70M.
156. 156. The multivalent CD80 polypeptide of any one of claims 144-155, wherein the one or more amino acid modifications comprise the amino acid substitutions E35D / M47V / N48K / V68M / K89N, H18Y / A26E / E35D / M47L / V68M / A71G / D90G, E35D / D46E / M47V / V68M / D90G / K93E or E35D / D46V / M47L / V68M / L85Q / E88D.
157. The multivalent CD80 polypeptide of any one of claims 144-156, wherein the unmodified CD80 is human CD80.
158. The multivalent CD80 polypeptide of any one of claims 144-157, wherein the extracellular domain of unmodified CD80, or a portion thereof, (i) comprises an amino acid sequence as set forth in SEQ ID NO:2, (ii) comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO:2; or (iii) is a portion of (i) or (ii) that comprises an IgV domain or a specific binding fragment thereof.
159. The multivalent CD80 polypeptide of claim 158, wherein said extracellular domain of unmodified CD80 or a portion thereof is an extracellular domain portion that is or comprises an IgV domain or a specific binding fragment thereof.
160. The multivalent CD80 polypeptide of claim 159, wherein said extracellular domain portion of unmodified CD80 comprises an IgV domain but does not comprise an IgC domain or a portion of an IgC domain.
161. The multivalent CD80 polypeptide of claim 159 or claim 160, wherein the extracellular domain portion of unmodified CD80 is set forth as amino acids 35 to 135 of SEQ ID NO:2 (SEQ ID NO:76) or 35 to 141 of SEQ ID NO:2 (SEQ ID NO:150).
162. The multivalent CD80 polypeptide of any one of claims 144-161, wherein vCD80 is an extracellular domain portion that does not include an IgC domain or a portion of an IgC domain.
163. The multivalent CD80 polypeptide of any one of claims 144-162, wherein the vCD80 comprises the sequence of amino acids 35 to 135 of SEQ ID NO:2 (SEQ ID NO:76) or 35 to 141 of SEQ ID NO:2 (SEQ ID NO:150), wherein said vCD80 contains one or more amino acid substitutions.
164. The multivalent CD80 polypeptide of any one of claims 144-163, wherein the vCD80 has a sequence of amino acids 35 to 135 of SEQ ID NO:2 (SEQ ID NO:76) or 35 to 141 of SEQ ID NO:2 (SEQ ID NO:150), which contains one or more amino acid substitutions.
165. 165. The multivalent CD80 polypeptide of any one of claims 144-164, wherein vCD80 comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acid modifications, optionally wherein said amino acid modifications are amino acid substitutions.
166. 166. The multivalent CD80 polypeptide of any one of claims 144-165, wherein vCD80 comprises no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13 amino acid modifications, optionally wherein said amino acid modifications are amino acid substitutions.
167. 167. The multivalent CD80 polypeptide of any one of claims 144-166, wherein vCD80 has at least, or at least about, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the sequence of amino acids 35 to 135 of SEQ ID NO:2 (SEQ ID NO:76) or 35 to 141 of SEQ ID NO:2 (SEQ ID NO:150).
168. 168. The multivalent CD80 polypeptide of any one of claims 144-167, wherein said Fc region is that of an Immunoglobulin G1 (IgG1) or Immunoglobulin G2 (IgG2) protein.
169. The multivalent CD80 polypeptide of any of claims 144-168, wherein the Fc region exhibits one or more effector functions.
170. 169. The multivalent CD80 polypeptide of any of claims 144-168, wherein the Fc region is a variant Fc region comprising one or more amino acid substitutions in a wild-type Fc region, wherein the variant Fc region exhibits one or more reduced effector functions compared to the wild-type Fc region, and optionally wherein the wild-type human Fc is that of human IgG1.
171. The multivalent CD80 polypeptide of any of claims 144-170, wherein each vCD80 is the same.
172. The multivalent CD80 polypeptide of any one of claims 144-171, wherein the linker is a flexible linker.
173. The multivalent CD80 polypeptide of any one of claims 144-172, wherein the linker is a peptide linker.
174. The multivalent CD80 polypeptide of claim 173, wherein the linker is GSGGGGS (SEQ ID NO: 1522) or 3xGGGGS (SEQ ID NO: 1504).
175. 175. A nucleic acid molecule encoding a fusion protein of the multivalent CD80 polypeptide of any one of claims 144-174.
176. A vector comprising the nucleic acid of claim 175.
177. The vector of claim 176 which is an expression vector.
178. 178. A host cell comprising the nucleic acid of claim 175 or the vector of claim 176 or claim 177.
179. 175. A method for producing a multivalent CD80 polypeptide according to any one of claims 144-174, comprising introducing a nucleic acid of claim 175, or a vector of claim 176 or claim 177, into a host cell under conditions for expressing the protein in said cell.
180. The method of claim 179, further comprising the step of isolating or purifying said protein comprising said multivalent CD80 polypeptide.
181. 175. An engineered cell comprising the multivalent CD80 polypeptide of any one of claims 144-174.
182. The engineered cell of claim 181, wherein said multivalent CD80 polypeptide comprises a fusion protein encoded by a nucleic acid molecule operably linked to a sequence encoding a secretory signal peptide.
183. 183. The engineered cell of claim 181 or claim 182, wherein said multivalent CD80 polypeptide, when expressed, is capable of being secreted from the engineered cell.
184. 178. An engineered cell comprising the nucleic acid molecule of claim 175 or the vector of claim 176 or 177.
185. 185. The engineered cell of claim 184, wherein said nucleic acid molecule comprises a sequence encoding a secretory signal peptide operably linked to a sequence encoding said fusion protein.
186. The engineered cell of claim 184 or claim 185, wherein said nucleic acid molecule encodes a fusion protein of a multivalent CD80 polypeptide, wherein the multivalent CD80 polypeptide, when expressed, is capable of being secreted from the engineered cell.
187. 187. The engineered cell of any one of claims 182 and 184-186, wherein said signal peptide is a non-native signal sequence.
188. The engineered cell of any one of claims 182 and 184-186, wherein said signal peptide is an IgGκ signal peptide, an IL-2 signal peptide, a CD33 signal peptide, or a VH signal peptide.
189. The engineered cell of any one of claims 182-188, wherein said nucleic acid molecule further comprises at least one promoter operably linked to control expression of said fusion protein.
190. 190. The engineered cell of claim 189, wherein said promoter is a constitutively active promoter.
191. 190. The engineered cell of claim 189, wherein said promoter is an inducible promoter.
192. The engineered cell of claim 189 or claim 191, wherein said promoter is responsive to an element responsive to T cell activation signaling, and optionally said promoter contains a binding site for NFAT or a binding site for NF-κB.
193. 193. The engineered cell of any one of claims 181-192, which is an immune cell, optionally an antigen presenting cell (APC) or a lymphocyte.
194. The engineered cell of any one of claims 181-193, wherein said cell is a lymphocyte that is a T cell, a B cell or a NK cell, and optionally said lymphocyte is a T cell that is CD4+ or CD8+.
195. The engineered cell of any one of claims 181-193, wherein said cell is a primary cell obtained from a subject, optionally wherein the subject is a human subject.
196. The engineered cell of any one of claims 181-195, further comprising a chimeric antigen receptor (CAR) or an engineered T cell receptor (TCR).
197. 175. A pharmaceutical composition comprising the multivalent CD80 polypeptide of any one of claims 144-174.
198. 202. A pharmaceutical composition comprising the engineered cell of any one of claims 181-196.
199. (i) a variant extracellular domain comprising one or more amino acid substitutions at one or more positions in the amino acid sequence set forth as amino acid residues 35-230 of the wild-type human CD80 extracellular domain corresponding to the residues set forth in SEQ ID NO:1; and (ii) an Fc region having effector activity wherein the extracellular domain of the variant CD80 fusion protein specifically binds to the ectodomain of human CD28 and does not bind to the ectodomain of human PD-L1, or binds to the ectodomain of PD-L1 with a similar binding affinity as the extracellular domain of wild-type human CD80 for the ectodomain of PD-L1.
200. 200. The variant CD80 fusion protein of claim 199, wherein the extracellular domain of the variant CD80 fusion protein exhibits increased binding affinity to the ectodomain of human CTLA-4 compared to the binding affinity of the extracellular domain of wild-type CD80 to the ectodomain of human CTLA-4.
201. 201. The variant CD80 fusion protein of claim 199 or claim 200, wherein the extracellular domain of the variant CD80 fusion protein exhibits increased binding affinity to the ectodomain of human CD28 compared to the binding affinity of the extracellular domain of wild type CD80 to the ectodomain of human CD28.
202. The variant CD80 fusion protein of any of claims 199-201, wherein the wild-type human CD80 extracellular domain has an amino acid sequence as set forth in SEQ ID NO:2, or a sequence having at least 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:
2.
203. 203. The variant CD80 fusion protein of any of claims 199-202, wherein said one or more amino acid substitutions comprise one or more amino acid substitutions selected from L70Q, K89R, D90G, D90K, A91G, F92Y, K93R, I118V, T120S or T130A, with reference to the numbering set forth in SEQ ID NO:2, or conservative amino acid substitutions thereof.
204. The one or more amino acid substitutions are selected from the group consisting of amino acid modifications L70Q / K89R, L70Q / D90G, L70Q / D90K, L70Q / A91G, L70Q / F92Y, L70Q / K93R, L70Q / I118V, L70Q / T120S, L70Q / T130A, K89R / D90G, K89R / D90K, K89R / A91G, K89R / F92Y, K89R / K93R, K89R / I118V, K89R / T120S, K89R / T130A, D90G / A91G, D90G / F92Y, D90G / K93R, D90G / I118V 204. The variant CD80 fusion protein of any one of claims 199-203, comprising: D90G / T120S, D90G / T130A, D90K / A91G, D90K / F92Y, D90K / K93R, D90K / I118V, D90K / T120S, D90K / T130A, F92Y / K93R, F92Y / I118V, F92Y / T120S, F92Y / T130A, K93R / I118V, K93R / T120S, K93R / T130A, I118V / T120S, I118V / T130A or T120S / T130A.
205. 203. The variant CD80 fusion protein of any of claims 199-202, wherein said one or more amino acid substitutions comprise one or more amino acid substitutions selected from among H18Y, A26E, E35D, D46E, D46V, M47I, M47L, M47V, V68M, A71D, A71G, L85M, L85Q or D90G, or conservative amino acid substitutions thereof, with reference to the numbering of SEQ ID NO:
2.
206. The one or more amino acid substitutions are selected from the group consisting of the amino acid substitutions H18Y / E35D, E35D / D46E, E35D / D46V, E35D / M47I, E35D / M47L, E35D / M47V, E35D / V68M, E35D / L85M, E35D / L85Q, D46E / M47I, D46E / M47L, D46E / M47V, D46V / M47I, D46V / M47L, D46V / M47L, D46E / V68M 206. The variant CD80 fusion protein of any one of claims 199-202 and 205, comprising: D46V / V68M, H18Y / M47I, H18Y / M47L, H18Y / M47V, M47I / V68M, M47L / V68M or M47V / V68M, M47I / E85M, M47L / E85M, M47V / E85M, M47I / E85Q, M47L / E85Q or M47V / E85Q.
207. The variant CD80 fusion protein of any one of claims 199-206, wherein the Fc region is that of Immunoglobulin G1 (IgG1).
208. 208. A nucleic acid molecule encoding the variant CD80 fusion protein of any one of claims 199-207.
209. 209. A vector comprising the nucleic acid of claim 208, optionally an expression vector.
210. 209. A host cell comprising the nucleic acid of claim 208 or the vector of claim 209.
211. 211. A method of producing a variant CD80 fusion protein of any of claims 199-210 comprising introducing the nucleic acid of claim 208 or the vector of claim 209 into a host cell under conditions for expression of the protein in said cell, and optionally further comprising isolating or purifying the protein comprising the variant CD80 fusion protein.
212. 208. A pharmaceutical composition comprising the variant CD80 fusion protein of any one of claims 199-207.
213. 213. The pharmaceutical composition of any one of claims 197, 198, and 212, comprising a pharma- ceutically acceptable excipient.
214. The pharmaceutical composition of any one of claims 197, 198, 212, and 213, which is sterile.
215. An article of manufacture comprising the pharmaceutical composition of any one of claims 197, 198, and 212-214 in a container, optionally wherein the container is a vial.
216. The article of manufacture of claim 215, wherein the container is sealed.
217. 216. A method of modulating an immune response in a subject comprising administering to the subject a pharmaceutical composition according to any one of claims 197, 198, and 212-214.
218. 175. A method of modulating an immune response in a subject, comprising administering to the subject a multivalent CD80 polypeptide of any one of claims 144-174.
219. 202. A method of modulating an immune response in a subject comprising administering to the subject the engineered cell of any one of claims 181-196.
220. The method of claim 219, wherein said engineered cells are autologous to the subject.
221. The method of any one of claims 217-220, wherein modulating the immune response treats a disease or condition in a subject.
222. The method of claim 221, wherein the disease or condition is a tumor or cancer.
223. 19. A method of treating cancer in a subject comprising administering to the subject a pharmaceutical composition of any one of claims 197, 198, and 212-214, administering to the subject a multivalent CD80 polypeptide of any one of claims 144-174, or administering to the subject an engineered cell of any one of claims 181-196.
Citation Information
Patent Citations
Compositions that bind to multiple epitopes of IGF-1R
JP2010538012A
Tetravalent bispecific antibody
JP2016514676A
Bispecific tetravalent antibody and method of making and using same
JP2018509175A
CD80 variant immunomodulatory proteins and uses thereof
JP2019521643A
Secreted variant immunomodulatory proteins and engineered cell therapies
JP2020500010A
